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Abstract 
During fetal development there is a progressive maturation of the hypothalamo- 
pituitary- adrenal (HPA) axis which is responsible for co- ordinated fetal maturation 
and the onset of birth. The aim of this thesis is to investigate the neuroendocrine 
regulation of the developing HPA axis. The first approach was to investigate the role 
of putative neurotrophic factors in the functional maturation of hypothalamic arginine 
vasopressin (AVP) neurons. The role of AVP in the release of adrenocorticotropic 
hormone (ACTH) has been extensively demonstrated but little is known about the 
factors controlling the development of AVP neurons. The objective of this study was 
to chart the growth and development of AVP neurons in cell culture in response to 
various neurotrophic factors. Functional maturation of the neurons was assessed in 
terms of the secretory response to potassium- induced depolarisation whilst 
development of neuronal morphology was to be monitored by immunocytochemistry. 
Fetal rat hypothalamic neurons were cultured in the presence and absence of insulin - 
like growth factor -1 (IGF -1), which has been implicated as a putative neurotrophic 
factor, for periods of up to 20 days. IGF -1 had no significant effect on either basal or 
stimulated levels of AVP secretion, suggesting that AVP neurons do not appear to be 
the specific target population for IGF -1 within the developing fetal hypothalamus. 
Despite extensive screening of several different antibodies, we were unable to 
specifically identify AVP neurons in culture by immunocytochemistry. 
The second approach to studying the neuroendocrine regulation of the HPA axis 
utilised the sheep as an animal model as it affords chronic in utero manipulation of the 
fetus. In the ovine fetus, maturation of the HPA axis is pivotal in the onset of 
parturition. The hypothesis that POMC- derived peptides of the ovine fetal pituitary 
are subject to tonic dopamine inhibition throughout gestation was investigated. 
Removal of this inhibitory tone may induce synthesis and release of adrenal active 
peptides which in turn elicit cortisol secretion from the fetal adrenal gland. The 
approach to the hypothesis was to investigate the effects of dopaminergic manipulation 
of the fetus, on the secretion of POMC- derived peptides and cortisol into the fetal 
circulation, on pituitary content of POMC -derived peptides and on the level of POMC 
gene expression. Specifically, fetal sheep at day 131 gestation (gestation =145 days) 
were treated with a 72 hour intravenous administration of the dopamine agonist 
bromocriptine, the dopamine antagonist sulpiride or vehicle control. Treatment with 
bromocriptine significantly decreased the concentration of a -MSH in the fetal plasma, 
Abstract ix 
represented by an abolition of the pulsatile mode of secretion of a -MSH. In response 
to sulpiride infusion, plasma concentrations of both a -MSH and ACTH were 
significantly elevated, with a -MSH secretion displaying increased pulse amplitude 
with decreased pulse frequency. By contrast, the pulsatile characteristics of ACTH 
were unaltered by sulpiride infusion. Despite increased plasma concentrations of a- 
MSH and ACTH following sulpiride infusion, the concentration of cortisol in the fetal 
plasma was unaltered. 
a -MSH and ACTH were identified by immunohistochemistry and determination of 
peptide content in the pars distalis and pars intermedia of the fetal pituitary. The 
content of ACTH in the pars intermedia tended to increase in response to 
bromocriptine and decrease in response to sulpiride treatment. Pituitary a -MSH 
content was unaffected by either treatment. POMC mRNA levels in the fetal pars 
intermedia was significantly reduced following bromocriptine treatment and were 
unaltered by treatment with sulpiride. The level of POMC gene expression in the pars 
distalis was not significantly altered by either treatment. 
Studies on the ontogeny of POMC gene expression and the development of a -MSH 
and ACTH immunoreactivity revealed that POMC gene expression, ACTH and a- 
MSH immunoreactivity can be detected as early as day 40 gestation. ACTH 
immunoreactivity was detected in both the pars intermedia and pars distalis of the 
pituitary. In contrast, a -MSH immunoreactivity was confined to the pars intermedia 
at most gestational ages examined. However, at day 40 -50 gestation a -MSH 
immunopositive cells were also identified in the pars distalis. POMC mRNA levels 
were consistently higher in the pars intermedia compared to the pars distalis and 
increased progressively from day 40 until day 134 gestation. In the pars distalis, 
POMC mRNA levels were high at day 40 gestation, decreased at day 50 and then rose 
progressively until day 134 gestation. 
Fetal plasma prolactin concentrations were also influenced by treatment with 
bromocriptine and sulpiride. Secretion of prolactin into the fetal plasma was 
influenced by season, with concentrations peaking in the summer months and 
decreasing to very low levels in the winter. Winter prolactin concentrations could be 
further suppressed by infusion of bromocriptine. Conversely, sulpiride treatment 
significantly increased prolactin concentrations in fetuses treated in the winter months 
Abstract x 
however, concentrations in sulpiride- treated winter fetuses were still lower than those 
of vehicle controls in the summer months. The seasonal alteration in plasma prolactin 
concentrations was mirrored by a significant decline in the number of immunopositive 
lactotrophs in the winter. The number of immunopositive lactotrophs was unaffected 
by bromocriptine or sulpiride infusion in either season. 
These results demonstrate the existence of an endogenous inhibitory system regulating 
the release of ACTH, a -MSH and prolactin from the fetal pituitary gland. However, 
these results do not support the hypothesis that peptides released upon removal of the 
inhibitory dopaminergic tone are capable of eliciting the secretion of cortisol from the 
fetal adrenal gland. 
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Chapter 1. Introduction 
Premature birth is a major problem in clinical obstetrics with 5 -9% of all births in 
the United Kingdom occurring preterm. Preterm births are the leading cause of 
perinatal mortality and morbidity, accounting for almost 85% of cases of perinatal 
death which are not attributed to congenital malformations. Moreover, surviving 
preterm infants have an increased risk for long -term morbidity, including cerebral 
palsy and mental retardation. Whilst about one -third of these premature deliveries 
occur in association with infection, for the majority of presentations, the 
mechanisms initiating preterm labour remain undetermined. Indeed, little is known 
about the mechanisms which govern the precise timing of the onset of normal labour 
or whether the same mechanisms are involved in the onset of preterm birth. 
The sequential maturation of the hypothalamo- pituitary -adrenal (HPA) axis during 
fetal life plays a significant role in prenatal development, preparing the fetus for 
birth and subsequent existence in the external environment. Corticotrophin - 
releasing factors, arginine vasopressin (AVP) and corticotrophin releasing hormone 
(CRH) are secreted from the fetal hypothalamus and act at the pituitary gland to 
elicit the release of adrenocorticotropic hormone (ACTH). ACTH in turn stimulates 
the secretion of cortisol from the fetal adrenal gland. Increased cortisol secretion in 
late gestation is essential for maturation of the fetal lung and gut and this knowledge 
is now exploited clinically by the use of corticosteroids to advance lung maturation 
in cases of threatened preterm delivery. In addition, increased fetal cortisol levels 
induce biochemical changes in the steroid biosynthesis pathway of the placenta 
resulting in an increase in oestrogen and a decline in progesterone production. This 
shift in the oestrogen to progesterone ratio ultimately stimulates enhanced 
contractility in the myometrium and culminates in the initiation of labour. Thus, the 
maturation of the fetal HPA axis is pivotal in the preparation for life outwith the 
uterus and for the initiation of parturition. 
This thesis aims to investigate the regulation of the hypothalamo- pituitary axis in the 
late gestation fetus. Whilst the role of the hypothalamic releasing factors CRH and 
AVP in the release of ACTH from the fetal pituitary gland has been well 
demonstrated, little is known about the factors influencing the development of these 
neuropeptide neurons within the fetal hypothalamus. The study presented in 
Chapter 4 was designed to investigate the role of putative neurotrophic factors in the 
growth and functional maturation of hypothalamic AVP neurons. However, it 
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became clear that the culture system was inappropriate for the needs of the study as 
it was not possible to specifically identify AVP neurons within the culture system. 
The remainder of the studies presented in this thesis concentrate on the ontogeny and 
neuroendocrine regulation of the pituitary component of the HPA axis, and focused 
primarily on the proopiomelanocortin (POMC) family, of which ACTH is a 
member. These studies utilised the fetal sheep as an animal model at it affords 
chronic in utero manipulation of the fetus. In addition, the pivotal role of the fetal 
HPA axis in the initiation of parturition in the sheep has been widely demonstrated. 
However, although ACTH is believed to be the main regulating hormone for fetal 
adrenal cortisol during the last third of gestation, adrenal activation in the absence of 
increased plasma ACTH concentrations and discordance in the pulse characteristics 
of the ACTH and cortisol has led to the suggestion that ACTH may not be solely 
responsible for driving cortisol secretion from the fetal adrenal gland in late 
gestation. In this respect, a -MSH, a peptide secreted from the intermediate lobe of 
the fetal pituitary has been implicated in the induction of cortisol secretion from the 
adrenal gland. As the secretion of a -MSH from the adult pituitary gland has been 
shown to be under the inhibitory influence of dopamine, the studies presented in 
Chapters 6 -8 of this thesis were designed to test the hypothesis that POMC - derived 
peptides of the fetal pituitary gland are subject to tonic dopaminergic regulation 
during fetal life and that removal of this inhibitory tone will result in the release of 
adrenal active peptides which elicit cortisol secretion from the fetal adrenal gland. 
Specifically, the role of dopamine in the regulation of POMC- derived peptide 
secretion, on pituitary content of these peptides, and on the level of POMC gene 
expression was investigated. 
As it has been demonstrated that plasma prolactin concentrations in the ovine fetus 
are modulated both by dopamine and external photoperiod, an additional study to 
determine the extent to which season influences the dopaminergic regulation of 
prolactin in the late gestation fetus is presented in Chapter 9. 
Chapter 2. Review of the literature 
2.1 The fetal pituitary -adrenal axis and fetal maturation 
The significance of the fetal pituitary- adrenal axis in the timing of parturition was 
first realised in the 1960's when sheep grazing on Veratrum californicum were seen 
to deliver deformed fetuses at the end of an extended gestational period. Further 
investigation of the fetuses revealed lesions of the fetal brain and pituitary and 
hypoplasia of the adrenal gland (Binns, Anderson and Sullivan, 1960). This led to 
the suggestion that disruption of the fetal pituitary- adrenal axis was responsible for 
anomalous fetal maturation and the failure to deliver at term. 
Liggins and co- workers did a series of elegant experiments to investigate the extent 
to which the fetal pituitary -adrenal axis was involved in parturition. 
Electrocoagulation of the fetal pituitary resulted in delayed parturition in those 
fetuses in which more than 70% of the pituitary had been destroyed (Liggins, 
Kennedy and Holm, 1967). This experiment was followed by one in which the 
major pituitary hormones were replaced either individually or in combination in an 
attempt to identify the specific factors from the pituitary that were necessary to 
precipitate delivery. Administration of growth hormone, prolactin, luteinizing 
hormone or follicle -stimulating hormone alone had no effect on the timing of 
parturition. However, administration of these hormones concomitantly with 
adrenocorticotropic hormone (ACTH) or administration of ACTH alone resulted in 
the onset of parturition. Moreover, administration of ACTH with a corticosteroid 
synthesis inhibitor, metyrapone prevented the induction of parturition (Liggins, 
1968). Liggins (1969) went on to show that intrafetal infusion of cortisol was 
capable of inducing premature delivery in the sheep. Moreover, fetuses delivered 
prematurely following activation of the fetal adrenal were viable, implicating a role 
for glucocorticoids in fetal lung and organ maturation. The timing of parturition is 
unaltered by maternal hypophysectomy or maternal administration of ACTH or 
glucocorticoids (Liggins, Fairclough, Grieves, Kendall and Knox, 1973) illustrating 
the active role of the fetus in this regard. 
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The demonstration that fetal plasma cortisol concentrations rise dramatically during 
the final days before parturition (Basset and Thornburn, 1968) gave credence to the 
now generally accepted hypothesis that activation of the fetal hypothalamo- pituitary- 
adrenal axis gives rise to parturition in the sheep. 
2.2. Ontogeny of the fetal hypothalamic- pituitary -adrenal (HPA) 
axis 
2.2.1. Plasma concentrations of ACTH and cortisol 
During fetal development there is a progressive increase in plasma concentrations of 
ACTH and cortisol in the last 15 -20 days of gestation and a dramatic pre -parturient 
surge in both hormones in the final few days before birth. 
Early studies (Rees, Jack, Thomas and Nathanielsz, 1975) suggested that the 
increase in plasma ACTH concentrations follow the cortisol surge. However, with 
more rigorous sampling protocols and sensitive radioimmunoassays the rise in 
ACTH has been shown to precede the increase in cortisol concentrations (Norman, 
Lye, Wlodek and Challis, 1985, Challis and Brooks, 1989). Brooks and Challis 
(1991) demonstrated that the final preparturient surge in ACTH and cortisol 
concentrations is highly pulsatile, with cortisol pulses displaying increased pulse 
amplitude and decreased pulse frequency 1 -2 days compared to 3 -4 days prior to 
parturition. ACTH pulses occurred on average once every 40 minutes but there was 
no change in the pulse frequency or amplitude in the 4 days before birth. 
Interestingly, in this study and one other (Apostolakis, Longo, Veldhuis and Yellon, 
1992), not all ACTH pulses were coincident with cortisol pulses suggesting that 
ACTH is not solely responsible for driving cortisol secretion from the fetal adrenal 
in late gestation and that other factors may be involved in regulation of fetal adrenal 
gland secretion. 
The fetal sheep pituitary gland contains several high molecular weight species that 
are immunoreactive for ACTH (Silman, Holland, Chard, Lowry, Hope, Thomas and 
Nathanielsz, 1979; Jones and Roebuck, 1980). These high molecular weight 
molecules are present in greater amounts in the fetus than in the adult and the late 
gestation increase in adrenal activity coincides with a marked increase in the relative 
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proportion of ACTH1_39 in the circulating fetal plasma compared to the larger 
molecular weight peptides (Roebuck, Jones, Holland and Silman, 1980). Jones and 
Roebuck (1980) cultured adrenal cells with three high molecular weight ACTH 
molecules (50 -60 kD, 30kD and 20kD) in the presence or absence of ACTH1_39 and 
demonstrated an inhibition of ACTH -induced cortisol production, suggesting that 
the high molecular weight molecules act as antagonists to ACTH. If this is the case, 
a change in the ratio of the high molecular weight molecules and ACTH1_39 in the 
fetal plasma could influence the late gestation surge from the adrenal gland. Brieu 
and Durand (1987) used an in vitro bioassay to compare the biological and 
immunological properties of ACTH -like activity released from cultured pituitary 
cells between day 63 and 144 gestation and newborn lambs. During fetal life, levels 
of immunoreactive ACTH were always higher than bioactive ACTH. However, the 
ratio of bioactive to immunoreactive ACTH increased with advancing gestation 
implying an increase in drive to the adrenal by bioactive ACTH. 
Recently, the secretion of ACTH1_39 in late gestation relative to its precursors, 
proopiomelanocortin (POMC) and pro -ACTH has been investigated using perifused 
slice cultures (McMillen, Merci, White, Crosby and Schwartz, 1995). Slices of 
anterior pituitary from three gestational ages, day 106 -113, day 120 -136 and day 
140 -143 were analysed and a significant increase in the secretory rate of ACTH1_39 
reported between day 120 -136 and day 140 -143 gestation. In contrast, there was no 
change in the rate of secretion of the precursors resulting in an increase in the ratio 
of ACTH1_39: ACTH precursors between 120 and 143 days of gestation. 
This alteration in the post -translational processing of POMC late in gestation to 
favour production of ACTHi_39 may be associated with the change in corticotroph 
cell type seen at this time (section 2.2.3) and may be important in the increase in 
trophic drive to the adrenal prior to parturition. 
2.2.2. Corticotrophin releasing factors of the fetal hypothalamus 
Following the discovery in 1981 (Vale et al .) of a 41 -amino acid residue in the 
ovine hypothalamus that acted as a corticotrophin releasing factor, now referred to 
as corticotrophin releasing hormone (CRH), and the subsequent confirmation of 
arginine vasopressin (AVP) as an ACTH -releasing factor (Antoni, 1986; 1993, for 
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review) rapid advances have been made in the study of these hypothalamic releasing 
factors in the control of the ACTH- adrenal axis. 
CRH and AVP neurons from the parvocellular portion of the hypothalamic 
paraventricular nucleus (PVN) project extensively to the external lamina of the 
median eminence (Swanson, Sawchenco, Rivier and Vale, 1983) where AVP and 
CRH are released into the portal blood supply. In addition to the presence of 
hypothalamic neuropeptides in the portal blood, high concentrations of 
catecholamines, dopamine, norepinephrine, and epinephrine are also secreted into 
the portal circulation (Paradisi, Frank, Grossi, Venturoli, Porci, Capelli, Galassi and 
Flamignin, 1989). Development of the portal connection between the hypothalamus 
and pituitary in the fetal sheep is complete by day 45 gestation (Matwijiw, Thliveris 
and Fairman, 1989, Levidiotis, Wintour, McKinley and Oldfield, 1989). AVP 
positive terminals have been identified in the external lamina of the median 
eminence as early as day 42 of gestation in the fetal sheep (Levidiotis, Oldfield and 
Wintour, 1987). Although CRH positive connections to the median eminence were 
not identified until day 105 gestation in this study, CRH neurons were detected in 
the paraventricular nucleus from day 90 gestation. More recently, CRH containing 
cell bodies have been identified in the hypothalamus by day 49 gestation with 
corresponding positive fibres projecting to the median eminence (Watabe, 
Levidiotis, Oldfield and Wintour, 1991). The coexistence of CRH and AVP within 
neurosecretory vesicles in the rat median eminence has been demonstrated with 
double -labelling immunocytochemistry (Whitnall, Mezey and Gainer, 1985) with 
50% of the CRH containing neurons also containing AVP (Whitnall, Smyth and 
Gainer, 1987). These workers have also show that AVP -containing and AVP - 
deficient CRH neurons have differential distributions within the PVN (Whitnall and 
Gainer, 1988) and that the AVP -containing population of CRH neurons are 
selectively activated in response to stress (Whitnall, 1989). 
Thus, the neuronal connections from the PVN to the median eminence and the portal 
blood supply connecting the hypothalamus with the fetal pituitary are already intact 
in the first third of gestation. 
Contents of immunoreactive CRH and AVP in the fetal sheep hypothalamus 
increase with advancing gestational age (Currie and Brooks, 1992), with the greatest 
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increases between day 100 to day 130 gestation. AVP is always found in greater 
concentrations than CRH. The ratio of AVP to CRH in the hypothalamus falls with 
advancing gestational age (Brieu, Tonon, Lutz -Bucher and Durand, 1989, Currie and 
Brooks, 1992) reflecting a dramatic increase in the concentration of CRH, thought to 
play a more significant role in late gestation (Norman et al., 1985). CRH release 
from perifused hypothalamic pieces also increases with advancing gestational age 
(Brooks, Power, Jones, Yang and Challis, 1989). This rise in immunoreactive CRH 
released from the mediobasal hypothalamus is in accordance with significantly 
increased levels of CRH mRNA seen in the paraventricular nucleus of the intact 
fetus between days 105 -107 and days 128 -130 gestation (Myers, Myers, Grober, 
Nathanielsz, 1993). The increase in CRH mRNA and CRH secretory activity 
precedes the surge of adrenocortical activity seen in the last days of gestation. More 
recently, Keiger et al. (1994) have extended these observations demonstrating that 
the abundance of CRH mRNA continues to increase with a two -fold increase in 
CRH mRNA in day 140 -142 gestation hypothalami compared to day 128 -138 
gestation. 
2.2.3. Development of the fetal pituitary gland 
The pituitary gland contains three distinct regions: the anterior lobe (pars distalis), 
the intermediate lobe (pars intermedia) and the neural lobe (pars nervosa). The 
intermediate and anterior lobes of the pituitary constitute the true endocrine gland 
whereas the neural lobe is not in itself an endocrine organ but rather it consists of a 
bundle of nerve endings with cell bodies originating in the hypothalamus. A 
common epithelial progenitor gives rise to five distinct cell types which produce the 
anterior pituitary hormones: sommatotrophs produce growth hormone, lactotrophs 
produce prolactin, thyrotrophs produce thyroid -stimulating hormone, gonadotrophs 
produce follicle -stimulating and luteinizing hormone and corticotrophs produce 
ACTH. The appearance of these five glandular epithelial cell types is both spatially 
and temporally regulated such that each cell type arises at a different period in 
gestation and occupies a specific area within the gland. Of these hormones ACTH 
produced by fetal corticotrophs is significant in the development of the HPA axis. 
Fetal pituitary corticotrophs have been identified as early as day 40 gestation (Perry, 
Mulvogue, McMillen and Robinson, 1985). By day 87 gestation, they exist as two 
morphologically distinct types (Perry et al., 1985). Fetal type corticotrophs are 
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columnar, palisade cells that stain weakly for ACTH while adult type corticotrophs 
are small angular cells that stain more intensely for ACTH. Fetal corticotrophs are 
the dominant type in the anterior pituitary until day 130 gestation, after which time 
the numbers decline and more adult type cells are present (Mulvogue, McMillen, 
Robinson and Perry, 1986). It is possible that the switch from fetal to adult type 
corticotrophs represents a shift in responsiveness to hypothalamic factors such that 
the adult corticotrophs are more responsive to CRH. This would correlate with the 
observed increase in stimulatory capacity of CRH and corresponding decrease in 
AVP stimulation late in gestation (Norman et al., 1985; Norman and Challis, 
1987a). The same workers also describe the presence of an intermediate -type cell 
(Antolovich Perry, Trahair, Silver and Robinson, 1989) with characteristics of both 
adult and fetal type cells suggesting that the adult population arises from the fetal 
population following a transitional period. The relative proportions of fetal to adult 
type corticotrophs can be influenced by bilateral adrenalectomy at day 120 gestation 
or by premature treatment of fetuses with exogenous cortisol between day 109 and 
day 115 gestation (Antolovich et al., 1989) implicating cortisol from the fetal 
adrenal gland in maturation of corticotrophs from fetal to adult type and illustrating 
the feedback effect of the adrenal gland on the fetal pituitary. Destruction of the 
paraventricular nucleus (McDonald, Hoffman and Nathanielsz, 1992) and fetal 
hypothalamo- pituitary disconnection (HPD : Antolovich, McMillen, Robinson, 
Silver, Young and Perry, 1991) also prevents normal maturation of the fetal 
corticotrophs in the anterior pituitary demonstrating the need for an intact 
hypothalamo- pituitary connection. It is possible that the influence of HPD and PVN 
lesion on corticotroph maturation reflects altered cortisol concentrations after these 
procedures. However, whilst PVN lesioned fetuses fail to show increased cortisol 
concentrations with advancing gestation (McDonald and Nathanielsz, 1991), 
Antolovich et al. (1991) reported that cortisol concentrations in HPD fetuses were 
not significantly different from those in sham -operated control fetuses. 
The intermediate lobe of the pituitary is a compact region of glandular epithelium 
that develops between the anterior and neural lobes. Melanotrophs of the 
intermediate pituitary secrete a- melanocyte stimulating hormone (a -MSH), 
corticotrophin -like intermediate peptide (CLIP) and acetylated ß- endorphin. 
Cytoplasmic differentiation of the pars intermedia cells is completed by day 100 
gestation. High levels of exocytosis and the presence of fenestrated capillaries, both 
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accepted morphologies of peptide secreting organs, have been demonstrated (Perry, 
Robinson and Ryan, 1982) although the intermediate lobe is less well vascularised 
than the anterior lobe. The same authors found a greater frequency of exocytosis in 
the intermediate lobe cells from late gestation fetal sheep compared to those of the 
adult intermediate lobe, suggesting that the peptides secreted by the intermediate 
lobe may have an important role in the fetus. Both stimulatory and inhibitory nerve 
terminals have been identified terminating directly on the epithelial cells of the 
intermediate lobe. Stimulatory 13- adrenergic (Tilders, Post, Jackson, Lowry, and 
Smelik, 1981) and serotonergic (Westlund and Childs, 1982) fibres have been 
identified in the intermediate lobe of the rat and GABAergic (Vincent, Hokfelt and 
Wu, 1982) and dopaminergic (Tilders and Smelik, 1978) fibres terminating in the 
intermediate lobe have been implicated in the inhibition of a -MSH release from 
melanotrophs. The intermediate lobe is prominent in many species during fetal 
development, including the human fetus. However, the intermediate lobe is not 
present in adult humans suggesting a specific role for the lobe during fetal 
development. 
2.2.4 Ontogeny of POMC gene expression 
Whether or not the increase in pituitary ACTH secretion seen in late gestation is 
accompanied by an increase in POMC gene expression is the subject of much 
interest. POMC is a polypeptide precursor gene that is processed to produce several 
biologically active peptides, including ACTH (Eipper and Mains, 1980). The 
corticotrophs of the anterior lobe and the melanotrophs of the intermediate lobe both 
express POMC. Differential post- translational processing of the POMC gene results 
in different peptides being found in these two cell types. ACTH and 13- lipotrophin 
are the major products of corticotrophs while melanotrophs synthesise a -MSH, 
CLIP and acetylated ß- endorphin. 
The differential processing of POMC in the anterior and intermediate lobes of the 
pituitary reflects the expression of POMC processing enzymes, prohormone 
convertase 1 (PC 1) and prohormone convertase 2 (PC2). PC 1 and PC2 are 
expressed exclusively in endocrine and neuroendocrine cells (Seidah, 
Marcinkiewicz, Benjannet, Gasper, Beaubien, Mattei, Lazure, Mbikay and Chrètien, 
1991). In the rodent pituitary PC2 is abundantly expressed in the intermediate lobe 
whilst PC1 expression dominates in the anterior lobe (Seidah et al., 1991; Hakes, 
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Birch, Mezey and Dixon, 1991). Cotransfection of POMC with PC1 and /or PC2 
into the constitutively secreting cell line BSC -40 and the endocrine tissue -derived 
cell lines PC12 and AtT -20 has shown that POMC cotransfected with PC1 alone 
generates the peptides of the anterior pituitary, notably ACTH whilst cotransfection 
with both PC1 and PC2 generated a -MSH and CLIP characteristic of intermediate 
lobe melanotrophs (Benjannet, Rondeau, Day, Chretien and Seidah, 1991). The 
role of PC2 in the additional processing of the POMC molecule in the intermediate 
pituitary has been demonstrated using the AtT -20 mouse corticotroph cell line. AtT- 
20 cells transfected with PC2 aquire the ability to perform the additional cleavage of 
the POMC molecule seen in intermediate pituitary melanotrophs (Zhou, Bloomquit 
and Mains, 1993). 
In the ovine fetus, POMC mRNA has been detected in the pituitary as early as day 
60 by Northern analysis (Yang, Challis, Han and Hammond, 1991; McMillen, 
Mercer and Thornburn, 1988). Reports describing ontogenic changes in POMC 
mRNA levels measured by Northern analysis in the late gestation ovine fetus have 
produced conflicting data, with some groups indicating a decline in levels at term 
(McMillen et al., 1988; Brooks, Currie, Gibson and Thomas, 1992), while others 
report an increase (Yang et al., 1991; Myers et al., 1993). Myers et al. (1993) 
employed the more sensitive technique of in situ hybridisation to investigate late 
gestation POMC expression and reported that POMC mRNA levels increase 
significantly between days 105 -107 gestation and days 138 -140 gestation. This late 
gestation increase in POMC gene expression mirrors that of CRH mRNA in the 
paraventricular nucleus and corresponds with the increase in plasma ACTH 
concentrations seen at this time. More recently, Matthews et al. (1994) have used in 
situ hybridisation to look at the ontogeny and distribution of POMC gene expression 
in the developing fetal sheep pituitary. They report that POMC mRNA is detectable 
by day 60 in both the anterior and the intermediate lobes of the pituitary and 
describe a regional distribution within the anterior pituitary. Levels of POMC 
mRNA in the inferior region (the area around the base of the gland) of the anterior 
pituitary rose during mid and late gestation whilst levels in the superior region (the 
area around the intermediate lobe) were unchanged throughout gestation. Levels of 
POMC mRNA in the intermediate lobe were higher than in the anterior and 
increased significantly in mid gestation. 
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2.2.5. Maturation of the fetal adrenal gland 
The adrenal glands of the fetal sheep are first recognisable at day 28 gestation and 
by day 60 two distinct zones are apparent in the fetal cortex (Webb, 1980). The fetal 
adrenal in the sheep has cortical zones similar to that of the adult in that there is no 
distinct 'fetal zone'. The outer zone has the morphological characteristics of the 
adult zona glomerulosa by day 80 whilst the inner zone cells remain 
morphologically immature until day 120 when the innermost cells begin to mature 
and develop the smooth endoplasmic reticulum and mitochondria with vesicular 
cristae characteristic of adult zona fasciculata cells (Robinson, Rowe and Wintour, 
1979). Progressively more cells of the zona fasciculata mature as gestation proceeds 
to term. The adrenal glands undergo a rapid phase of hypertrophy and hyperplasia 
in the last 14 days of gestation, at the same time as fetal plasma levels of cortisol 
start to rise. During this period the gland doubles in weight. These changes are 
dependant on ACTH from the fetal pituitary as they can be abolished by fetal 
hypophysectomy and restored by intrafetal infusion of ACTH (Liggins et al., 1973). 
The primate adrenal glands also exhibit a remarkable increase in weight in the final 
third of gestation (Pepe and Albrecht, 1990). The increase in weight of the primate 
growth of makes 
to 80% of the gland during fetal life. The primate fetal zone lacks 3 3- 
hydroxysteroid dehydrogenase (3ß -HSD) activity and therefore secretes mainly 
dehydroepiandrosterone sulphate (DHAS), the androgenic precursor for placental 
oestrogens. In the smaller adult zone there is an increase in 3ß -HSD activity late in 
gestation associated with a rise in serum cortisol concentrations. 
The capacity of the ovine fetal adrenal to secrete cortisol in response to ACTH 
follows a triphasic pattern such that the response before day 90 gestation and after 
day 120 gestation is much greater than in the intervening period of day 90 to 120 
gestation (Wintour, Brown, Denton, Hardy, McDougall, Oddie and Whipp, 1975; 
Glickman and Challis, 1980). The diminished capacity of the fetal adrenal to 
produce cortisol between day 90 and 120 gestation has been attributed to the very 
low levels of mRNA encoding the cytochrome P -450 steroid hydroxylase enzymes 
necessary for cortisol biosynthesis (Tangalatis, Coghlan, Connell, Crawford, 
Darling, Hammond, Haralambidis, Penschow and Wintour, 1989). These enzymes 
are ACTH -inducible and the low levels between day 90 and day 120 reflect low 
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circulating ACTH concentrations at this time. However, if ACTH levels are 
increased during this period by infusion of exogenous ACTH, the steroidogenic 
enzymes are activated (Tangalakis, Coghlan, Crawford, Hammond and Wintour, 
1990). It is also of interest that this period of reduced cortisol biosynthetic capacity 
is accompanied by the period of organisation and maturation of the adrenal cortex. 
Bilateral adrenalectomy of the fetus during the period of day 90 -day 120 gestation 
does not influence the circulating concentrations of cortisol in the fetal plasma 
(Wintour, Coghlan, Hardy, Hennessy, Lingwood and Scoggins, 1980) and it has 
since been demonstrated that all the cortisol present in the fetal plasma during this 
period can be accounted for by transplacental passage from the maternal circulation 
(Hennessy, Coghlan, Hardy, Scoggins and Wintour, 1982). The same workers have 
shown that as gestation proceeds the contribution of maternal cortisol to the fetal 
circulation diminishes illustrating the increased activity of the fetal adrenal gland. 
2.3. Functional maturation of the HPA axis 
The section which follows describes the development HPA function in the fetal 
sheep. Many of the studies regarding the functionality of the HPA axis have been 
carried out in adult animals and these will be discussed in the absence of any fetal 
data. Where data for the fetal sheep is unavailable reference has also been made to 
work carried out in other species. 
2.3.1 Hypothalamic control of ACTH secretion 
The critical role of the hypothalamus in the control of ACTH secretion has been 
demonstrated in hypothalamo -pituitary disconnected fetuses (Antolovich, Clarke, 
McMillen, Perry, Robinson, Silver and Young, 1990; Antolovich et al., 1991; 
Ozolins, Young and McMillen, 1992). HPD involves surgical disconnection of the 
pituitary from the hypothalamus by removal of the neural component of the median 
eminence above the level of the portal blood supply. In contrast to the previously 
used technique of pituitary stalk section, HPD does not disturb the blood supply of 
the pars tuberalis and therefore the amount of infarction following surgery is 
minimal (Antolovich et al., 1990). Prolactin release in response to thyrotrophin- 
releasing factor demonstrates the functional integrity of the pituitary following the 
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surgical procedure and the reduced response to chlorpromazine, a dopamine 
antagonist, indicates the disruption of hypothalamic input to the pituitary. After 
HPD, the preparturient surge in fetal ACTH concentrations is completely abolishes 
but surprisingly there is a significant increase in basal ACTH concentrations 
(Antolovich et al., 1991) although there is no corresponding increase in plasma 
cortisol levels. It is possible that this increase in basal ACTH originates from the 
pars intermedia since this region of the gland undergoes a marked hypertrophy 
following HPD (Antolovich et al., 1990). Parturition in HPD fetuses is delayed for 
at least 8 days beyond term demonstrating the need for an intact hypothalamo- 
pituitary axis in generating the preparturient cortisol rise and the onset of parturition 
in the fetal sheep. Ozolins et al., 1992 have further addressed the role of an intact 
hypothalamo- pituitary connection in pituitary- adrenal function and report that HPD 
prevents the normal pituitary- adrenal response to intrauterine hypoxemia and 
hypoglycaemia. More recently, Deayton et al. (1994) have used HPD at two 
different time points in late gestation (day 123 -127 and day 133 -135) to demonstrate 
that an intact hypothalamo- pituitary connection is required until at least day 135 of 
gestation for parturition to occur at the correct time point. 
Parturition in the fetal sheep can also be delayed by bilateral lesions to the 
hypothalamic paraventricular nucleus (McDonald and Nathanielsz, 1991). As in 
HPD fetuses, the preparturient surge in ACTH and cortisol was prevented and the 
fetuses were not delivered at term suggesting a critical role for the PVN in the 
sequence of events leading to parturition. 
The role of CRH and AVP in the release of ACTH from the anterior pituitary gland 
and subsequent cortisol release from the fetal adrenal gland has been extensively 
demonstrated in vivo (Brooks, Challis and Norman, 1987; Apostolakis, Longo and 
Yellon, 1991; Brooks and White, 1990) and in vitro (Durand, Cathaird, Dacheux, 
Naaman and Saez, 1986; Brooks et al., 1987; Lü, Yang and Challis, 1994). The two 
neuropeptides have been shown to act synergistically (Brooks and White, 1990; 
Norman and Challis, 1987a; Gillies, Linton and Lowry, 1982) such that concomitant 
administration of CRH and AVP results in a greater ACTH response than after CRH 
or AVP administered alone. The relative abilities of CRH and AVP to stimulate 
ACTH secretion appears to be species specific. In rats, CRH is the main ACTH - 
releasing factor (Vale, Vaughan, Smith, Yamamoto, Rivier and Rivier, 1983; 
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Familari, Smith, Smith and Funder, 1989) whereas in sheep AVP is the more potent. 
Intravenous injection of AVP elicits a greater ACTH response compared with CRH 
(Pradier, Davicco, Safwate, Tournaire, Dalle, Barlet and Delost, 1986) and in vitro 
responses of sheep anterior pituitary cells to AVP and CRH also reflect the more 
potent effects of AVP compared to CRH ( Familari et al., 1989; Brooks and Gibson, 
1992). The response of the fetal pituitary to hypothalamic factors is greater earlier 
in gestation (Durand et al., 1986), a response that is seen to decline with advancing 
gestational age (Brooks and White, 1990; Norman and Challis, 1987a). The greater 
response to AVP in the sheep may reflect the number of receptors present in the 
anterior pituitary since membrane binding studies have shown that the adult sheep 
pituitary gland contains twice as many AVP receptors as the rat but only one tenth of 
the number of CRH receptors (Shen, Clarke, Canny, Funder and Smith, 1990). 
The decline in responsiveness of the pituitary to hypothalamic stimulation at a time 
when ACTH secretion into the fetal plasma is increasing is puzzling. It is possible 
that the decline in pituitary responsiveness is a function of the increased levels of 
glucocorticoids in the fetal plasma at this time which negatively feedback to inhibit 
the pituitary or that the pituitary is desensitised by increasing exposure to 
hypothalamic stimulation. Desensitisation in response to repeated stimulation with 
CRH and AVP has been demonstrated in perifusion culture with the ACTH response 
to repeated pulses of CRH and AVP declining with time (Evans, Brett, McIntosh, 
McIntosh, McLay, Livesey and Donald, 1988). Desensitisation to each 
secretogogue occurred independently of the other. Desensitisation induced by 
repeated stimulation with one secretagogue could be overcome by administration of 
the other, thus, when the ACTH response to CRH was diminished a single pulse of 
AVP resulted in a considerably greater response of ACTH. Rat pituitary cells 
cultures treated with CRH display a reduced response to subsequent stimulation 
which is accompanied by a reduced ability of CRH to stimulate cAMP production. 
This implies that desensitisation results from CRH receptor down regulation or 
uncoupling of the CRH receptor from adenylate cyclase (Hoffman, Ceda and 
Reisine, 1985). When fetal sheep were given pulses of CRH and/or AVP every 4 
hours, there was a decline in ACTH response which was negatively correlated with 
increased basal concentrations of cortisol. No evidence for desensitisation could be 
found since dispersed pituitary cells prepared from fetuses treated with CRH pulses 
in vivo had a greater accumulation of cAMP compared with controls (Brooks et al., 
Chapter 2 Literature Review 15 
1987). This suggests that stimulated ACTH secretion is tightly regulated by cortisol 
feedback mechanisms. In support of this hypothesis, Norman and Challis (1987b) 
found that treatment of day 113 -116 fetuses with dexamethasone prior to 
concomitant injection of CRH plus AVP did not affect the basal values of ACTH but 
significantly suppressed the CRH plus AVP -stimulated release of ACTH. In day 
126 -130 fetuses, both basal and stimulated responses were suppressed. This study 
illustrates the development of glucocorticoid feedback mechanisms influencing 
pituitary responsiveness in late gestation and suggests that different mechanisms 
may be employed for the control of basal and stimulated release of ACTH. The 
number of CRH binding sites in membrane preparations from the fetal sheep 
anterior pituitary follows a similar time -course to the changes in responsiveness of 
the pituitary such that the number of binding sites increases from day 70 to reach a 
maximum at day 125 -130 before levels decline towards term (Lü, Yang and Challis, 
1991). The reduced number of binding sites may contribute to the reduction in 
pituitary responsiveness at this time. 
Despite the well documented role of CRH and AVP in the release of ACTH from the 
fetal pituitary, pulsatile infusion of CRH or AVP or a combination of CRH plus 
AVP does not induce premature delivery (Brooks and White, 1990). In contrast, 
continuous infusion of a high dose of CRH to fetuses at day 125 gestation has been 
reported to induce premature delivery (Wintour, Bell, Carson, MacIsaac, Tregear, 
Vale and Wang, 1986) suggesting that the dose and mode of administration are 
important factors. However, in this study maternal progesterone concentrations did 
not decrease in the manner that normally precedes delivery suggesting that the 
processes of birth in this case are not comparable to the normal situation. 
2.3.2. Maturation of adrenal sensitivity to ACTH 
As well as increased drive from the hypothalamus to increase circulating ACTH 
concentrations, the increase in fetal plasma cortisol concentrations late in gestation 
can also be accounted for by increased adrenal sensitivity to ACTH at this time 
(Wintour et al., 1975; Manchester and Challis, 1982). Rose et al. (1982) examined 
the effect of injection of ACTH1_24 at three time points in gestation on fetal plasma 
cortisol concentrations and report an increase in adrenal response to ACTH between 
day 115 gestation and term. The mechanism by which adrenal sensitivity in late 
gestation is increased has yet to be elucidated however, the correlation with 
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increasing plasma cortisol levels at this time has led to the suggestion that cortisol 
itself is involved in the adrenal activation process. Increased cortisol production 
from fetal adrenal cells, either spontaneously in late gestation (Durand, Cathaird, 
Morera, Dazard and Saez, 1981) or in response to ACTH1_24 (Durand, Cathaird, 
Locatelli, Dazard and Saez, 1981) is associated with increased production of cAMP. 
Adrenal cells isolated following concomitant in vivo administration of metopirone, 
an 1113- hydroxylase inhibitor and ACTH1_24 do not respond to in vitro ACTH 
challenge with cAMP accumulation and increased cortisol output, as is the case 
following in vivo administration of ACTH alone (Lye and Challis, 1984). Moreover, 
glucocorticoid administration, together with ACTH plus metopirone restores adrenal 
cell response to ACTH (Challis, Huhtanen, Sprague, Mitchell and Lye, 1985). The 
time of increased adrenal responsiveness to ACTH correlates with an increased 
number of ACTH receptors between day 140 and term (Durand, 1979; Durand, 
Cathiard and Saez, 1985). 
These studies suggest that cortisol functions locally in a paracrine and /or autocrine 
manner to enhance the action of ACTH on the fetal adrenal. In this way, increasing 
cortisol levels in late gestation could be positively regulating the sensitivity of the 
adrenal gland resulting in a further elevation of plasma cortisol levels. 
The effect of cortisol on adrenal sensitivity to ACTH is mediated by glucocorticoid 
receptors (GR) found in the adrenal cortex (Yang and Challis, 1989). The 
expression of GR in the adrenal cortex is developmentally regulated such that GR 
number in the adrenal increases significantly at day 100 -110, decreases at day 125- 
130 and increases again at term (Yang and Challis, 1989). Regulation must occur at 
a post -transcriptional level since the abundance of GR mRNA in the adrenal does 
not change with gestation (Yang, Hammond and Challis, 1992). 
As well as being responsive to ACTH, the fetal adrenal gland may be influenced by 
other factors. The presence of ACTH -like peptides in the fetal pituitary (Silman et 
al., 1979) raises the possibility that these peptides may also be trophic to the adrenal 
gland. Of the POMC- derived peptides of the pituitary, a -MSH from the 
intermediate lobe has been shown to stimulate cortisol secretion both in vivo in fetal 
sheep, newborn lambs (Llanos, Ramachandran, Creasy, Rudolph and Serón -Ferré, 
1979; Glickman, Carson and Challis, 1979) and rabbits (Challis and Torosis, 1977) 
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and from fetal sheep and human adrenal cells in culture (Glickman et al., 1979; 
Baird, Kan and Solomon, 1983). This has led to the suggestion that a -MSH is a 
trophic factor for the adrenal gland and may contribute to the increasing cortisol 
concentrations seen in the late gestation fetus. Notably, the stimulatory effect of a- 
MSH on fetal sheep adrenal cells occurs at a time before the gland is responsive to 
ACTH and could not be reproduced using adult cells (Glickman et al., 1979), 
suggesting a fetal specific mode of action. a -MSH has been identified in fetal sheep 
plasma in concentrations which are significantly higher than in the adult (Newman, 
Wardlaw, Stark, Daniel and Frantz, 1987), again alluding to an intrauterine role. 
However, whilst this evidence points towards a role for a -MSH in the control of 
steroidogenesis, there are a number of conflicting reports concerning the action of a- 
MSH. Glickman et al. (1979) report that a -MSH and ACTH are equipotent in 
stimulating the secretion of cortisol from human fetal adrenal cells. However, 
Branchault et al. (1978) were only able to stimulate cortisol production using a- 
MSH concentrations 1000 times greater than ACTH. The low potency of a -MSH in 
eliciting a steroidogenic response from adrenal cells has also been described 
elsewhere (Baird et. al., 1983). In this study, Baird and co- workers report a 
differential effect of a -MSH on cortisol and dehydroepiandrosterone (DHAS) 
secretion by human fetal adrenal cells in culture such that high concentrations of a- 
MSH elicit release of both cortisol and DHAS but lower concentrations stimulate 
only DHAS secretion suggesting that the intensity of the signal from the pituitary is 
important in the regulation of adrenal steroidogenesis. a -MSH has also been shown 
to stimulate DNA synthesis in the fetal adrenal (Rudman, Hollins, Lewis and 
Chawla, 1980) suggesting a role in adrenal growth. 
The fragments resulting from cleavage of the N- terminal portion of the POMC 
molecule (N -POMC 1 -77) have been implicated in adrenal growth in the rat 
(Estivariz, Iturriza, McLean, Hope and Lowry, 1982). These fragments act as potent 
stimulators of DNA synthesis and mitogenesis, whilst the intact precursor, N -POMC 
1 -77 has been shown to potentiate the action of ACTH on adrenal gland RNA 
synthesis (Al- Dulaili, Williams, Edwards, Salacinski and Lowry, 1982). The 
possibility that N- terminal fragments of POMC may influence the developing 
adrenal gland led Saphier et al. (1993) to investigate the concentrations of N- 
terminal POMC and the cleavage product y3 -MSH in the plasma of late gestation 
fetal sheep. The y -MSH fragment has been shown to activate cholesterol ester 
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hydolase (Pedersen, Brownie and Ling, 1980), an enzyme of the corticosteroid 
biosynthesis pathway. Saphier and co- workers found relatively high concentrations 
of N -POMC in the fetal plasma compared to ACTH. Levels of N -POMC declined 
towards term, coincident with increasing ACTH concentrations, although the 
concentration of N -POMC on a molar basis was always greater that for ACTH, 
leading the authors to suggest that much of the N -POMC was of intermediate lobe 
origin. The decline in N -POMC concentrations was accompanied by an increase in 
circulating y3 -MSH concentrations suggesting that N -POMC is further processed to 
its constituent fragment with advancing gestation. 
The extent to which POMC- derived peptides other than ACTH are involved in the 
preparturient cortisol surge remains to be determined. However, the evidence 
presented above suggests that the fetal intermediate lobe could be of fundamental 
importance in the maturation of the fetal adrenal and the late gestation drive in 
adrenal stimulation necessary for the initiation of parturition. 
The relative importance of increasing ACTH concentrations as a result of increased 
hypothalamic drive to the pituitary and increased sensitivity of the adrenal gland to 
ACTH in the initiation of parturition is unclear. To address this issue, Jacobs et al. 
(1994) administered a constant low dose of ACTH to hypophysectomised fetal 
lambs to determine whether increasing plasma ACTH concentrations or increased 
adrenal sensitivity to ACTH was the more potent stimulus for initiation of 
parturition. The hypophysectomised fetuses receiving low dose ACTH from day 
125 gestation delivered at the same time as the intact controls. Hypophysectomised 
lambs that did not receive the ACTH infusion showed no rise in cortisol and failed 
to deliver at term. The preparturient rise in cortisol concentrations in the ACTH 
treated fetuses mimicked that of intact non -infused controls. These data confirm the 
obligatory role of ACTH in driving cortisol secretion from the fetal adrenal gland 
but also suggest that an increase in adrenal sensitivity to ACTH in late gestation is 
important for the preparturient rise in cortisol and the initiation of parturition at the 
normal time. 
Therefore, the fetal adrenal gland displays increased sensitivity to ACTH in late 
gestation. The mechanism for increased sensitivity is not yet clear however, it is 
likely that cortisol itself is involved in priming the adrenal to exhibit increased 
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responsiveness to ACTH (Darbeiba and Durand, 1987; Challis and Hooper, 1989). 
The contribution of other pituitary factors to adrenal steroidogenesis and their 
relevance to parturition remains to be determined. 
2.4. Glucocorticoid negative feedback 
Glucocorticoids from the fetal adrenal gland act through a classical negative 
feedback loop to influence the HPA axis at the level of both the pituitary and the 
hypothalamus. Glucocorticoid inhibition of CRH and AVP secretion from the 
hypothalamus has been demonstrated in vitro from hypothalamic neurons (Clarke 
and Gillies, 1988; Currie, Gillies and Brooks, 1994) and from perifused hypothalami 
(Brooks et al., 1989). In vivo, the negative effects of glucocorticoids have been 
demonstrated by employing the technique of bilateral adrenalectomy, thereby 
removing the source of endogenous glucocorticoids and allowing an escape from the 
constraints of negative feedback. In contrast, exogenous glucocorticoids are often 
used in whole animal experiments to replace or add to the endogenous hormone. 
Adrenalectomy of the adult rat results in increased immunostaining for CRH and 
AVP in the hypothalamus and this increase can be prevented by insertion of 
glucocorticoid implants around the paraventricular nucleus (Kovacs, Kiss and 
Makara, 1986). These dexamethasone implanted rats are unable to produce the 
increased plasma ACTH levels in response to hypotension as seen in control 
animals. Dexamethasone implants placed near the ovine fetal PVN at day 108 -111 
gestation also resulted in decreased CRH immunostaining in the PVN and 
eliminated CRH immunostaining in the median eminence. Similarly, AVP 
immunostaining in the median eminence was eliminated, although no effect was 
seen at the level of the PVN (McDonald, Hoffman, Myers and Nathanielsz, 1990). 
Glucocorticoid effects on the expression of CRH and AVP mRNA in the PVN has 
also been investigated. Adrenalectomy of adult rats results in increased expression 
of prepro -CRH mRNA, the precursor of CRH in the PVN and this effect can be 
abolished by glucocorticoid replacement (Jingami, Matsukura, Numa and Imura, 
1985). Similar effects on AVP mRNA have been reported (Davies, Arentzen, Ried, 
Manning, Wolfson, Lawrence and Baldino, 1986). Adrenalectomy of ovine fetuses 
at day 116 -121 gestation results in significantly increased levels of CRH gene 
expression (McMillen, Antolovich, Mercer, Perry and Silver, 1990; Myers, Ding and 
Nathanielsz, 1991) whilst dexamethasone implants inserted adjacent to the PVN 
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suppress expression of CRH mRNA (Myers, McDonald, Dunn, Moss and 
Nathanielsz, 1992). These data illustrate the ability of the fetal PVN to respond to 
glucocorticoid negative feedback both with altered gene expression and peptide 
secretion. 
The negative feedback regulation of glucocorticoids has also been demonstrated at 
the level of the pituitary gland. CRH and AVP- induced ACTH secretion in late 
gestation fetal sheep is suppressed by administration of exogenous glucocorticoids 
(Norman and Challis, 1987b). Similarly, pre- treatment of pituitary cell cultures 
from day 125 gestation fetuses with cortisol for 3 days significantly inhibits the 
ACTH response to CRH stimulation (Brooks, Howe, Porter and Naylor, 1994). 
Wintour et al. (1980). adrenalectomised fetuses at day 90 -127 gestation in order to 
study the feedback mechanism between the adrenal and the pituitary gland and were 
the first to report an increase in plasma ACTH concentrations following 
adrenalectomy in the fetal sheep. Elevated plasma ACTH concentrations following 
adrenalectomy have since been described by others (McMillen et al., 1990; Myers et 
al., 1991). The glucocorticoid inhibition the pituitary is also reflected in the 
modulation of POMC mRNA in response to glucocorticoid manipulation. The 
increase in plasma fetal adrenalectomy (Wintour 
al., 1980) is accompanied by significantly increased levels of POMC mRNA in the 
anterior pituitary (McMillen et al., 1990; Myers et al., 1991). Studies in the adult rat 
have shown that POMC gene expression is increased in response to adrenalectomy 
and decreased by treatment with dexamethasone (Jingami et al., 1985; Birnberg, 
Lissitzky, Hinman and Herbert, 1983; Lundblad and Roberts, 1988). Bruhn et al. 
(1984) demonstrated that the increase in POMC mRNA that occurs following 
adrenalectomy is dependant upon the hypothalamus. The paraventricular nucleus of 
adrenalectomised rats was destroyed to determine whether the increase in POMC 
levels following adrenalectomy was dependant upon PVN production of 
hypothalamic releasing factors. The abundance of POMC mRNA in the PVN 
ablated rats was significantly lower than adrenalectomised controls illustrating the 
need for an intact PVN in mediating the increase in POMC mRNA normally 
associated with adrenalectomy. 
Therefore, circulating glucocorticoids can feedback at the level of the hypothalamus 
and the pituitary. The increases in CRH mRNA following adrenalectomy and the 
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reduced POMC response in PVN lesioned animals suggests that glucocorticoid 
effects at the pituitary result from action at the hypothalamus. However, 
glucocorticoids can suppress anterior pituitary POMC gene expression in 
hypothalamo- pituitary disconnected adult sheep (Mercer, Clements, Clarke and 
Funder, 1989) suggesting that glucocorticoid negative feedback can act directly at 
the level of the pituitary. In support of the direct effects of glucocorticoids on 
pituitary POMC expression, a specific region of the POMC gene promoter has been 
identified which contains a binding site for the glucocorticoid receptor (Drouin, Sun 
and Nemer, 1989). Drouin and co- workers reasoned that the high level of pituitary 
expression of POMC is likely to involve DNA sequences that confer tissue 
specificity. They utilised transgenic mice to demonstrate that the 51- flanking region 
of the POMC gene was responsible for pituitary specificity (Trembley, Tretjakoff, 
Peteson, Antakly, Zhang and Drouin, 1988). Glucocorticoids influence gene 
transcription via specific glucocorticoid response elements (GRE) which bind 
glucocorticoid receptor. In the case of the POMC gene promoter, the glucocorticoid 
receptor binding site acts to suppress transcription and has been termed the negative 
glucocorticoid response element (nGRE : Drouin et al., 1989). It is possible that GR 
binding to the nGRE prevents the binding of a factor necessary for POMC 
transcription. To this end, Drouin et al. (1989) demonstrated that members of the 
DNA -binding transcription factor family COUP could effectively compete with GR 
for the binding site. Thus, it appears that binding of GR to the nGRE of the POMC 
promoter represses transcription of the POMC gene and therefore provides a 
mechanism by which glucocorticoids negatively feedback at the level of the pituitary 
to influence POMC expression. However, the reason why GR should act as an 
inhibitor to transcription in this case when it is a transcription factor in other tissues 
remains to be determined. 
2.4.1. Overcoming negative feedback 
Despite this apparent negative feedback system, ACTH and cortisol concentrations 
rise concomitantly in the final 15 -20 days gestation The mechanism by which the 
fetus is somehow able to overcome the negative influences of rising glucocorticoid 
concentrations has been the subject of intense investigation. This section will look 
at some of the potential explanations for how this phenomenon may occur. 
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Increased hypothalamic drive 
It is likely that a major factor involved in producing increased plasma ACTH 
concentrations is an upregulation of the hypothalamus such that the drive to the 
pituitary is increased and is able to overcome the negative feedback effects of rising 
cortisol concentrations. A definitive answer to this problem can only be provided by 
direct measurement of CRH and AVP concentrations in the fetal portal blood 
supply. Despite the success of portal blood sampling in the adult sheep, the 
technique has yet to be applied to the fetus. As a result of the inability to directly 
measure hypothalamic secretions to the portal blood, a number of indirect methods 
have been utilised in an attempt to tackle the problem. 
Immunocytochemical staining for the immediate -early gene c -fos as a sign of 
neuronal activity has demonstrated the stimulation of CRH neurons at the time of 
parturition (Hoffman, McDonald, Shedwick and Nathanielsz, 1991). At the time of 
active labour, 70% of the CRH neurons in the PVN expressed c -fos. Interestingly, 
these workers observed a population of PVN neurons which were activated during 
labour that did not contain CRH. Whilst there identity remains to he determined, it 
is likely that they are AVP neurons. 
Despite the demonstration of the negative influence of cortisol on CRH and POMC 
gene expression described above, both CRH and POMC mRNA levels are 
significantly increased in late gestation (Myers et al., 1993). This increase in CRH 
gene expression in late gestation is associated with an increase in hypothalamic 
content of immunoreactive CRH from day 100 gestation to day 135 gestation 
(Brooks et al., 1989). CRH release from perfused hypothalamic pieces is greater in 
day 140 gestation pieces compared to day 100 pieces (Brooks et al., 1989) 
supporting the theory of increased hypothalamic drive. However, dexamethasone 
inhibition of CRH release was greater at day 140 gestation than at day 100 gestation 
suggesting, if anything a greater negative feedback effect in late gestation. 
In contrast, dexamethasone implants placed directly adjacent to the PVN display a 
reduced capacity to suppress basal CRH mRNA with increasing gestational age 
(Myers et al., 1992) thus providing a mechanism whereby continued hypothalamic 
drive to the pituitary may occur in the presence of elevated cortisol. The 
mechanisms by which this apparent escape from the constraints of negative feedback 
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are mediated remains to be determined. CRH neurons have been identified in rats 
that do not appear to express glucocorticoid receptor (Agnati, Fuxe, Yu, Harfstrand, 
Okret, Wilkstrom, Goldstein, Soli, Vale and Grustafsson, 1985) suggesting that 
some CRH neurons are outside the negative feedback loop. Myers et al. (1993) 
identified a subset of CRH mRNA containing neurons that continue to express CRH 
when the overall expression level has fallen. It would be of interest to discover if 
this population of neurons are also devoid of glucocorticoid receptors. This subset 
of CRH neurons could provide the fundamental drive to the pituitary necessary for 
parturition to occur and certainly, ablation of the paraventricular nucleus in which 
the CRH neurons reside prevents the preparturient surge in adrenocortical activity 
(McDonald and Nathanielsz, 1991). 
Altered responsiveness to glucocorticoids 
Another possible way in which the late gestation fetus overrides the negative 
feedback influence of cortisol is by altering the sensitivity of the pituitary to 
circulating cortisol levels. Infusion of increasing concentrations of cortisol to fetal 
sheep (day 132 -142 gestation) does not result in decreased response of nitroprusside- 
induced ACTH release which one might expect if the negative feedback system was 
performing as it does earlier in gestation (Wood, 1988). However, fetal sheep of 
gestationarages between 121 days and 131 days infused with cortisol do show a 
dose -dependant inhibition of ACTH release (Wood and Rudolph, 1983) suggesting 
that there is an alteration in the negative feedback threshold at around day 132 
gestation. A similar maturation in the response to nitroprusside- induced ACTH 
release in the presence of cortisol has been demonstrated by others (Hargrave and 
Rose, 1985; Dix, Rose, Mavis, Hargrave and Meis, 1984). However, the ACTH 
response to hypotension requires an intact PVN (McDonald, Rose, Figueroa, 
Gluckman and Nathanielsz, 1988) suggesting that the altered effects of negative 
feedback described by Wood and others reflects a change in responsiveness at a 
level above that of the pituitary, such as the PVN. The role of the PVN in the 
development of cortisol negative feedback has been investigated using HPD fetuses. 
After day 138 gestation, cortisol infusion significantly decreased basal ACTH 
concentrations in intact fetuses but had no effect in HPD fetuses (Ozolins, Young 
and McMillen, 1990). This implies that an intact hypothalamo -pituitary connection 
is necessary for the development of cortisol negative feedback on basal ACTH 
concentrations. In contrast, ACTH release in response to CRH was abolished in 
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both intact and HPD fetuses following cortisol infusion. Therefore, it seems that the 
negative feedback effects of cortisol on CRH- induced ACTH release can occur 
directly at the level of the pituitary whilst control of basal ACTH concentrations 
occurs within the hypothalamus. The study of Ozolins et al. (1990) is at odds with 
that of Wood and co- workers (1988) with respect to the negative influences of 
cortisol on baseline ACTH values. Whereas Ozolins et al. (1990) demonstrate an 
inhibitory effect of cortisol on basal ACTH concentrations in day 138 -140 gestation 
fetuses, Wood (, 1988) was unable to demonstrate any negative influence of cortisol 
on basal ACTH concentrations between day 132 and 142 gestation. This is in 
accordance with the work of Myers et al. (1992) who report no effect of 
dexamethasone implants to the PVN on basal ACTH levels whilst demonstrating a 
reduction in feedback efficacy with advancing gestational age. 
The alteration in responsiveness to glucocorticoids may reflect a change in the 
expression of glucocorticoid receptors in the developing fetus. The number of 
glucocorticoid receptors in the fetal pituitary and hypothalamus rises dramatically 
between day 60 -70 and day 100 -110 gestation before falling until day 125 -130 
gestation (Yang, Jones and Challis, 1990). GR number in the pituitary then 
increases at those of the 
abundance of GR mRNA in the pituitary and hypothalamus, measured by Northern 
blot analysis, does not change throughout gestation (Yang et al., 1992). More 
recently, in situ hybridisation studies revealed an increase in GR mRNA 
immediately prior to parturition (Matthews, Yang and Challis, 1995) which was 
unaffected by cortisol infusion. Thus, glucocorticoids do not directly regulate the 
expression of GR mRNA in the pituitary and hypothalamus. Perhaps more 
importantly, the up- regulation of GR mRNA and receptor number at term suggests 
that GR availability in late gestation is not limited by increasing cortisol levels. 
These data are therefore inconsistent with the hypothesis of limited GR availability 
as a mechanism by which the negative feedback of effects of glucocorticoids are 
reduced. 
Modulation of circulating cortisol concentrations 
The late gestation increase in cortisol concentrations are mirrored by a parallel 
increase in the high affinity binding protein for cortisol, corticosteroid binding 
globulin (CBG) in fetal plasma (Fairclough and Liggins, 1975; Ballard, Kitterman, 
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Bland, Cylman, Gluckman, Platzker, Kaplan and Grumbach, 1982). A similar 
increase in CBG can also be in preterm labor induced by pulsatile administration of 
ACTH (Challis, Nancekievill and Lye, 1985). The major site of CBG production in 
the fetus is the liver (Berdusco, Yang, Hammond and Challis, 1995) although the 
fetal pituitary also produces CBG. CBG mRNA in the fetal liver increases 
significantly from day 125 to day 140 and then declines at term. Glucocorticoid 
infusion to fetuses increases the abundance of CBG mRNA in the liver and increases 
the corticosteroid binding capacity of fetal plasma (Berdusco, Hammond, Jacobs, 
Grolla, Akagi, Langlois and Challis, 1993; Berdusco, Milne and Challis, 1994). 
Thus, cortisol may regulate its own availability in fetal plasma by modulating the 
production of CBG and therefore the concentrations of free cortisol in the fetal 
circulation. 
ACTH from another source 
The problem of rising plasma ACTH concentrations in the face of elevated cortisol 
concentrations late in gestation could be accounted for, at least in part if the ACTH 
in the fetal plasma was to come from a source other than the anterior pituitary. The 
intermediate lobe of the pituitary is one such possible source. The intermediate lobe 
of many species is well developed in fetal life and intense immunocytochemical 
staining for ACTH has been demonstrated in the fetal sheep pars intermedia 
(Mulvogue et al., 1986; Matthews et al., 1994). Rat neurointermediate lobes in 
superfusion culture secrete an ACTH -like peptide that is biologically active when 
added to an adrenal cortical cell suspension (Tilders et. al., 1981). Similarly, 
dispersed pars intermedia cells in vitro respond to hypothalamic extracts by 
releasing an ACTH -like activity (Kraicer and Morris, 1976) which has proved to be 
high molecular weight ACTH (Kraicer, Elliot and Zimmerman, 1978). More 
recently, Kraicer et al. (1985) have demonstrated the release of bioactive ACTH 
from perfused rat intermediate lobes in response to CRH. Abundant CRH 
immunoreactivity has been demonstrated in the neurohypophysis (Burlet, Tonon, 
Tankosic, Coy and Vaudry, 1983) and this would be an appropriate pathway for 
hypothalamic AVP and CRH to directly influence the release of intermediate lobe 
peptides. This pathway is made more likely due to the largely avascular nature of 
the intermediate lobe. CRH receptors have been identified on the melanotrophs of 
the intermediate lobe CRH (Aguilera, Millan, Hauger and Catt, 1987; De Souza and 
Kuhar, 1986). The levels of CRH peptide within the nerve terminals of the neural 
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lobe are significantly increased by adrenalectomy (Jeandal, VanDorsselaer, Lutz - 
Butcher and Koch, 1987) and decreased following pituitary stalk section (Saavedra, 
Rougeot, Culman, Israel, Niwa, Tonon, Vaudry and Dray, 1984). Osmotic stress 
also results in increased neurointermediate lobe content of CRH (Jessop, Eckland, 
Todd and Lightman, 1989). Thus it appears that the neurointermediate lobe, of the 
rat at least contains an ACTH -like factor that is biologically active and is released in 
response to CRH stimulation. It is interesting to speculate that this intermediate lobe 
peptide may provide additional drive to the adrenal gland in late gestation thereby 
contributing to the pre -parturient surge in cortisol. 
Thus, there are many ways in which the fetus can overcome the negative feedback 
influences of cortisol on the HPA axis and evidence exists for possible mechanisms 
at all levels of the axis. It is likely that no single mechanism exists to overcome 
negative feedback, but rather the fetus employs a combination of mechanisms, 
including those described above, in order to escape from the constraints of negative 
feedback, thus providing the endocrine environment resulting in the onset of 
parturition. 
2.5. Dopaminergic regulation of the pituitary gland 
The synthesis and release of pituitary hormones is under a complex hypothalamic 
regulatory system which comprises both stimulatory and inhibitory factors. The 
catecholamine, dopamine is a neurotransmitter in the mammalian brain that acts as a 
neurohormone at the pituitary gland where it conveys a largely inhibitory influence. 
The section which follows describes the dopaminergic system which influences 
pituitary function and reviews the role of dopamine in the regulation of prolactin and 
POMC- derived peptide secretion from the pituitary gland. 
2.5.1. Dopaminergic neurons of the hypothalamus 
Dopaminergic neurons of the mammalian brain are classified according to the 
location of their cell bodies and axon terminals. Accordingly, the dopaminergic 
neurons of the mediobasal hypothalamus are divided into two major groups, the 
tuberoinfundibular (TIDA) and the tuberohypophysial (THDA) neurons. TIDA 
neurons originate in the rostro- caudal portion of the arcuate nucleus, corresponding 
to the Al2 cell group of Dahlsröm and Fuxe (1964). The axons of the TIDA 
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neurons terminate in the external zone of the median eminence where dopamine is 
released into the portal blood supply. Dopaminergic terminals are abundant in the 
external zone of the median eminence, where they make up to one third of all 
terminals (Ben- Jonathan, 1985). THDA neurons also arise in the Al2 cell group of 
the rostral arcuate nucleus, although the distribution of these neurons is less widely 
spread than that of the TIDA neurons. The THDA neurons project to the 
neurointermediate lobe of the pituitary. In the neural lobe, the dopamine axon 
terminals are found in close proximity with magnocellular axon terminals and 
precapillary spaces and it has been suggested that the dopamine acts to modulate the 
secretion of the magnocellular hypothalamic hormones from the axons terminating 
in the posterior pituitary (Holzbauer and Rackè, 1985). The axons innervating the 
intermediate lobe make close contact with melanocytes. By contrast, the anterior 
pituitary is highly vascularised but very poorly innervated. 
More recent evidence suggests that the dopaminergic neurons terminating in the 
intermediate lobe do not arise from the arcuate nucleus as was previously thought, 
but rather they originate in the periventricular nucleus (A14 cell group of Dahisröm 
and Fuxe). Injection of the rat neurointermediate lobe with the retrograde tracer 
horse radish peroxidase results in labelling of tyrosine -hydroxylase immunopositive 
cells in the periventricular nucleus (Luppi, Sakai, Salvert, Berod and Jouvet, 1986; 
Kawano and Daikoku, 1987). However, the same technique does not label cells in 
the arcuate nucleus (Luppi et al., 1986; Kawano and Daikoka, 1987; Kelly and 
Swanson, 1980). Similarly, tyrosine hydroxylase immunostaining (Davies, 
Lichtensteiger, Schlumph and Bruink, 1984) and dopamine content (Dawson, 
Valdes and Annau, 1985) of the pituitary are unaffected following the destruction of 
dopaminergic neurons of the arcuate nucleus by administration of the neurotoxin 
monosodium glutamate which causes selective destruction of the retinal and arcuate 
nuclear neurons (Nemeroff, Konkol, Bissette, Youngblood, Martin, Brazeau, Rone, 
Prange, Breese and Kizer, 1977). A greater insight into the innervation of 
intermediate lobe melanocytes comes from the demonstration that surgical isolation 
of the periventricular nucleus from the mediobasal hypothalamus results in a 50% 
decrease in the levels of dopamine and the dopamine metabolite 3,4- 
dihydroxyphenylacetic acid (DOPAC) extracted from the intermediate lobe 
(Goudreau, Lindley, Lookingland and Moore, 1992). The decrease in dopamine 
content is accompanied by an increase in plasma concentrations of a -MSH. 
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Conversely, plasma a -MSH can be decreased by electrical stimulation of the 
periventricular nucleus. This study suggests that up to 50% of the dopaminergic 
neurons innervating the intermediate lobe arise in, or project through the 
periventricular nucleus. It also demonstrates the negative influence of the 
dopaminergic neurons on the secretion of a -MSH. Injection of the periventricular 
nucleus with the anterograde tracer Phaseolus vulgaris leucoagglutinin (PHA -L) and 
the subsequent analysis of terminals in the intermediate and neural lobes for tyrosine 
hydroxylase and PHA -L has shown that periventricular dopaminergic neurons 
innervate the intermediate lobe but not the neural lobe of the pituitary (Goudreau, 
Falls, Lookingland and Moore, 1995). The possibility that dopaminergic neurons 
innervating the intermediate lobe arise in the periventricular nucleus rather than the 
arcuate nucleus as previously thought means that some of the initial observations 
regarding dopaminergic regulation of the intermediate lobe, particularly those 
involving ablation of the arcuate nucleus must be interpreted with caution. 
Thus, dopaminergic neurons of the mediobasal hypothalamus exist as two distinct 
populations. The tuberoinfundibular neurons terminate at the level of the median 
eminence where they release dopamine into the hypophysial portal blood, and are 
responsible for the dopaminergic regulation of the anterior pituitary gland. By 
comparison, the tuberohypophysial neurons (or tuberoperiventricular neurons) 
directly innervate and regulate the neural and intermediate lobes of the pituitary 
gland. 
2.5.2. The dopamine receptor family 
The physiological effects of dopamine on the pituitary gland are mediated via 
dopamine interaction with the pituitary dopamine receptor. The pituitary dopamine 
receptor is one of a family of multiple dopamine receptor subtypes. Dopamine 
receptors are classically placed in two distinct categories, D1 -like and D2 -like 
receptors (Kebabian and Calne, 1979) according to pharmacological and 
biochemical criteria. Generally, Dl receptors activate cAMP coupling to second 
messenger systems and are antagonised by ergot derivatives such as bromocriptine 
whilst D2 receptors inhibit adenylate cyclase activity and are potently activated by 
bromocriptine. The knowledge that dopamine receptors were coupled to guanine 
nucleotide regulatory proteins (G- proteins) (Vallar and Melddesi, 1989) led to their 
molecular characterisation. Homology screening of the G- protein coupled receptor 
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superfamily has allowed identification of multiple dopamine receptor subtypes. To 
date, five structurally different dopamine receptors have been identified using 
molecular cloning techniques. D3 and D4 receptors are most closely related to D2, 
although each has a distinct morphological profile and D5 receptor is similar to D1 
in that it stimulates adenylate cyclase activity but it has a higher affinity for 
dopamine. The rat D2 dopamine receptor was identified using homologous 
sequences to the hamster f3-adrenergic receptor, a member of the G- protein coupled 
receptor superfamily (Bunzow, VanTol, Grandy, Albert, Salon, Christie, Machida, 
Neve and Civelli, 1988) and was found to be abundant in brain and pituitary tissue. 
The pituitary D2 receptor can exist as two isoforms (Eidne, Taylor, Zabavnik, 
Saunders and Inglis, 1989; Giros, Martres, Sokoloff, Riou, Emorine and Schwartz, 
1989), a long and a short form that differ by the insertion of 29 amino acids within 
the third cytoplasmic loop, a region involved in G- protein coupling. Expression of 
the long receptor form in the adult rat pituitary is 5 -10 fold greater than for the short 
form. The two isoforms display indistinguishable high -affinity for the radiolabelled 
dopamine antagonist spiroperidol, [3H]spiroperidol and both inhibit adenylate 
cyclase activity (Dal Toso, Sommer, Ewert, Herb, Pritchett, Bach, Shivers and 
Seeburg, 1989) 
2.5.3. Dopaminergic regulation of POMC -derived peptides 
The presence of dopamine receptors on the melanotroph cells of the intermediate 
lobe has long been inferred from the ability of dopaminergic compounds to 
influence the release of a -MSH from these cells (Bower, Hadley and Hruby, 1974; 
Tilders and Mulder, 1975). Electrothermic lesions of the mediobasal hypothalamus 
of rats encompassing the median eminence demonstrate that the effects of dopamine 
on the release of a -MSH were occurring directly at the level of the pituitary rather 
than at the hypothalamus. Treatment with the dopamine agonist bromocriptine 
prevented the lesion- induced fall in pituitary a -MSH content seen in vehicle treated 
animals ( Tilders and Smelik, 1978), presumably by inhibition of a -MSH secretion 
from the pituitary. This lead to the conclusion that dopamine delivered to the 
intermediate lobe can act on pars intermedia melanotrophs directly, rather than 
influencing a -MSH secretion at the level of the hypothalamus, and suggested that 
direct innervation of the lobe was likely to be an important mechanism by which 
dopamine regulates the melanotrophs. The participation of the tuberohypophysial 
dopaminergic neurons in the inhibitory control of a -MSH secretion was validated 
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further by the demonstration that dispersed and intact neurointermediate lobes in 
perifusion culture respond differentially to elevated potassium (Randle, Moor and 
Kraicer, 1983). Whereas dispersed pars intermedia cells responded with a transient 
release of a -MSH, intact neurointermediate lobes responded with a sustained 
decrease in the secretion of a -MSH. This observation led to the suggestion that the 
effect of potassium on the intact neurointermediate lobes was a result of the 
dopaminergic neurons within the gland being stimulated to release dopamine, which 
in turn was acting on the melanotrophs to inhibit the release of peptide. In contrast, 
potassium acts directly on the dispersed pars intermedia cells to evoke the transient 
release of a -MSH (Randle et al., 1983). In order to test this hypothesis, the 
dopamine antagonist d- butaclamol was added to the perifusion system. The finding 
that d- butaclamol converted the intact neurointermediate lobe response from a 
sustained decrease to a transient increase in release of a -MSH, characteristic of 
dispersed cells supports the hypothesis that dopaminergic innervation of the pars 
intermedia is involved in the inhibitory control of a -MSH from the gland. 
Binding of [3H]spiroperidol to rat neurointermediate lobes has identified specific 
dopamine binding sites (Cronin and Weiner, 1979; Stefanini, Devoto, Marchiso, 
Vernaleone and Collu, 1980). The binding of [3H]spiroperidol satisfies the criteria 
for receptor binding, including high affinity binding, saturability and reversibility. 
Comparison of the properties of spiroperidol binding with the adenylate cyclase 
diminishing properties of dopamine receptor activity (Frey, Cote, Grewe and 
Kebabian, 1982) in the intermediate lobe suggest that some or all of the spiroperidol 
binding sites are D2 receptors, indirectly illustrating the presence of dopamine 
receptor sites in the intermediate lobe. Treatment of dispersed rat intermediate lobes 
with dopamine or dopamine agonist inhibits the spontaneous release of a -MSH into 
the culture medium without altering the basal level of cAMP (Munemura, Eskay and 
Kebabian, 1980) suggesting that dopaminergic effects on the intermediate lobe are 
mediated through a D2 -like receptor. Further pharmacological characterisation of 
the dopaminergic effects on melanotrophs (Munemura, Cote, Tsuruta, Eskay and 
Kebabian, 1980) suggested the receptor fulfilled the criteria of a D2 -like dopamine 
receptor (Kebabian and Calne, 1979). D2 receptor gene expression in the 
intermediate lobe of the rat pituitary has been demonstrated and expression is 
dopamine dependant, such that treatment with a dopamine antagonist results in 
increased expression of D2 receptor mRNA in intermediate lobe cells (Autelitano, 
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Snyder, Sealfon and Roberts, 1989). Expression of D2 receptor mRNA in the 
anterior lobe was unaltered by treatment with dopamine antagonist suggesting that 
the regulation of dopamine receptor mRNA by dopamine is tissue -specific. More 
recently, an ontogeny study of dopamine receptor during rat fetal development has 
identified the D2 receptor in the intermediate lobe of the fetal pituitary at embryonic 
day 17 (René, Hindelang, Stoeckel and Félix, 1994). High levels of expression at 
day 20 precede dopaminergic innervation of the intermediate lobe by 4 -5 days (Gary 
and Chronwell, 1992). 
Dopaminergic regulation of the POMC peptides in the intermediate pituitary occurs 
as a result of altered gene expression. Intraperitonial injection of the dopamine 
antagonist haloperidol over a period of 7 -21 days significantly increases the amount 
of [3H]phenylalanine incorporated into isolated neurointermediate lobes and cell - 
free translation studies demonstrate a 100 -150% increase in the amount of 
translatable mRNA encoding for POMC (Höllt, Haarmaan, Seizinger and Herz, 
1982). In situ hybridisation studies reveal that individual cells respond to 
dopaminergic drugs in keeping with the known responses of peptide secretion. 
Chronic agonist treatment decreases the amount of POMC mRNA, as measured by 
grain counts to 10% of control values whilst chronic antagonist treatment results in 
an elevation of grain counts to 300% of control values (Chronwall, Millington, 
Griffin, Unnerstall and O'Donohue, 1987). In this same study, chronic agonist and 
antagonist treatment also altered the thickness of the intermediate lobe. The increase 
in the thickness of the intermediate lobe following antagonist treatment resulted 
from an increase in the rate of cell proliferation within the lobe as demonstrated by 
an increase in the level of incorporated [3H]thymidine. The influence of 
dopaminergic drugs on the size of the intermediate lobe has also been described by 
others (Beaulieu, Goldman, Miyazaki, Askay, Kebebian and Cote, 1984). The 
increase in POMC mRNA in the intermediate lobe in response to a specific stress, 
that of hyperosmosis can be blocked by a D2 receptor antagonist and mimicked by a 
D2 receptor agonist (Pardy, Carter and Murphy, 1990) illustrating that the decrease 
in POMC mRNA in response to hyperosmotic stimulation is mediated by dopamine 
acting through D2 receptors in the intermediate lobe. 
The inhibitory effect of bromocriptine on POMC gene expression and peptide 
secretion can be reversed by pre -treatment with pertussis toxin (Loeffler, Demeneix, 
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Kley and Höllt, 1988). Pertussis toxin inactivates nucleotide -binding proteins and 
uncouples the D2 receptor from the regulatory Ni subunit, therefore abolishing the 
ability of the receptor to inhibit adenylate cyclase activity (Cote, Frey and Sekura, 
1984). Pertussis toxin also inactivates another G- protein, No which has been 
implicated in the control of the Cat+ pathway. Since G- proteins can couple 
neurotransmitter receptors to specific ion channels and therefore modulate Ca2+ 
entry to the cell (Holz, Rane and Dunlap, 1986), it has been suggested that D2 
receptor inhibition of POMC can occur through the Cat+ pathway in addition to the 
cAMP pathway. In support of this hypothesis, Cat+ has been shown to regulate 
POMC gene expression in primary cultures of intermediate lobe cells (Loeffler, 
Kley, Pittius and Höllt, 1986). 
Thus, dopaminergic regulation of the intermediate lobe, in the adult at least is well 
characterised. Dopaminergic innervation of the pars intermedia by 
tuberohypophysial neurons has been demonstrated and dopaminergic effects on the 
melanotroph occur through the dopamine D2 receptor which has been localised on 
pars intermedia melanotrophs. In contrast to the adult, dopaminergic modulation of 
the fetal intermediate lobe is less widely studied. However, the fetal sheep pituitary 
is able to respond to dopamine from day 116 gestation (Newman et al., 1987) when 
an intravenous bolus of the dopamine receptor antagonist metoclopramide results in 
increased levels of a -MSH in the fetal circulation implying the existence of 
dopamine receptors in the fetal sheep pituitary gland and illustrating the presence of 
a functioning dopaminergic system during fetal life. 
In contrast to the well documented influence of dopamine on intermediate pituitary 
secretion, the role of dopamine in the regulation of anterior pituitary ACTH 
secretion has been less widely investigated. Unlike the melanotrophs of the 
intermediate lobe, anterior pituitary corticotrophs are not directly innervated by 
hypothalamic neurons. Thus, any regulatory influence of dopamine on ACTH 
section would likely occur indirectly through action on CRH and /or AVP secretion 
from the hypothalamus. In this respect, dopaminergic innervation of the 
paraventricular nucleus has been demonstrated (Buijs, Geffard, Pool and 
Hoorneman, 1984; Lindvall, Bjorklund and Skagerberg, 1984) and dopamine has 
been shown to stimulate the release of both CRH and AVP from adult rat median 
eminence in vitro (Bridges, Hillhouse and Jones, 1975; Negro -Vilar, 1979). Further 
Chapter 2 Literature Review 33 
evidence that dopamine acts on hypothalamic factors to influence anterior pituitary 
ACTH secretion comes from the finding that ACTH secretion in the intact animal is 
increased by administration of haloperidol (Giraud, Littitsky, Conte- Devolx, Gillioz 
and Oliver, 1980) but there is no effect of dopaminergic manipulation of anterior 
pituitary cells in vitro (Giguère, Cotè and Labrie, 1981; Rosa, Policastro and 
Herbert, 1980). A similar lack of effect on anterior pituitary POMC gene expression 
has been reported (Levy and Lightman, 1988; Peiltier, 1990; Chen et al., 1983). A 
1.5 fold increase in anterior pituitary POMC gene expression in response to 
haloperidol has been reported by Autelitano and co- workers (Autelitano, Clements, 
Nikolaidis, Canny and Funder, 1987). The discrepancy in these results may reflect 
the different periods of exposure. In the study of Autelitano et al., rats were treated 
for a period of 14 days compared to the maximum of 7 days of treatment used in 
other studies (Chen et al., 1983; Levy and Lightman, 1988) There was no indication 
of the duration of treatment in the report by Pelletier (1990). 
2.5.4. Dopaminergic regulation of prolactin 
In contrast to the sparse data on dopaminergic regulation of POMC- derived 
peptides, the role of dopamine in the regulation of prolactin secretion from the fetal 
anterior pituitary has been extensively demonstrated. Prolactin concentrations in 
fetal plasma increase in late gestation (Winters, Colston, MacDonald and Porter, 
1975; Mueller, Gluckman, Kaplan, Rudolph and Grumbach, 1979) and this increase 
parallels a similar increase in circulating oestrogen levels. Oestrogen has been 
shown to influence the level of circulating prolactin and it is likely that the increase 
in plasma prolactin occurs as a result of elevated oestrogen concentrations. Prolactin 
concentrations in human fetal cord plasma correlate positively with increasing 
adrenal weight in the human fetus (Winters et al., 1975) during late gestation and 
fall abruptly post- partum when the adrenal cortex involutes. This lead Winters et al. 
(1975) to suggest that prolactin is trophic to the adrenal gland in fetal life. However, 
continuous infusion of prolactin to fetal sheep for 10 -27 days does not stimulate 
production of adrenal cortisol (Lowe, Jansen, Thomas and Nathanielsz, 1977) or 
DHAS (Ballard, Gluckman, Brehier, Kitterman, Rudolph, Kaplan and Grumbach, 
1978). Thus, it seems likely that prolactin concentrations in the fetus reflect 
oestrogen concentrations and that the post -partum decline results from the loss of the 
rich placental source of these oestrogens. 
Chapter 2 Literature Review 34 
Dopaminergic regulation of fetal plasma prolactin concentrations has been 
demonstrated in vivo. Intravenous infusion or bolus injection of the dopamine 
agonists bromocriptine and apomorphine significantly reduces the level of prolactin 
in the plasma of fetuses at day 118 -136 gestation and in neonatal lambs (Gluckman, 
Marti -Henneberg, Thomsett, Kaplan, Rudolph and Grumbach, 1979). The level of 
suppression was always greater in the neonates compared to fetuses. This could be a 
result of the increased concentrations of oestrogen in the fetuses compared to the 
neonatal lambs since oestradiol has been shown to exhibit potent anti -dopaminergic 
activity on prolactin secretion from the pituitary (Raymond, Beaulieu, Labrie and 
Bossier, 1978). Administration of haloperidol, a dopamine antagonist, to fetuses 
from day 92 -140 gestation resulted in elevated plasma prolactin concentrations in 
fetuses over day 106 gestation, thus demonstrating the presence of an inhibitory 
dopaminergic pathway. At this stage of gestation fetal plasma prolactin 
concentrations have not yet begun to increase, suggesting that the high prolactin 
concentrations are not merely due to an immature dopaminergic regulatory 
mechanisms. Studies on stalk -sectioned fetuses reveal a dopaminergic influence on 
prolactin secretion that arises from somewhere other than the hypothalamus, as 
demonstrated by the persistence of a response to haloperidol after the pituitary has 
been isolated from the hypothalamus (Gluckman, Leisti, Kaplan and Brumbach, 
1983). In this study, the expected rise in plasma prolactin concentrations following 
release from the inhibitory regulation of dopamine after stalk section of the pituitary 
does not occur and the authors suggest that an extra -hypothalamic source of 
dopamine is involved. The source of extra -hypothalamic dopamine influencing 
pituitary prolactin secretion remains to be determined, although dopamine has been 
identified in the fetal circulation and amniotic fluid (Ben -Jonathan and Maxson, 
1978). More recently, and in contrast to the study of Gluckman et al. (1983), 
hypothalamo- pituitary disconnection of adult sheep resulted in a short term increase 
in circulating prolactin concentrations. This increase had been attributed to loss of 
hypothalamic inhibition by dopamine neurons. Removal of posterior pituitary 
function by electrical lesioning of the hypothalamo -hypophysial tract resulted in a 
two -fold increase in circulating plasma prolactin concentrations in the days 
immediately following surgery (Thomas, Cummins, Canny, Rundle, Griffin, 
Katsahambas and Clarke, 1989) and raises the possibility that the increase in 
prolactin following HPD occurs as a result of atrophy of the posterior lobe rather 
than loss of hypothalamic influence. The short portal blood vessels that connect the 
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posterior and anterior pituitary (Daniels and Pritchard, 1975) provide a functional 
link whereby the secretions of the posterior pituitary can actively influence anterior 
pituitary function. The possibility of posterior control over anterior pituitary 
function will be discussed later (see section 2.6). 
Dopamine binding sites in the anterior pituitary have been identified by specific 
binding of [3H]Spiroperidol and other radiolabelled ligands for the dopamine 
receptor in a variety of species including rat, sheep steer and cow (Cronin and 
Weiner, 1979; Stefanini et al., 1980; Cronin, Roberts and Weiner, 1978; Caron, 
Beaulieu, Raymond, Gagne, Drouin, Lefkowitz and Labrie, 1978; Levant, 
Grigoriadis and DeSouza, 1993). D2 receptor binding sites in the rat anterior 
pituitary have been localised specifically to the prolactin- secreting lactotrophs 
(Goldsmith, Cronin and Weiner, 1979; Schoors, Vauguelin, De Vos, Smets, 
Velkeniers, Vanhaelst and Dupont, 1991) by combined radioligand binding and 
immunohistochemistry. The dopaminergic control of prolactin release from 
lactotrophs has been extensively demonstrated. Dopamine and its agonists 
specifically inhibit basal adenylate cyclase activity and prolactin release from rat 
anterior pituitary homogenates, and this inhibition can be blocked by antagonists 
(Enjalgert and Bockaert, 1982). A similar correlation between dopamine stimulus 
and inhibition of prolactin secretion is found in intact anterior pituitary cells in 
culture (Foord, Peters, Dieguez, Scalon and Hall, 1983). Together with effects on 
secretion of prolactin, dopaminergic stimulation of anterior pituitary cells in vitro 
specifically inhibits prolactin synthesis, as measured by incorporation of 
[35S]methionine and also results in decreased concentration of prolactin mRNA 
(Maurer, 1980) suggesting that the effects on prolactin synthesis are ultimately 
mediated by influencing transcription of prolactin mRNA. Treatment of dispersed 
pituitary cells with the potent dopaminergic agonist ergocryptine results in 
significantly decreased hybridisation of a radiolabelled recombinant DNA plasmid 
(pPRL -2), containing the complete prolactin coding sequence to extracted nuclear 
RNA samples (Maurer, 1981) suggesting that ergocryptine treatment inhibits 
prolactin gene transcription. Further, cell -free translation of RNA was significantly 
decreased by pre- treatment with ergocryptine and this effect could be partially 
blocked by concomitant cAMP treatment. Treatment with cAMP alone resulted in a 
rapid stimulation of prolactin gene transcription suggesting that the inhibitory effects 
of dopamine on prolactin gene transcription are mediated by cAMP. 
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In addition to the well documented inhibitory role for dopamine in the control of 
prolactin synthesis and release, evidence also exists to suggest that dopamine can act 
to stimulate prolactin release. Dopamine administered to rat anterior pituitary 
monolayer and superfused cultures at concentrations 1000 fold less than those 
required for inhibition stimulates the release of prolactin by at least 50% when 
compared to control cultures (Denef, Manet and Dewals, 1980). Pharmacological 
evidence based on interactions with the D2 receptor agonists and antagonists 
suggests that the stimulatory effects of dopamine are mediated by a receptor distinct 
from the D2 receptor (Burris, Stringer and Freeman, 1991). The discovery of D1 
and D5 dopamine receptor subtypes that stimulate adenylate cyclase raises the 
possibility that the stimulatory action of dopamine is mediated by dopamine 
receptors other than the D2 class of receptors. The role of different dopamine 
receptor subtypes in the regulation of prolactin secretion can be examined using 
GH4C1 cells, which secrete prolactin but do not express dopamine receptors. 
Transfection of GH4C1 cells, with either the D2, D1 or D5 receptor and subsequent 
exposure to dopamine demonstrates that both D1 and D5 receptors are capable of 
stimulating prolactin release from the transfected cells (Porter, Grandy, Bunzow, 
Wiles, Civelli and Frawley, 1994). Further, using reverse transcription polymerase 
chain reaction, the authors were able to identify D5 receptor mRNA in the rat 
anterior pituitary gland. D1 receptors have also been identified on lactotrophs 
(Schoors et al., 1991). In this study administration of fenoldopam, a selective D1 
receptor agonist resulted in a dose- dependant decrease in prolactin secretion both in 
vivo and in vitro without influencing the levels of adenylate cyclase suggesting that 
D1 receptors are involved in the inhibition rather than stimulation of prolactin 
release, by providing a non -adenylate cyclase mechanism for inhibiting prolactin 
secretion. The existence of a dopamine receptor distinct from the D2 receptor that is 
uncoupled to adenylate cyclase and involved in inhibition of prolactin secretion from 
rat anterior pituitary lactotrophs has also been inferred from a study utilising 
antisense oligonucleotides to identify the mRNA species regulating prolactin release 
(Valerio, Alberici, Tinti, Spano and Memo, 1994). Addition of antisense 
oligonucleotides that recognise the initiation codon of D2 receptor mRNA to 
pituitary cultures for 7 days decreased the level of D2 receptor mRNA and the 
number of [3H]spiropeiidol binding sites and also prevented bromocriptine- induced 
reduction of adenylate cyclase and prolactin mRNA. However, the antisense 
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oligonucleotide treatment did not affect the bromocriptine- induced inhibition of 
prolactin release suggesting that the release of prolactin may be regulated by a 
dopamine receptor that is distinct from the mRNAs encoding the D2 receptor. 
The mechanisms by which dopamine receptor stimulation inhibits, or indeed 
stimulates prolactin secretion remains to be elucidated. It is possible that the Dl 
receptors described by Schoors et al. (1994) are the same as those described by 
Valerio et al. (1994). It is likely that they are linked to an alternative signal 
transduction pathway and may represent a subset of dopamine receptors distinct 
from the Dl receptors that classically stimulate adenylate cyclase activity. 
2.6. Interactions between the neurointermediate and anterior lobes 
of the pituitary gland 
Recently, much interest has been expressed in the possible role of the 
neurointermediate lobe in the regulation of prolactin secretion. The existence of 
short portal blood vessels which link the posterior and anterior pituitary (Daniels and 
Pritchard, 1975) make it possible for a posterior pituitary derived factor to influence 
the lactotrophs of the anterior pituitary. Whilst dopamine has been established as 
the prolactin inhibitory factor, the existence of a prolactin -releasing factor (PRF) has 
also been alluded to (Shin, 1980; Grosvenor and Mena, 1980). Removal of the 
posterior lobe of the rat pituitary abolishes the suckling- induced rise in prolactin 
(Murai and Ben -Jonathan, 1987) and provides evidence for the existence of a PRF 
within the posterior pituitary which is released in response to suckling. In vitro 
studies utilising perifused anterior pituitary cells have been used to show that 
posterior pituitary extracts contain potent PRF activity (Hyde, Murai and Ben - 
Jonathan, 1987). Extracts of mediobasal hypothalamus also contained PRF activity 
although the amount was significantly less suggesting that the PRF, unlike the other 
pituitary releasing hormones is preferentially located in the posterior pituitary rather 
than the hypothalamus. Further characterisation revealed that the PRF could 
stimulate prolactin secretion in the presence of dopamine and estimation of its 
molecular weight using 5000 and 1000 molecular weight cut -off membranes, 
together with treatment with proteolytic enzymes suggest that the PRF is a small 
peptide (Hyde and Ben -Jonathan, 1988a). This study, together with previous studies 
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utilising antagonists to oxytocin (Hyde et al., 1987) suggested that the peptide was 
distinct from all previously characterised prolactin secretagogues. 
Posterior pituitary extracts administered via intracarotid injection to adult rats 
stimulated prolactin release in a dose -dependant fashion (Hyde and Ben -Jonathan, 
1988b), illustrating the ability of the PRF to act in vivo and in the presence of the 
tonic dopaminergic inhibitory system. Similar in vivo effects of PRF activity in 
posterior lobe extracts have been described by others (Samson, Martin, Mogg and 
Fulton, 1990). Dissection of the posterior pituitary into the constituent neural and 
intermediate lobes revealed that 90% of the PRF activity of the posterior lobe was 
localised in the intermediate lobe (Laudon, Grossman and Ben -Jonathan, 1990). 
Murai and Ben -Jonathan (1990) went on to demonstrate that the prolactin surge in 
ovariectomised rats following oestradiol treatment was dependent on the presence of 
an intact neurointermediate lobe. The authors concluded that the oestrogen effects 
on prolactin secretion were mediated by release of a PRF from the neurointermediate 
lobe which was transported to the anterior pituitary via the short portal blood 
vessels. 
The influence of neurointermediate lobe (NIL) cells on oestrogen- induced prolactin 
secretion demonstrated in vivo by Murai and Ben -Jonathan (1990) has been further 
studied using in vitro co- culture techniques. Co- culture of anterior and posterior 
pituitary cells for 4 days induces a 2 -3 fold increase in the total prolactin cell 
content, with a significant elevation in prolactin secretion measurable after 8 days of 
co- culture (Dymshitz and Ben -Jonathan, 1991). The increased release of prolactin 
into the medium can be mimicked by culture of anterior pituitary cells in posterior 
pituitary conditioned medium, implicating a releasable factor from the posterior 
pituitary in the stimulation of prolactin release. The increase in prolactin content 
and secretion reflects increased prolactin mRNA levels which increase in response 
to posterior pituitary co- culture (Corcia, Steinmetz, Liy and Ben -Jonathan, 1993). 
Thymidine incorporation studies suggest that the increased levels of prolactin 
mRNA, content and secretion do not occur as a result of cell proliferation but rather 
reflect a stimulation of gene expression within existing lactotrophs. The presence of 
NIL cells in anterior pituitary cultures exposed to oestradiol increased by 12% the 
total number of prolactin secreting cells within the culture (Ellerkmann, Nagy and 
Frawley, 1991). The data of Corcia et al. (1993) suggests that this increase is due to 
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recruitment of existing cells rather than by cell proliferation. The secretory capacity 
of individual lactotrophs is also augmented by concomitant culture with NIL cells. 
Moreover, removal of the NIL cells immediately prior to administration of 
oestradiol completely abolished the oestrogen- induced release of prolactin 
illustrating the need for continued presence of the NIL cells in mediating the 
prolactin response. The high abundance of oestrogen receptor mRNA found within 
the intermediate lobe of the rat pituitary (Pelletier, Liao, Follea and Govindan, 1988) 
suggests that the PRF released in response to oestrogen is of intermediate origin as 
opposed to being a neural lobe factor. The finding that dopamine, acting to inhibit 
a -MSH release prevented the oestradiol- induced recruitment of lactotroph cells and 
the ability of a -MSH to substitute for both oestradiol and NIL cell presence in the 
co- culture system (Ellerkman, Nagy and Frawley, 1992) suggests that the prolactin- 
releasing factor released from the neurointermediate lobe in response to oestradiol 
stimulation is a -MSH. 
Since any factor carried by the short portal blood vessels from the neurointermediate 
lobe to the anterior lobe preferentially bathes the area closest to the NIL, Porter and 
Frawley (1992) separated the anterior pituitary into two distinct regions, that which 
is proximal to the NIL and the remaining area of the gland not in direct contact with 
the NIL. Dispersed cell cultures of the two distinct areas monitored by reverse 
haemolytic plaque assay to measure prolactin release. In the control cultures, the 
outer region of the gland contained the greatest number of prolactin secreting. cells. 
Treatment of the cells proximal to the NIL with either a -MSH, E3-endorphin or 
oestradiol in the presence of NIL cells resulted in an 8% increase in the number of 
prolactin secreting cells. No effect was observed in cultures of the outer region of 
the gland. 
The increase in the number of prolactin releasing cells induced by oestradiol 
treatment in the presence of NIL cells has been shown to involve recruitment of 
growth hormone secreting sommatotrophs. All newly recruited prolactin secreting 
cells also secrete growth hormone and the increase in the number of cells releasing 
both prolactin and growth hormone coincides with a decrease in the number of cells 
secreting growth hormone alone (Porter, Ellerkmann and Frawley, 1992). This 
suggests that prolactin recruitment induced by NIL and oestradiol treatment involves 
induction of prolactin secretion in cells that formerly secreted growth hormone. 
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Further characterisation of the recruitment of prolactin secreting cells (Porter et al., 
1992) reveals that it occurs post -transcriptionally since inhibitors of RNA synthesis 
do not affect the recruitment of prolactin secreting cells whereas treatment with a 
protein synthesis inhibitor completely abolishes the recruitment response to NIL and 
oestradiol treatment. Thus, the oestradiol induced NIL factor appears to induce 
translation of previously transcribed prolactin mRNA within growth hormone 
secreting cells to convert them to prolactin secreting cells. The reason for the post - 
transcriptional block on prolactin synthesis and the mechanisms by which it occurs 
remain to be elucidated. However, the existence of a store of transcribed prolactin 
mRNA waiting to be translated provides a rapidly accessible pool of prolactin that is 
not dependant upon mitosis or transcription of existing prolactin secreting cells. The 
evidence above suggests a role for a -MSH in the release of prolactin although the 
mechanisms by which a -MSH overcomes the post- transcriptional block to prolactin 
synthesis remains to be determined. 
Recently, transgenic mice bearing intermediate lobe tumours, induced by ligation of 
the POMC gene promoter to the simian virus 40 large T antigen have been utilised 
to study the regulation of prolactin secretion (Allen, Low, Allen and Ben -Jonathan, 
1995). Serum prolactin levels were 5 to 6 times higher in mice bearing intermediate 
lobe tumours compared to control mice. Bioassay of fractionated tumours revealed 
potent PRF activity which could be separated into two distinct classes, one big PRF 
molecule with an estimated molecular weight of 70 -80 kilodaltons and two small, 
hydrophobic peptides. Contrary to the evidence reviewed above, the elution profiles 
of the three PRFs differed from all POMC derived peptides tested, including cc-MSH 
and from other known prolactin secretagogues suggesting that the PRF is indeed 
produced by melanotrophs of the intermediate lobe but is not a -MSH or any other 
POMC- derived peptide. Whilst the large PRF producing intermediate lobe tumours 
of the transgenic mice may provide a useful source for the purification of PRF it is 
important to note that the transgenic mice do not represent the normal physiological 
situation, indeed POMC processing in the intermediate lobe tumours is significantly 
altered (Low, Liu, Hammer, Rubenstein and Allen, 1993). 
Scope of this thesis 
The overall aim of this thesis was to investigate the neural control of the pituitary 
gland during fetal development. An initial approach (Chapter 4) utilised primary 
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cultures of fetal rat hypothalamic neurons in an attempt to monitor the growth and 
development of fetal AVP neurons and to gain some insight into the factors 
influencing the functional maturation of these neurons. Later studies, were 
concerned with the developing fetal pituitary- adrenal axis with particular reference 
to the pro -opiomelanocortin system during fetal life. The ontogeny of POMC gene 
expression and expression of the translated peptides ACTH and a -MSH are 
described in Chapter 5. The main aim of this thesis was to test the hypothesis that 
POMC- derived peptides from the fetal pars intermedia are subject to tonic 
dopaminergic regulation and that removal of this tone may result in increased 
synthesis and release of adrenal active peptides. The approach to this hypothesis 
was three -fold, to study the effects of dopaminergic manipulation of the fetus on the 
secretion of POMC- derived peptides and cortisol into the fetal circulation (Chapter 
6), on the pituitary content of POMC -derived peptides (Chapter 7) and on the levels 
of expression of the POMC gene (Chapter 8). Possible differential effects of 
dopamine on prolactin secretion in summer and winter fetuses was also studied 
(Chapter 9). 
Chapter 3. General materials and methods 
This chapter describes the techniques common to a number of studies presented in 
this thesis. Other methods unique to specific experiments are described in the 
relevant chapters. 
3.1. Sheep. 
Sheep of mixed breeds were obtained from the Roslin Institute, Edinburgh and 
housed at The University of Edinburgh Marshall Building, Roslin, Midlothian. Prior 
to surgery, sheep were maintained in pens containing between 10 -15 animals and fed 
a constant diet of concentrates twice daily with hay and water given ad libitum. 
Following surgery, sheep were transferred to individual metabolism crates and 
continued on the same diet throughout the experimental period. Sheep were 
maintained under natural lighting conditions prior to surgery and artificial light 
cycles corresponding to natural photoperiod thereafter. 
Sheep were time -mated by intravaginal treatment with sponges containing 60mg 
medroxyprogesterone acetate (Upjohn Ltd, Crawley, Sussex). The sponges were in 
place for 13 days after which they were withdrawn and 48 hours later ewes were 
penned with proven rams. The rams were removed after 24 hours and the ewes 
considered to have an insemination date with day 0 of pregnancy taken as the date 
upon which the rams were introduced. 
3.2. Surgical procedures. 
3.2.1 Anaesthesia 
Prior to surgery, food but not water was withdrawn for a 24 hour period. 
Anaesthesia was induced by intravenous injection of pentobarbitone sodium and 
thiopentane sodium (Sagattal and Intraval respectively; Rhone Mèrieux Ltd., 
Harlow, Essex) prepared on a per kilogram weight basis. The ewe was placed in the 
supine position, intubated and maintained with 3 -4% halothane (Fluothane, ICI 
Pharmaceuticals, Macclesfield, Cheshire) in a nitrous oxide /oxygen mixture 
(-1l/min) using a closed circuit anaesthetic machine before the ewe was secured to 
the operating table. The abdomen was clipped and cleaned repeatedly with 
antiseptic solution (Betadine, Napp Laboratories, Cambridge). 
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3.2.2. Cannulation 
A midline incision was made in the skin of the abdomen between the navel and the 
mammary gland with care taken to avoid the mammary vein. An incision was 
then made in the peritoneum underlying the midline ridge. A trochar was passed 
through the flank and sterile catheters inserted through the opening from the 
exterior. A small incision was made in the uterine wall to expose the hind hooves 
taking care to avoid the placental cotyledons. The legs of the fetus were then 
delivered and cannulation of the femoral vein and artery performed. A small 
incision was made in the skin of the fetus overlying the inner thigh and the 
femoral vein and artery exposed by blunt dissection with curved forceps. Two 
sutures were passed under both the artery and vein individually and the most 
caudal was tied off. A 10cm polyvinyl cannula filled with heparinied saline 
(100IU /m1) was inserted into the femoral vein and secured in position. An 
identical cannula was placed in the femoral artery. The cannulae were then 
secured to underlying muscle and the incision closed. The catheters were further 
secured by suturing firmly to the skin of the fetus. An additional catheter for 
sampling amniotic fluid was secured to the rump of the fetus and the fetus 
repositioned in the body of the uterus. The uterus and underlying amnion were 
tightly sutured before closing the peritoneum overlying skin layer. 
3.2.3. Post -operative care 
Ewes made a quick recovery from the surgical procedure and were awake and 
eating within half an hour of leaving the operating table. Ewes received 
antibiotics (4m1 Depocillan, Glaxovet) two days pre- and two days post- 
operatively and fetuses were treated with lx106 penicillan (Crystapen, Glaxovet) 
administered intravenously and to amniotic fluid for three days post- operatively. 
Cannulae were attached to a three -way stopcock (Connecta, Viggo AB, 
Helsinborg, Sweden) and were kept patent between surgery and the start of the 
experiment by daily flushing with heparinised saline. 
Animals were allowed to recover overnight in pens before being moved to 
metabolism crates for the duration of the experiment. 
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3.3. Blood sampling and infusions. 
Blood samples were withdrawn into a fresh sterile syringe and cannulae were 
flushed with sterile heparinised saline after each sample. A closed system was 
used in which the initial volume of blood withdrawn to fill the cannula at each 
sample point was returned to the fetus to minimise the overall lose of blood 
volume. Fetal blood gases, pO2, pCO2 and pH were monitered in an additional 
0.2ml blood withdrawn at various times throughout the course of the experiment 
using a blood -gas analyser (IL 1306 ; Instrumentation Laboratories, Warrington 
Cheshire, UK). Blood collected was immediately transfered to heparinised tubes 
on ice. Samples were spun at 3000rpm in a refrigerated centrifuge for 15 mins and 
the plasma collected into aliquots which were stored at -200C until assayed. 
Experimental drugs were infused intravenously via a 0.21.tm filter (Millipore, 
Hertfordshire, UK) at a continuous rate of 0.5m1/hour. 
3.4. Radioimmunoassays. 
All samples were assayed in duplicate and standards and quality controls were 
assayed in triplicate. Each radioimmunoassay contained at least two standard 
curves, one at the beginning and one at the end with an additional curve in the 
middle if required. Each standard curve included three tubes in which standard and 
antibody were replaced with equal voumes of assay buffer alone to assess non- 
specific binding (NSB tubes) of the tracer, and three tubes containing antibody but 
no standard to assess the binding of the antibody to the tracer in the absence of 
standard (Bo tubes). 
3.4.1. a- Melanocyte stimulating hormone 
Buffer Phosphate buffered saline (PBS) was prepared by dissolving 8g 
NaC1 in one litre of 0.05M sodium phosphate solution (1 litre 0.5M phosphate 
buffered stock solution contained 53.25g Na2HPO4, 19.5gNaH2PO4.2H2O, pH 
7.5). Assay buffer consisted of 0.05M PBS containing 0.1% gelatin and 0.01% 
thiomersal (BDH) 
Antibody a -MSH antibody R6FB was the kind gift of Dr. Bridget Baker, 
University of Bath. The antibody was raised in a rabbit against synthetic a -MSH 
and has previously been validated for the measurement of a -MSH in sheep plasma 
(Lincoln and Baker 1995). There was negligable cross -reactivity with ACTH(1 -39) 
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or CLIP(18_39). The antibody was added to the assay at an initial dilution of 
1:25,000. 
Iodination a -MSH (Cambridge Research Biochemicals, Cambridge, UK) was 
iodinated using the chloramine T method (Greenwood, Hunter and Glover, 1963). 
5µg of a -MSH stored in 100 0.5M phosphate buffer was utilised for each 
iodination. 1mCi Na125I (Amersham International, Aylesbury, Bucks) was added 
to the hormone and 100 of chloramine T (1mg /m1 in 0.05M phosphate stock) was 
added to start the reaction. After 15 seconds the reaction was stopped by addition 
of 250 sodium metabisulphite (1mg/m1 in 0.05M phosphate buffer). The reactant 
was purified by loading onto a Sep -pak C -18 column (Millipore, Hertfordshire, 
UK) which had been prewetted sequentially with 2m1 1% trifluoroacetic acid 
(TFA; Aldrich, Poole, Dorset) in water, 5m1 80% methanol/20% 0.1% TFA and 
3m1 0.1% TFA . Free iodine was eluted from the column with lml 0.1% TFA in 
water. The column was then subjected to the following increasing concentrations 
of methanol (10 %, 20 %, 30 %, 40 %, 42 %, 43 %, 45 %, 46 %, 47 %, 48 %, 49 %, 50 %, 
51 %, 52 %, 54 %, 58 %, 60 %, and 80 %) in 0.1% TFA. Each fraction was counted 
for 10 seconds in a miniassay gamma counter (Type 6 -20, Mini Instruments, 
Burnham on Crouch, Essex) to determine presence of radiolabelled hormone. 
Radiolabelled a -MSH eluted from the column as a single peak (Figure 3.1). The 
fractions containing the highest radioactivity were stored at -20°C in 3m1 25% 
methanol and 3m1 0.05M phosphate stock containing 0.25% bovine serum 
albumin (BSA, Sigma Chemicals, Poole, Dorset : RIA grade, fraction V) and 0.1% 
mercaptoethanol (Sigma). The fraction which showed the highest binding to the 
a -MSH antiserum was used for asssay. Radiolabelled tracer was used at 
15000cpm in S00 assay buffer per tube. 
Standards and Quality controls cc-MSH used for standards was the same as 
that used for iodination. Standards in the range 8000pg /ml to 30 pg /ml were 
prepared by double diluting in a -MSH assay buffer from an 8000pg /ml stock. 
Results are expressed as pg a- MSH /ml. Quality controls consisted of a -MSH 
added to dexamethasone suppressed sheep plasma at three different dilutions. 
Separation Bound hormone was separated by second antibody precipitation 
using normal rabbit serum (1:400) and donkey anti rabbit serum (1:16, both from 
The Scottish Antibody Production Unit, SAPU). 
Method 100µl of standard, sample or quality control and 2000 assay buffer 
was added to a 3m1 polystyrene tube. Standards and QCs were assayed in 
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Figure 3.1. Radioactivity in fractions eluted from Sep -pak C -18 column after 
radioiodination of a -MSH. Dark circles show those fractions that were retained 
for binding analysis. 
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triplicate and samples were assayed in duplicate. 50µ1 of diluted antiserum 
(1:25000 in assay buffer) was added to the tubes which were vortexed and 
incubated overnight at 4 °C. After an 18 hour incubation at 4 °C, 50µ1 of 
radiolabelled tracer (15000cpm /500) was added to each tube and incubated 
overnight at 4 °C. On the third day l00µ1 normal rabbit serum and l000 donkey 
anti -rabbit serum were added to the tubes to precipitate bound hormone and the 
tubes were again incubated overnight at 4 °C. Precipitated hormone was separated 
by addition of 1ml 0.9% saline containing 0.2% triton X -100 (Sigma). Tubes 
were spun at 3000rpm for 30 minutes at 4 °C and the supernatent poured off to 
leave the precipitated pellet. Radioactivity in the tubes was counted for 60 
seconds in a gamma counter (1261 Multigamma, LKB, Wallac OY, Finland) 
Sensitivity - The assay had a lower limit of detection of 32 pg/ml and the intra- 
and inter -assay coefficients of variation were 12.7% and 12.5% respectively. 
3.4.2. Prolactin 
Buffer Assay buffer consisted of 1% BSA in 0.075M phosphate buffered 
saline(150m1 0.5M phosphate buffer stock, 8.77g NaCl, 0.1g thiomersal per litre) 
Antibody Prolactin antibody ( #50) was raised in rabbits by Professor A. 
McNeilly, Reproductive Biology Unit, Edinburgh and has previously been 
characterised for prolactin radioimmunoassay (McNeilly and Andrews, 1974). 
The antiserum is used in the assay at a working dilution of 1:128000. 
Iodination Purified ovine prolactin, NIADDK - oPRL -19 (NIH) was iodinated 
using the lactoperoxidase method. 50 (500pCi) of Na1251 (Amersham 
International) and 5µg lactoperoxidase (Sigma) in 10111 thiomersal -free BSA were 
added to 5µg purified ovine prolactin (NIADDK - oPRL -19, NIH). 10m1 hydrogen 
peroxide (10µ1H202/ 150 ml distilled water was added to start the reaction. After 
20 seconds, the reaction was stopped by addition of 10µ1 of a lmg/ml solution of 
2- mercaptoethylammonium chloride in distilled water. lml of thiomersal -free 
1 %BSA/PBS was added to increase the volume of the reaction mixture. The 
resulting mixture was subjected to gel filtration on a Sephadex G -100 (Pharmacia 
AB, Uppsala, Sweden) column. The gel was allowed to swell in thiomersal -free 
BSA that had first been allowed to equilibrate to room temperature. After the 
column was poured and allowed to pack down, it was coated with thiomersal -free 
1 %BSA/PBS. The iodination mixture was added to the column and eluted with 
1 %BSA/PBS. The eluate from the column was collected in 8m1 polysterene tubes 
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using a programmable electronic fraction collector (Gilson model 203, Middleton, 
WI, USA) and the radioactivity in each fraction monitored (Mini -assay type 6 -20, 
Mini Instruments, Burnham -on- Crouch, Essex). The first peak eluted from the 
column was radiolabelled oPRL tracer (Figure 3.2). The fractions from this peak 
containing the highest radioactivity were pooled and stored in 200µ1 aliquots at 








Figure 3.2. Radioactivity in fractions eluted from column after radioiodination of 
prolactin. Dark circles show those fractions that were pooled and subsequently 
used in radioimmunoassay. 
Standards and Quality controls Prolactin standard (NIH-S15) was stored as 
1001.tg/m1 aliquots and diluted in assay buffer to produce standards in the range 
200 -0.8 ng /ml. Dexamethasone -suppressed sheep plasma with oPRL standard 
added at three different concentrations was used as a quality control. 
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Separation Separation was by the second antibody precipitation method using 
normal rabbit serum (1:400) and donkey anti -rabbit serum (1:16: both from 
SAPU). 
Method 3O111 of sample (diluted if required) or standard was added to 1O0µ1 
assay buffer, 100111 prolactin antibody and 1001.t1 radiolabelled prolactin and 
incubated overnight at 4 °C. The next day l000 NRS and l00111 DARS, was 
added to the tubes which were vortexed and returned to 4 °C overnight. 1ml of 
0.9% saline was added and the tubes spun at 3000rpm for 30 minutes at 4 °C. The 
supernatant was discarded and tubes counted for 60 seconds in a Multigamma 
counter. 
Sensitivity - The assay had a lower limit of detection of 0.6ng /ml and intra- and 
inter -assay coefficients of variation of 8.5% and 10.2% respecively. 
3.4.3. ACTH 
Buffer Assay buffer consisted of 0.4% EDTA in phosphate buffer with 
0.02% sodium azide; pH 7.4. On the day of use 11.11/m1 Triton X -100 and 
250KIU /m1 aprotinin (Sigma) was added to the stock buffer solution. 
Antibody ACTH antibody (AFP6328031; NIDDK) was stored in frozen 
aliquots and added to the assay at an initial dilution of 1:100,000 diluted in assay 
buffer. A fresh aliquot was used for each assay and discarded after single use. 
Standards and Quality controls Synthetic ACTH (Cambridge Research 
Biochemicals) was stored as 100ng/ml aliquots and diluted in assay buffer to 
produce a standard range of 500 - 1pg /1O0u1. As with the antibody, aliquots of 
standard were discarded after single use. Dexamethasone- suppressed sheep 
plasma with ACTH added at three concentrations was used as a quality control. 
Iodination 2µg ACTH in 5111 0.O1M HC1 was iodinated by the chloramineT 
method as described above. The resultant mixture was purified by gel filtration on 
a Sephadex G50 column (Pharmacia AB, Uppsala, Sweden). The Sephadex gel 
was allowed to swell in assay buffer and was packed into a 50 x lcm glass column 
(Amicon Ltd., Stonehouse, Gloustershire). The column was then coated with 
10m1 5% BSA. The iodination reaction was loaded onto the column and eluted in 
assay buffer. The elùate was collected as lml fractions in 8m1 polystyrene tubes 
using a programmable electronic fraction collector (Gilson model 203, Middleton, 
WI, USA) and the radioactivity in each fraction monitored. Radiolabeled ACTH 
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eluted from the column as a single peak (Figure 3.3) and appropriate fractions 
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Figure 3.4. Radioactivity in fractions eluted from Sephadex G -100 column after 
radioiodination of ACTH. Dark circles represent fractions that were pooled and 
used as 125I -ACTH tracer. 
Separation Bound hormone was separated by 30 minute incubation with 5000 
donkey anti -rabbit IgG magnetic particles (gift of Dr Rodney Kelly, MRC 
Reproductive Biology Unit) diluted 1:80 in 0.05M phosphate buffer containing 
0.015% Triton X -100. Tubes were vortexed and placed onto magnetic separation 
racks (Amersham International). After 15 minutes, the supernatant was decanted 
and the magnet was removed. 300µl of wash buffer (0.075M PBS, 0.01% 
thiomersal) was added to the tubes before returning to the magnet for a further 15 
minutes. Supernatant was decanted and the tubes left inverted to drain for 30 
minutes. The radioactivity in the pellet was counted for 60 seconds. 
Method 1001.l of ACTH antiserum diluted 1:100K was added to 100111 
standard, sample or quality control in a 3ml polypropelene tube and incubated 
50 
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overnight at 4 °C. The next day 10011l of radioladelled 125I ACTH was added to 
each tube (15000cpm /1001.11), tubes were vortexed and incubated overnight at 4 °C. 
On the third day, bound antibody was separated by magnetic separation as 
described above and tubes counted for 60 seconds in a gamma counter. 
3.4.4. Cortisol 
Buffer Assay buffer (0.1% gelatin in 0.1M PBS pH 7.4) was prepared as 
described in section 3.4.1. 
Extraction Steroids were extracted from 50µ1 plasma in 2.5ml diethyl ether 
(BDH Ltd, Poole, Dorset : Analar grade). After vortexing for 10 minutes, the 
aqueous phase was frozen in a dry ice /methanol bath and the organic phase 
decanted into boroscilicate tubes and evaporated under nitrogen. The dried tubes 
were stored at -20 °C and reconstituted in 250µ1 assay buffer at the time of assay. 
Reconstituted samples were vortexed and allowed to stand at room temperature for 
30 minutes prior to assay. Each batch of samples were extracted in parallel with 
six l000 aliquots of dexamethasone suppressed sheep plasma containing a l01.11 
aliqout of 125I cortisol to calculate the efficiency of each extraction. The mean 
extraction efficiency was 95% 
Antibody Anti -cortisol 5004 -201 (SAPU) was raised in sheep against 
cortisol -3- (carboxymethyl) -oxime -BSA conjugate. Aliquots of antibody were 
diluted 1:8000 in assay buffer prior to use. Antibody crossreativity as quoted by 
SAPU are: corticosterone, 0.18 %; cortisone, 0.07 %; 21- deoxycortisone, 0.30 %; 
11- deoxycorticosterone, 0.03 %; 17a- progesterone, 2.10 %. 
Iodination 125I- Cortisol (cortisol -3 -( carboxymethyl )- oximino- (2- [1251]- 
iodohistamine) was purchased from Amersham International and used at 
15000cpm /100µ1. 
Standards and Quality controls Cortisol standard (Sigma) was stored as a 
lmg/ml solution in ethanol in a glass vial at -20 °C. From the top stock solution a 
working stock of 10014/10ml was prepared in assay buffer and stored at 4 °C. 
Standards for assay in the range 8000- 15.6pg/100u1 were prepared on the day of 
use from the 4 °C stock. Dexamethasone- suppressed sheep plasma with cortisol 
added at three concentrations was used as quality controls. 
Separation Separation was by the second antibody precipitation method using 
normal sheep serum (NSS, 1:600) and donkey anti -sheep serum (DASS, 1:30, 
both from SAPU) diluted in assay buffer. 
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Method On day one, l000 aliqouts of extracted sample were incubated with 
l000 anti -cortisol antibody and l00111 of the radiolabelled tracer for at least 4 
hours at room temperature. After the incubation period, all tubes except the total 
counts received 100111 NSS and 100 [11 DASS and the tubes were incubated 
overnight at 4 °C. The next day, lml 0.9% saline containing 0.2% Triton X -100 
was added to all tubes except total counts and the tubes spun at 2500rpm for 30 
minutes at 4 °C. The supernatant was decanted and the tubes counted for 60 
seconds in a Multigamma counter. Results were corrected for extraction 
efficiency by reference to the control extraction samples. 
Sensitivity The assay had a lower limit of detection of 0.5ng /ml and intra- and 
inter -assay coefficients of variation of 13% and 15% respectively. 
3.5. ACTH Immunoradiometric assay. 
Buffer Assay buffer was made by addition of 5g BSA, 1ml TritonX -100 
and 0.01g sodium azide to 1 litre of 0.1M phosphate buffer. 
Tracer /antibody Iodinated ACTH antibodies were purchased from Europath 
Ltd, Cornwall, UK. Lyophilised vials were reconstituted on the day of use 
according to the manufacturers instructions. 
Standards Synthetic ACTH1_39 (Cambridge Research Biochemicals) standard 
was stored as 100ng/m1 aliquots in 0.05M phosphate buffer, 0.5% BSA, 0.02% 
sodium azide. A fresh aliquot was used for each assay and was diluted in assay 
buffer to give a standard range of 5000 -5 pg/mi. 
Separation Bound hormone was separated by second antibody precipitation 
using normal rabbit serum (NRS, 1:400) and donkey anti -rabbit serum (DARS, 
1:20, SAPU). 
Method Standard curves were set up as described previously except for the 
addition of 1000 dexamethasone suppressed plasma to all standard and Bo tubes. 
NSB tubes were not included since the radiolabelled tracer was also the antibody. 
1000 of sample, 100µ1 assay buffer and 100µ1 of the labelled antibody cocktail 
were incubated overnight at 4 °C. The next day 1000 NRS (1:400) and l00111 
DARS (1:20) was added to all tubes except total counts and the tubes were left to 
incubate for 4 hours at room temperature. 1 ml of 2.5% polyethylene glycol 600 
(BDH Ltd) in 0.9% saline was added to each tube before spinning at 3000rpm for 
30 minutes at 4 °C. Tubes were inverted and drained for 30 minutes before 
counting for 60 seconds in a Multigamma counter. 
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Sensitivity The assay had a lower limit of detection of 15pg/ml and the intera- 
and inter -assay coefficients of variation were 9.8% and 6.2% respectively. 
3.6. Tissue collection and processing. 
3.6.1. Collection to paraformaldehyde 
Ewes were killed with an intravenous overdose of anaesthetic (Euthasate; Willows 
Fransic Veterinary, Crawley, Sussex) and fetuses were removed through an 
abdominal incision. Fetuses received an anaesthetic overdose in the form of a 
cardiac puncture and intact fetal pituitaries were collected immediately. Tissues 
were fixed for 24 hours in 4% paraformaldehyde (BDH Ltd.) in phosphate buffered 
saline before transferring to 70% ethanol for temporary storage before processing. 
3.6.2. Processing and sectioning of fixed tissue 
Tissue was processed through a graded series of alcohols in an automatic 2LE 
Processor (Shandon Scientific Limited, Cheshire, England) using a standard 17.5 
hour cycle and embedded in paraffin wax. 
Glass microscope slides to be used for in situ hybridisation were washed, dried 
and baked at 300 °C for 8h. Slides were then rinsed sequentially in acetone (BDH 
Ltd.), 0.25% (v /v) 3- aminopropyl triethoxysilane (TESPA, Sigma) in acetone 
(BDH Ltd.) and filtered distilled water before air drying. 
Paraffin wax embedded tissue was sectioned to a thickness of 51.1.m using a hand 
operated Microtome (Jung RM 2035, Leica). Sections for in situ hybridisation 
were floated on RNase -free water (double -distilled water UV crosslinked to inhibit 
RNase activity), transferred onto the treated slides and dried overnight at 50 °C 
before use. Sections for use in immunostaining were sectioned as above but were 
floated on distilled water before drying onto treated slides. 
3.6.3. Collection to liquid nitrogen 
The intermediate lobe of the pituitary gland was dissected free of the anterior lobe, 
weighed and frozen in liquid nitrogen. A small coronal slice, 2 -3mm, was 
removed from the middle of the anterior lobe and placed in 4% paraformaldehyde 
and was processed for sectioning as described above. The remaining two pieces of 
anterior lobe were cut in half along the midline /intermediate lobe tract and 
opposing quarters were weighed and frozen together in liquid nitrogen. 
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3.7. Immunohistochemistry. 
3.7.1. Antibodies 
Three different antibodies for immunohistochemistry were routinely used in these 
studies. 
(i) anti- a- melanocyte stimulating hormone (R6FB). 
R6FB was the kind gift of Dr. Bridget Baker University of Bath and is the same 
antibody used in the radioimmunoassay studies in Chapter 6. a -MSH antibody 
was used for immunohistochemistry at a concentration of 1:1000. 
(ii) prolactin antibody #50. 
The prolactin antibody #50 was raised in a rabbit and was the kind gift of Prof. A 
McNeilly, MRC Reproductive Biology Unit, Edinburgh. Prolactin #50 was the 
same antibody used in the prolactin radioimunoassay studies in Chapter 6. The 
antibody was used at a concentration of 1:20000 for immunohistochemisty. 
(iii) corticotrophin -like intermediate lobe peptide (CLIP) antibody. 
The CLIP antibody was a gift from Professor L.Rees, Dept. of Clinical 
Endocrinology, St.Bartholomews Hospital, London. This is a rabbit antibody 
raised against ACTH(18_39) which also shows 100% cross -reactivity with 
ACTH(1_39). CLIP antibody was used at a dilution of 1:500. 
The optimal concentration for all primary antibodies was determined by testing 
various dilutions of each antibody in the immunohistochemical procedure outlined 
below. The optimal dilution was identified as the dilution that resulted in specific 
staining with the minimum amount of background staining. Specificity of the 
antibody staining was assessed by preabsorption of the antibody for 24 hours at 
4 °C with 5µM concentrations of the antigen. The preabsorbed antibody was then 
treated as a primary antibody in the method outlined below. 
3.7.2. Tissue pretreatment and primary antibody 
Tissue prepared as described in section 3.6 was dewaxed in histoclear (National 
Diagnostics, Atlanta, Georgia, USA) for 15 mins and rehydrated through an 
alcohol series to water. Endogenous peroxidase activity within the tissue was 
inhibited by a 30 mins incubation in a solution of 3% (v /v) hydrogen peroxide 
(Sigma) in methanol (BDH Ltd.). Slides were then washed in 0.5% triton X -100 
in water for 15 mins to increase antibody penetration followed by two 5 minute 
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washes in Tris buffered saline pH7.6 (TBS ; 0.9% NaC1 in 0.05M Tris buffer). 
Tris buffered saline was used in washes to reduce non -specific ionic interactions 
of the tissue with antibody. Slides were then treated with a blocking solution 
containing 5% (w /v) bovine serum albumin diluted in 25% normal swine serum in 
TBS and incubated in a humidity chamber for 30 mins at room temperature. The 
blocking solution was removed and replaced with primary antibody diluted to the 
required concentration in blocking solution and incubated overnight in the 
humidity chamber at 4 °C. 
3.7.3. Secondary antibody and detection system 
Horse radish peroxidase (HRP) detection system. The secondary antibody for the 
HRP detection system was biotinylated swine anti -rabbit immunoglobulins 
(SARB; Sigma). After removal of primary antibody with two washes in TBS, 
SARB diluted 1:500 in TBS was added to the tissue sections and incubated in a 
humidity chamber for 30min. Excess antibody was removed by 2 x 5min washes 
with TBS. Sections were incubated with an AB -HRP complex (Dako, Glostrup, 
Denmark) for 30min. This is a solution of avidin and biotinylated -HRP which 
serves to amplify the signal obtained from the primary antibody. The solution was 
prepared according to the suppliers instructions in 0.05M Tris /HC1 pH7.6 at least 
20min before use. Excess AB -HRP complex was removed by 2 x 5min washes in 
TBS and bound antibody visualised with a solution of 22511M diaminobenzidine 
(Sigma) in 0.05M Tris /HC1, pH7.6 containing 0.01% hydrogen peroxide. The 
slides were monitered microscopically until the colour reaction developed and the 
reaction terminated by rinsing in water. Slides were then counterstained in 
haematoxylin, dehydrated through the alcohol series and mounted with Pretex 
(Cell Path PLC, Hemel Hempstead, Herts., England). 
3.8. RNA extraction and separation. 
3.8.1. RNA extraction 
RNA was extracted from frozen tissue according to the method of Chomczynski & 
Sacchi (1987) with appropriate adjustment of volumes depending on tissue weight. 
The tissue was homogenised in solution D which consisted of 4M guanidine 
thiocynate (Fluka Biochemika, Gillingham, Dorset, UK), 25mM sodium citrate 
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(Sigma), 0.5% sarcosyl (Sigma) and 0.1M ß- mercaptoethanol (Sigma). Tissue 
was homogenised for approximately 30secs until completely dissociated. To this 
homogenate was added 2m1 2M sodium acetate (Sigma) pH4.0, 20m1 water 
saturated phenol (Gibco BRL, Paisley, Scotland) and 4ml chloroform /isoamyl 
alcohol (v /v 49:1, Sigma). The solution was mixed vigorously by shaking after 
each addition. The mixture was placed on ice for 15min and then centrifuged at 
10,000g for 20min at 4 °C. The top, aqueous phase containing the RNA was 
removed to a new tube and an equal volume of cold ( -20 °C) isopropanol (Sigma) 
was added. The RNA was precipitated at -20 °C for at least lh, centrifuged at 
10,000g for 20min at 4 °C, the supernatant was discarded and the RNA pellet 
redissolved in approximately lml solution D. An equal volume of isopropanol 
was added and the RNA reprecipitated at -20 °C for at least 1h. RNA was pelleted 
by centrifugation (10,000g for 20min), washed in lml 75% ethanol, recentrifuged 
and air dried. The RNA pellet was dissolved in RNase -free water by warming to 
65 °C for 10min and stored at -70 °C. 
RNA was scanned at 260 and 280nm on a spectrophotometer. The 260:280 ratio 
for each sample was calculated to give an estimation of the purity of the RNA. A 
ratio of 2.0 was taken to be pure. The concentration of the RNA was calculated 
from the 260nm value where an optical density of 1.0 is equal to 40 tg/m1 RNA. 
3.8.2. Separation of RNA on denaturing agarose gels 
RNA was separated on a 1.5% denaturing agarose gel. The gel was prepared by 
melting 2.25g Seakem agarose (Flowgen, Sittingbourne, England) in 127m1 
RNase -free water. This was cooled to about 60 °C and 15ml of 10 x running 
buffer (consisting of 200mM 3- [N- Morpholino]propanesulfonic acid (MOPS), 
10mM EDTA and 50mM sodium acetate, pH7.0) plus 8.1m1 37% formaldehyde 
(all from Sigma) added. The solution was mixed gently and poured into a gel tray 
(15 x 20cm) containing a 15 well comb in a fume hood. After setting, the comb 
was removed and the gel submerged in 1 x running buffer in a Sub -Cell 
electrophoresis cell (Bio -Rad, Hertfordshire, England). 
RNA (151.1g) in a volume of no greater than 51.11 was prepared by adding 15.41l of 
sample buffer and heating at 60 °C for 5min. Sample buffer consisted of 10011l 10 
x running buffer, 500µ1 deionised formamide and l78111 formaldehyde. After 
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heating, 811 of dye solution containing 7.5% (w /v) ficoll 400, 0.1% w/v 
bromophenol blue and 111 of lmg /ml ethidium bromide (all from Sigma) was 
added to each sample. RNA was loaded into individual wells of the gel and 
separated by running overnight at 35V or for 5hours at 120V. 
3.8.3. Concentration of RNA samples by ethanol precipitation 
For RNA samples that required concentration, one tenth of the sample volume of 
3M sodium acetate (pH 5.5 ; Sigma) was added . Two volumes of cold ( -20 °C) 
absolute alcohol (Sigma) was added and the sample left to precipitate overnight at 
-20 °C. The next day, the sample was centrifuged for 20 minutes at 13000rpm, 
supernatant decanted and the RNA pellet redissolved in RNase -free water. 
3.8.4. RNA transfer to membrane 
RNA separated on a denaturing gel (section 3.8.2) was transferred to nylon 
membrane (Hybond -N; Amersham International) by capillary blotting as shown in 
Fig 3.4. The nylon membrane was prewetted with RNase -free water followed by 
20 x SSC (175.3g naCl, 88.2g sodium citrate in 1 litre RNase -free water: pH 7) 
before placing carefully on the gel. Transfer using 20 x SSC was allowed to 
continue for a minimum of 12h. After transfer the position of the gel wells were 
marked on the membrane and RNA was bound to the membrane by exposure to 
UV light. Membranes were wrapped in cling film and stored at 4 °C until used for 
Northern analysis (Section 3.10). 
3.9. Plasmid preparation and analysis. 
3.9.1. Transformation of POMC plasmids into competent cells 
One 4011 vial of competent cells (XL -1 blue; Stratagene Ltd., Cambridge, 
UK), 800 µl SOC medium (0.5% Bacto yeast extract, 10mM NaC1, 2.5mM KC1, 
10mM MgC12, 10mM MgSO4, 20mM glucose) and POMC sense and antisense 
plasmid in TE buffer (consisting of 10mM Tris -HC1, pH8, 1mM EDTA) were 
thawed on ice. 111 (5 -10ng) of POMC probe (sense or antisense) was added to an 
aliquot of competent cells. The tube was tapped gently to mix and incubated on ice 
for 1 minute. The cell suspension was transferred to a 0.2cm cuvette and the cuvette 
placed in the Gene Pulser apparatus (BioRad, California, USA). The electrophoresis 
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Figure 3.4. Schematic representation of the apparatus used to transfer RNA from a 
denaturing gel onto Hybond N membrane by capillary action. 
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reaction was activated (2.5µF, 20052, 2.5V) and maintained for 15 seconds. After 
this time, the cuvette was removed from the machine and 800111 SOC medium 
quickly added and the cells resuspended with a pipette. The SOC /cell mix was 
transferred to a 12 ml tube and placed in an orbital shaker at 37 °C, 225 rpm for 1 
hour. During this time, Luria Bertani (LB) agar plates were prepared. LB agar (Bio 
101 Inc., Vista, CA, USA) containing 200µ1 ampicillan (5014/ml) was poured into 
the bottom of petri dishes and left to set. Once set, dishes were moved to an 
incubator at 37 °C to dry. 10014 50µ1 and 25111 of transformation reaction was 
spread onto agar plates and incubated overnight at 37 °C. 
3.9.2. Growth of bacterial cultures and glycerol stock preparation 
Individual colonies from LB agar plates were transferred to 10 ml LB broth (Bio 
101 Inc.) containing 50µg/ml ampicillin with a sterile plastic loop and incubated 
overnight at 37 °C, shaking at 225revs. The next day, two glycerol stocks 
consisting of 600µ1 of 50% glycerol and 300111 of LB culture were made. The 
resultant glycerol stocks were stored at -20 °C and -70 °C. 
3.9.3. Plasmid preparation from bacterial cultures 
Plasmid DNA was isolated from 10m1 bacterial cultures, after preparation of 
glycerol stocks where appropriate, by the alkaline lysis method using the 
WizardTM DNA purification system from Promega (Southampton, England). 
Briefly, suspensions were centrifuged at 1600g and the supernatant discarded, 
cells resuspended in buffer containing 50mM Tris/HC1, pH7.5, 10mM EDTA and 
100µg/ml RNase and lysed with an equal volume of 0.2M NaOH and 1% SDS. 
The suspension was neutralised with 1.32M potassium acetate and centrifuged for 
5min at 12,000g resulting in sedimentation of bacterial genomic DNA. The 
supernatant (approximately 600µ1) was removed, mixed with 1ml DNA 
purification resin and passed down a miniprep column which retarded only the 
plasmid DNA. The column was washed with an ethanol based solution containing 
0.2M NaCl, 20mM Tris/HC1, pH7.5 and 5mM EDTA. 50111 double distilled water 
heated to 65 °C was added to the column and incubated at room temperature for 
lmin. DNA was eluted from the column by centrifugation at 12,000g for 1 minute 
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and a further 500 double- distilled water added and the process repeated to give a 
final volume of 100µl. 
3.9.4. Plasmid DNA quality and concentration 
Purity of plasmid DNA was determined by analysis on a 0.8% agarose minigel. 
This was prepared using Seakem agarose dissolved in lx TBE buffer (l0X TBE 
consists of 0.089MTris base, 0.089M boric acid, 10mM EDTA; all from Sigma). 
The agarose was melted and approximately 20011g/m1 ethidium bromide was 
added for visualisation of DNA. The gel was poured into a 7cm by 10cm gel tray 
containing an 8 well comb and submerged in 1 x TBE buffer in an electrophoresis 
submarine cell.(Hoefer, Newcastle, England). Plasmid DNA (11.1l) was run in a 
sample solution containing 1111 'orange juice' (consisting of 0.25% (w /v) orange G, 
15% (w /v) ficoll and 0.5M EDTA at pH7.0) and 8111 water. Samples were 
separated in parallel with pGem DNA markers (range 36- 2,645bps, Promega) by 
electrophoresis at 100V for 1 -2h in 1 x TBE, viewed under UV light and 
photographed. Pure plasmid DNA appeared as two visible 'bands' of greater than 
2kb (depending on plasmid size); one for the circular DNA and the other 
representing supercoiled DNA which migrates more rapidly through the gel due to 
its compact form. Approximate plasmid DNA concentration was determined by 
comparing the sample with known concentrations, 10Ong and 200 ng of plasmid 
DNA standards (pBR322, Promega) also run on the gel. 
3.10. Preparation of radiolabelled probes for Northern blot 
analysis. 
3.10.1. Preparation of plasmids for labelling 
Plasmid DNA prepared as described previously (see section 3.9) was linearised in a 
reaction containing 11.1g DNA, l0U restriction enzyme (SP64 and SP65 utilise Hind 
III ; Boehringer Mannheim, Lewes, East Sussex), reaction buffer B (contains 
lOmmol /1 Tris /HC1, 5mmo1 /1 MgC12, 100mmo1/1 NaC1 and lmmol /1 13- 
mercaptoethanol, pH8 ; Boehringer Mannheim) and RNase -free water to a volume 
of 30p1. The reaction was incubated at 37 °C for 1 -1.5h. Thereafter, 3111 of reaction 
mix was run on a minigel (0.8% agarose) and compared to an uncut sample of the 
same plasmid run in a parallel lane to test efficiency of digestion. Digested DNA 
was then extracted once with Tris- buffered phenol:chloroform (CAMLAB, 
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Cambridge, England) and precipitated with 1 /10th volume 3M sodium acetate pH5.5 
and 2 volumes absolute ethanol overnight at -20 °C. Linearised DNA was pelleted, 
dried and resuspended in l0111 pure water. 
3.10.2. Radioactive labelling of riboprobe for Northern analysis 
Radioactive riboprobe was synthesised using linearised plasmid DNA (prepared as 
described in section 3.10.1) and SP6 RNA polymerase (Boehringer Mannheim). 
Linearised plasmid was incubated with 32P UTP in a reaction mixture containing 
containing 10mM DTT, 20U RNase inhibitor, 1mM each rATP, rCTP and rGTP, 
transcription buffer (1 x transcription buffer consisiting of 40mM Tris/HCI, pH7.9, 
6mM MgCl2, 2mM spermidine and 10mM NaCI; all from Promega) and 5011Ci 32P- 
UTP (Amersham International). The reaction was catalysed by addition of 30U of 
the appropriate RNA polymerase (SP6, Boehringer Mannheim) and incubated at 
37 °C for approximately lh. After this time 25111 phenol:chloroform was added and 
the tube vorted briefly and centrifuged at 13000rpm for 1 minute. The upper layer 
was decanted into a new tube and subjected to ethanol precipitation on dry ice for 30 
minutes. The superntant was decanted and the pellet dissolved in 50111 RNase -free 
water and the activity of 2 x 411 aliquots was determined by liquid scintillation 
spectroscopy. The radiolabelled riboprobe was then added to the hybridisation 
mixturé (section 3.10.3) 
3.10.3. Synthesis of 18S rRNA oligonucleotide 
18S rRNA oligonucleotide was synthesised using phosphoramadite chemistry on a 
Model 381 DNA synthesiser (Applied Biosystems, Warrington, UK). 
Oligonucleotides were recovered into lml of pure concentrated ammonia, 
deprotected by incubating overnight at 65 °C, recovered by two rounds of ethanol 
precipitation and resuspended in TE buffer (10mM Tris, 0.1mM EDTA). The 
concentration of the oligonucleotides were estimated by spectroscopy at 260nm 
where an optical density of 1.0 is equal to a concentration of 2011g/ml. 
3.10.4. Radioladelling of oligonucleotide for Northern analysis 
Oligonucleotides were labelled at the 5' end using polynucleotide kinase (PNK). 
DNA was incubated with [y - 32P]ATP in a reaction mixture containing 50ng DNA, 
3011Ci [y- 32P]ATP, 1 x kinase buffer (10 x buffer contains 0.5M Tris /HC1, 0.1M 
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MgC12, 50mM DTT, 1mM spermidine and 1mM EDTA) and 8U T4 PNK 
(Amersham). The reaction was allowed to continue at 37 °C for 30 minutes. 
Unincorporated nucleotides were removed by passing the reaction mixture down a 
Clontech ChromaSpin +TE -10 spin column. The labelled oligonucleotide was then 
added directly to DNA hybridisation mix (section 3.11). 
3.11. Northern blot analysis 
3.11.1. Hybridisation of radiolabelled probe to membrane 
Riboprobe Membranes were prehybridised at 65 °C for 2 -4 hours in buffer 
containing 0.2M sodium phosphate pH7.2, 1mM EDTA, 1% BSA, 7% SDS and 
45% formamide. Radiolabelled probe was added to the hybridisation mix at a 
final concentration of 0.5 - 1 x 106 cpm /ml buffer. Hybridisation was allowed to 
continue for 24 -48 hours at 65 °C. 
Oligonucleotide Probe Membranes were prehybridised at Tm of probe minus 
10 °C. Tm is the melting temperature of the probe dependent on the nucleotide 
content of the DNA and was calculated using the formula (4 x G +C) + (2 x A +T). 
Tm of 18S rRNA probe was 92 °C. Prehybridisation buffer contained 0.05% w/v 
BSA, w/v polyvinylpyrrolidine, 0.05% w/v ficoll, 0.1% w/v SDS, 0.1% w/v 
sodium pyrophosphate, 5 x SSC and 100jtg/ml sonicated salmon sperm DNA 
(Sigma). Labelled probe was added to the mix and hybridisation allowed to proceed 
for 24 -48 hours. 
3.11.2. Post -hybridisation washes 
Riboprobe Membranes were washed with buffer containing 40mM sodium 
phosphate pH7.2, 1mM EDTA and 1% SDS. Washes were at 65 °C for 2 x 30 
minutes. 
Oligonucleotide Probe Membranes were washed with 4 x SSC at Tm minus 
5 °C for 2 x 30 minutes. For more stringent washes 1 x SSC, 0.5 x SSC or 0.1 x SSC 
were used. 
3.11.3 Development of signal 
After washing, membranes were air dried briefly and wrapped in clingfilm. The 
membrane was then exposed to X -ray film (XAR -5 or X -Omat S; Kodak) in 
cassettes with Dupont enhancing screens at -70 °C. After a specific exposure time the 
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signal was developed using LX 24 developer and fixed using FX 40 fixative 
according to the suppliers recommendations (both Kodak). 
3.12. Probe preparation for in situ hybridisation. 
3.12.1. Template preparation 
Linearised plasmid for use in in situ hybridisation was prepared as for Northern 
analysis and is described in section 3.10.1. 
3.12.2. Preparation of radiolabelled riboprobe 
Synthesis of riboprgbes was carried out using 1µg linearised template in a reaction 
mix containing 10mM DTT, 20U RNase inhibitor, 1mM each rATP, rCTP and 
rGTP, transcription buffer (1 x transcription buffer consisiting of 40mM Tris/HC1, 
pH7.9, 6mM MgC12, 2mM spermidine and 10mM NaC1) and 50 tCi 35S -UTP. 
The reaction was catalysed by addition of 30U of the appropriate RNA polymerase 
(SP6) and incubated at 37 °C for approximately 1.5h. The DNA template was then 
removed by digestion with 40U RNase -free DNase for 10min at 37 °C. Enzymes 
and salts were removed by passing the radiolabelled sample through a Nu -Clean 
R50 disposable spin column (Kodak) according to the manufacturers instructions 
or by two cycles of phenol/chloroform extraction. RNA was precipitated with 
sodium acetate and ethanol overnight at -70 °C and recovered by centrifugation as 
above. 
Radiolabelled RNA was air dried, resuspended in 50µ1 RNase -free water and the 
activity of 2 x 1pl aliquots was determined by liquid scintillation spectroscopy. 
The average activity of the two samples was calculated and the volume of probe 
necessary to give 1 x 106 cpm was determined. 
3.13. Radioactive in situ hybridisation. 
3.13.1. Pretreatment of tissue and probe hydridisation. 
Paraffin wax embedded tissue was cleared in histoclear for 15min and rehydrated 
in a series of alcohols with decreasing concentrations. Tissue was placed in 0.2N 
HCl for 20min followed by two 5min washes in distilled water. Sections were then 
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incubated in 21.1g /m1 proteinase K (Sigma) in buffer consisting of 20mM Tris /HC1 
pH7.4 and 50mM EDTA at 37 °C for 20min followed by 0.2% glycine in water at 
4 °C for 10min. Sections were washed briefly in O.1M triethanolamine (TEA; 
Sigma), pH8.0 and acetylated in 0.25% acetic anhydride (BDH Ltd) in 0.1M TEA, 
pH8.0 for 10min. Finally, sections were rinsed in distilled water and prehybridised 
in buffer containing 4 x STE (1 x STE contains 150mM NaC1, 2.5mM Tris and 
0.25mM EDTA), 1 x Denhart's solution (50 x Denhart's contains 5g BSA, 5g 
polyvinylpyrrolidine and 5g ficoll in 500m1 solution), 10mM DTT, 12514/m1 
salmon sperm DNA, 1251.1g /ml yeast transfer RNA and 50% deionised formamide 
(all from Sigma) for 2 -4h at 55 °C. Excess prehybridisation buffer was removed 
from slides and replaced with probe at a concentration of 1x106 cpm /4O111 
hybridisation buffer (as prehybridisation buffer plus 10% dextran sulphate) /slide. 
Incubation with probe was carried out beneath gel bond film coverslips (Flowgen 
Instruments Ltd.) in a humidified chamber at 55 °C for 18hours. 
3.13.2. Post hybridisation washes 
After incubation, sections were washed twice with 4 x SSC over 15min to remove 
the coverslip and treated with RNase A (Sigma) at a concentration of 2014/m1 in 
0.5M NaC1, 0.1M Tris, pH8.0 and 1mM EDTA for 30min at 37 °C. Sections were 
washed for 30 min in RNase buffer alone at 37 °C, followed by two 30 min washes 
in 2 x SSC at room temperature and 45 °C, with a final 30 min wash in 0.5 x SSC at 
room temperature. 
3.13.3. Development of in situ hybridisation 
After post hybridisation washing, sections were dehydrated through alcohols 
containing ammonium acetate and air dried. Slides were warmed to 45 °C and 
dipped in prewarmed NTB2 emulsion (Kodak) at 45 °C in the dark. Emulsion 
coated slides were stored in a humidified, lightproof box overnight before transfer 
to a polyacetyl black trough (lightproof; Lamb's laboratory supplies, London, 
England) with silica gel. and stored at 4 °C until developed at times specified in the 
relevent chapters. Silver grains formed by reaction of the hybridised, 
radiolabelled probe with the emulsion were developed using Kodak D19 
developer as follows. Slides were placed in developer cooled to 14 °C for 4min, 
followed by a brief wash in distilled water and grains were fixed by a 5 min 
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incubation in Kodak unifix at 14 °C. Sections were washed in water, stained with 
haematoxylin, dehydrated and mounted in Pertex. 
Slides were analysed under dark field using either BIOMED or LABORLUX 12 
microscopes (Leitz, Wetzlar, Germany) or the Zeiss Photomicroscope III (Zeiss, 
Hertfordshire, England) to visualise the silver grains indicating areas of 
hybridisation. 
Chapter 4. Identification and maturation of AVP 
neurons in serum -free cell culture 
4.1. Introduction 
The role of the hypothalamic neuropeptides, CRH and AVP in the release of ACTH 
from the fetal pituitary gland has been extensively demonstrated both in vivo 
(Brooks et al., 1987; Apostolakis et al., 1991; Brooks and White, 1990) and in vitro 
(Durand et al., 1986; Brooks et al., 1987; Lü et al., 1994). However, the factors 
controlling the development of these neuropeptide neurons within the hypothalamus 
has been less widely studied. Recently, it has been suggested that growth factors 
play a role as putative neurotrophic factors to neurons of the central nervous system. 
Growth factors including basic fibroblast growth factor, nerve growth factor and 
brain derived neurotrophic factor have been shown to enhance survival and neurite 
outgrowth from CNS neurons (Walicke, Cowan, Ueno, Baird and Guillemin, 1986; 
Hofer and Barde, 1988; Alderson, Alterman, Barde and Lindsay, 1990; Arimatsu 
and Miyamoto, 1991). Insulin -like growth factor -1 has been implicated as a putative 
neurotrophic factor for fetal rat hypothalamic neurons (Torres -Aleman, Naftolin and 
Robbins, 1989; 1990). Addition of IGF -1 to primary hypothalamic cultures results 
in a significant dose -dependant increase in neuronal survival which is accompanied 
by increased levels of protein kinase C, which has previously been shown to 
increase in neuronal culture as a function of time and in parallel with increased 
neurite outgrowth and synaptogenesis (Girard, Wood, Freschi and Kuo, 1988). 
The complex interactions of the hypothalamus make it difficult to study constituent 
neuronal populations in the intact animal. The development of a serum -free cell 
culture system for maintenance of rat hypothalamic neurons (Clarke and Gillies, 
1988) provides a valuable tool for the investigation of hypothalamic neurons in a 
defined environment. In this way neurons of the hypothalamus can be studies in a 
defined situation, free from the complex interactions of the developing brain and the 
feedback influences of the HPA axis. AVP neurons in vitro respond to potassium 
depolarisation in a Ca2+ -dependant fashion with release of peptide and this response 
can be repeatedly evoked over a period of weeks. Stimulated release of AVP in 
response to potassium can be maintained for at least 4 hours, illustrating that 
cultured neurons are capable of synthesising mature peptide. In addition, secretion 
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can be inhibited by pretreatment with glucocorticoid demonstrating that the neurons 
maintain the ability to respond to physiological stimuli (Clarke and Gillies, 1988). 
The development of neuronal systems is presumed to be regulated by the availability 
of neurotrophic factors. However, for most neuronal populations, including the 
developing AVP neurons the identity of these factors is unknown. The aim of this 
study was to identify AVP neurons within an in vitro culture system and to chart 
their growth and development with the long term goal of identifying putative 
neurotrophic factors which may influence their maturation. Central to this project 
was the ability to identify AVP neurons in culture by immunocytochemistry in order 
that the effects of putative neurotrophic factors on neurite outgrowth and AVP cell 
number could be examined. The secretion of peptide into the culture medium in 
response to potassium- induced depolarisation is often used as a measure of 
functionality of peptidergic neurons (Clarke and Gillies, 1988; Clarke, Lowry and 
Gillies, 1987; Sarkar and Sakaguchi, 1990; Currie et al., 1994) and was used in this 
study to illustrate the presence of viable AVP neurons within the culture system. 
The influence of IGF -1 on the functional maturation of the neurons was assessed by 
determining the effect of incubation of hypothalamic cultures with differing doses of 
IGF -1 on basal and potassium- induced AVP secretion. 
4.2. Materials and methods 
4.2.1. Animals 
Adult Wistar rats were obtained from an 'in- house' colony at the Centre for 
Reproductive Biology, Edinburgh. The rats were maintained in a 12 hour light: dark 
cycle with lights on at lam and were given access to food and water ad libitum. 
Rats were . time -mated by monitoring intra- vaginal smears to determine the stage of 
the female reproductive cycle. Females were placed with males for 48 hours 
spanning the period of the next oestrus cycle. The day of oestrus was designated 
day 0 of pregnancy. Pregnant female rats were housed together until fetal 
hypothalami were collected at day 17.5 gestation (gestation =21 -22 days). 
4.2.2. Treatment of glassware. 
All glassware for use in the cell culture procedure was chemically cleaned to remove 
any surface contamination. Glassware was steeped overnight in 2% 'Micro' 
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detergent (International Products Ltd, Chislehurtst, Kent). The next day, the 
glassware was rinsed and immersed in sterile tissue culture grade water (Sigma) for 
several hours followed by a wash in 1M hydrochloric acid (BDH Ltd.). Glassware 
was then washed sequentially in sterile water, absolute alcohol and sterile water 
again before autoclaving and storing until ready for use. 
All glassware which was to come into contact with cell suspensions was siliconised 
before use to prevent cell adhesion. Glassware was briefly immersed in 'Sigmacote' 
(Sigma) and left to dry in a fume -hood. Upon drying, the glassware was rinsed in 
absolute alcohol and washed several times in sterile water before autoclaving. 
Pasteur pipettes (John Poulten Ltd, Barking Essex) of varying diameters were 
required during the tissue dispersion. Pipettes were heated gently in a Bunsen flame 
until the tips were red hot. Varying the amount of heating produced pipettes of 
differing tip diameter. 
4.2.3. Preparation of media for tissue dispersion and cell culture 
Dulbecco's Modified Eagle's Medium with phenol red and without 1- glutamine 
(DMEM), Dulbecco's Phosphate Buffered Saline (DPBS), Ham's F12 Medium (with 
phenol red and without 1- glutamine), Earle's Balanced Salt Solution without phenol 
red (EBSS) and Hank's Balanced Salt Solution with calcium and magnesium and 
without calcium and magnesium (HBSS with Ca2+ /Mg2+ and HBSS without 
Ca2+/Mg2 +) were purchased from ICN Flow Ltd, Rickmansworth, Hertfordshire. 
Culture grade progesterone, oestradiol, Sodium selenite, transferrin, putrescine, 
gentamycin, insulin, triiodo -thyronine (T3), glucose, bovine serum albumin (BSA: 
fraction V), double processed tissue culture water, HEPES (1M stock) and 
deoxyribonuclease Type 1 (DNase) were purchased from Sigma Chemicals Co. Ltd., 
Poole, Dorset. Penicillin /Streptomycin (Penstrep, 5000IU /ml and 500p.g/ml 
respectively) and glutamine were obtained from ICN Flow Ltd. Dispase (cell 
culture grade Neutral Protease) was obtained from BCL Ltd., London, UK. Insulin - 
like Growth Factor -1 was purchased from Peninsula Laboratories Europe Ltd., 
Merseyside, UK. 
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Media for tissue dispersion 
Media for tissue dispersion were prepared one day in advance, filter -sterilised and 
stored at 4 °C overnight. On the morning of dispersion, enzymes were added and the 
media were warmed to 37 °C. 
Collection buffer consisted of 100m1 HBSS without Ca2+ /Mg2+ containing 500111 
20% BSA in water, 2m1 1M HEPES and 2m1 Penstrep. 
Dispersion medium consisted of collection buffer containing an additional 1.5ml 
20% BSA. 20mg Dispase and 25mg DNase per 100m1 were added on the day of 
use. 
DNase medium was made according to the recipe for collection buffer, except that 
the HBSS contained Ca2 +/Mg2 +. 50mg DNase per 100m1 was added to the medium 
on the day of use. 
Stock solutions and media for cell culture 
Stock solutions for preparation of cell culture media were prepared under sterile 
conditions and stored as stock solutions at 4 °C or as frozen concentrates at -20 °C 
until required. Stock solutions were replaced regularly to ensure freshness and 
sterility. 
Triiodo- thyronine (T3) 5mg T3 were dissolved in 0.1M sterile sodium hydroxide 
solution to a concentration of 0.65mg /m1 (1x10-3M). This solution was further 
diluted in tissue culture grade water to a final concentration of 1x10-6M. Triiodo- 
thyronine solution was freshly prepared on each occasion. 
Insulin stock 20mg of insulin were dissolved in 0.5ml 10 %v /v acetic acid solution 
to a concentration of 10mg/ml. This solution was further diluted in tissue culture 
grade water to a final concentration of 5mg/ml, filter sterilised and stored at 4 °C for 
up to one month. 
Oestradiol -17ß 3.67m1 of sterile absolute ethanol was added to lmg powdered 
oestradiol -173, giving a lx10-3M solution. This was further diluted to a 
concentration of 1x10-6M and 5011l of this solution was added to 50m1 sterile EBSS, 
giving a final stock concentration of 1x10-9M. The stock solution was stored in a 
glass bottle at 4 °C far up to 3 months. 
Progesterone 1.59m1 of sterile absolute ethanol was added to lmg powdered 
progesterone, giving a final concentration of 2x10-3M. 500111 of this solution was 
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added to 50m1 sterile EBSS giving a final stock concentration of 2x10-5M. The 
stock solution was stored and replaced as for the oestradiol solution. 
Arachidonic acid 500mg arachidonic acid was diluted in absolute ethanol to a 
concentration of 100mg /ml. This solution was further diluted in DMEM/Hams F12 
(1:1 v /v) to a concentration of 10011g/ml. Fatty acid free BSA (Sigma) was added to 
the stock solution to a final concentration of 2.5mg/1001.tg arachidonic acid. The 
stock solution was stored in siliconised glass vials at -20 °C. 
Docosahexaenoic acid 500mg docosahexaenoic acid was diluted in absolute 
ethanol and subsequently in DMEM /Ham's F12 as for arachidonic acid, to yield a 
stock solution of 100µg /ml. Fatty acid free BSA was added as described for 
arachidonic acid and the solution stored at -20 °C in siliconised glass vials. 
Combined Supplement for SFCM SFCM stock supplement consisted of 20 ml 
glutamine solution (29.2mg /ml, 0.2M), 20m1 transferrin solution (10mg /m1), 2m1 
putrescine solution (16.11mg /ml, 0.1M) and 20µl sodium selenite (0.52mg/ml, 3x10 - 
3M). The supplement was filter -sterilised and frozen in aliquots at -20 °C for up to 
one month. 
Serum -Free Culture Medium 500m1 serum -free culture medium (SFCM) 
consisted of 250m1 Ham's F12 medium and 250m1 DMEM containing 5001'1 T3 
stock solution (1x10-6M), 50011l insulin solution (5mg/m1), 500µ1 oestradiol solution 
(1x10-9M), 500p1 progesterone solution (2x10-5M), 50011I gentamycin (50mg/m1), 
10m1 penstrep solution, 5m1 arachidonic acid (1)4/m1), 2.5ml docosahexaenoic acid 
(0.4tg/m1) and 10.5 ml of combined supplement. The serum -free medium was then 
filter -sterilised and stored at 4 °C for up to 7 days. The final composition of serum - 
free culture medium is described in Table 4.1. 
Insulin -like Growth Factor -I 10014 IGF -1 was diluted in 10mM hydrochloric acid 
to give a concentration of 10µg /ml. BSA was added at a concentration of lmg /ml 
and the stock aliquoted and stored at -70 °C until required. On the day of use the 
stock solution was further diluted in SFCM to the desired concentration. 
4.2.4. Coating of culture dishes 
On the morning of dispersion, a solution of poly -l- lysine (10µg/ml ; Sigma, MWt. 
70,000- 150,000kD) was prepared in sterile tissue culture grade water. lml of poly-1- 
lysine solution was added to each well of a 35 mm gamma- irradiated Nunc culture 
dish (Gibco Ltd., Paisley, Scotland) or to each well of a 22mm culture dish 
containing a glass coverslip cleaned as described above for 30 minutes. After this 
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Table 4.1. Composition of Serum -Free Culture Medium 
Component Final concentration 
DMEM/Ham's F12 50% : 50% 








Triiodo- thyronine lnmol/1 
Progesterone 20nmo1/1 
Oestradiol 1713 1pmol/1 
Arachidonic acid lµg/m1 
Docosahexaenoic acid 0.514/m1 
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time, the poly -l- lysine was aspirated and the wells were washed twice in sterile 
water. Subsequently. 1m1 of SFCM containing 20% fetal calf serum (ICN Flow 
Ltd.) was added to each well. Culture plates were returned to a humidified incubator 
at 37 °C, 95% air : 5% CO2 atmosphere until ready for use following the dispersion. 
4.2.5. Collection of fetal hypothalami and tissue dispersion 
On day 17.5 gestation, pregnant females were sacrificed by CO2 asphyxiation 
followed by cervical dislocation. Fetuses were removed aseptically, decapitated and 
placed into ice cold sterile saline. Fetal hypothalami were dissected and placed into 
20m1 sterile collection buffer. 
Hypothalami were washed by gentle rotation, centrifuged at 300rpm for 1 minute, 
and resuspended in fresh collection buffer prewarmed to 37 °C. The washing 
procedure was repeated 3 times. Following the washes, the tissue was resuspended 
in 20m1 dispersion medium and the suspension transferred to a 50m1 Bellco stirrer 
flask (Arnold Horwell Ltd., Werst Hampstead, London). The stirrer flask was 
placed in an incubator at 37 °C and the suspension was stirred at 75rpm. After 30 
minutes, the stirrer flask was removed from the incubator and large pieces of tissue 
were allowed to settle. The supernatant was aspirated to a sterile universal, hereafter 
called harvest 1 and returned to the incubator for short -term storage. A further 20m1 
of dispersion medium was added to the tissue in the stirrer flask and the tissue was 
triturated using two sterile, siliconised pipettes of decreasing diameter 
(approximately lmm and 0.5mm). The triturated cell suspension was returned to the 
incubator and allowed to stir for a further 30 minutes. The supernatant was then 
aspirated and stored in a sterile universal, hereafter called harvest 2. A little 
dispersion medium was left in the stirrer flask and the remaining tissue was further 
triturated with pipettes of approximately 0.5mm and 0.2mm diameter. The resultant 
cell suspension was added to harvest 2. Harvests 1 and 2 were centrifuged for 10 
minutes at 1000rpm for 10 minutes and the supernatants discarded. The pellets were 
resuspended and pooled in 20m1 of DNase medium and the suspension returned to 
the incubator for 20 minutes, with occasional end over end rotation. The suspension 
was then centrifuged at 1000 rpm for 10 minutes and the supernatant discarded. The 
cells were resuspended in 5ml of collection buffer and the suspension was gently 
pipetted on top of 20m1 collection buffer containing 4% BSA. The layered 
suspension was centrifuged at 1000rpm for 10 minutes to remove debris. The 
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pelleted cells were resuspended in 2 -3ml of SFCM containing 20% fetal calf serum. 
The total cell number and viability were assessed using a haemocytometer and 
trypan blue exclusion. The suspension was diluted to 2.5x106 cells /ml and lml of 
suspension was added to each 35mm culture well for stimulation experiments. For 
immunocytochemistry experiments, the suspension was diluted to 9.5x105 cells /ml 
to give the same cell density (2.5x105cells/cm2) in a smaller culture dish. 
4.2.6. Maintenance of cell cultures 
After 24 hours of culture, the medium was changed to SFCM containing 41.M 
cytosine ß -D arabinofuranoside, an anti -mitotic agent included to aid the reduction 
in the number .of dividing glial cells in the culture. After a further 24 hours, the 
medium was changed to SFCM alone or SFCM containing IGF -1 at either ing/ml, 
lOng /m1 or lOOng /ml. Thereafter, the media was replaced every 3 days or more 
often as required with fresh SFCM. For cells cultured in the presence of IGF, IGF 
was added to the SFCM at the same concentration at each media change. In some 
cultures insulin was omitted from the SFCM thereby providing two groups of cells, 
those cultured with IGF -1 in the presence of insulin and those cultured with IGF -1 in 
the absence of insulin. 
4.2.7. Peptide release media 
Basal Medium 100m1 of basal release media consisted of EBSS supplemented with 
1ml fresh ascorbic acid solution (Sigma, 3mg/m1 in tissue culture grade water), 1ml 
sterile bacitracin solution (Sigma, 3mg /m1 in tissue culture grade water), lml 
HEPES (1M stock), 2ml penstrep, 800111 aprotinin solution ('Trasylol', Bayer UK 
Ltd., Newbury, 10,000KIU /ml), 100mg D- glucose (Sigma) and 500111 20% BSA in 
water. The medium was filter sterilised and stored at 4 °C for up to 7 days. 
56mM Potassium -containing medium EBSS with raised potassium levels and 
isotonically reduced sodium levels was made in the laboratory. The components of 
the basic salt solution were accurately weighed and all, except for calcium chloride 
were dissolved in 400m1 tissue culture grade water. The calcium chloride was 
dissolved separately in 100m1 of sterile water and was added to the 400m1 salt 
solution slowly, with vigorous mixing of the salt solution to prevent precipitation. 
The solution was filter sterilised and stored at room temperature. The medium was 
supplemented prior to use as described above for the basal release medium. 
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4.2.8. Peptide release protocol 
SFCM was aspirated from the cultures and cells were equilibrated for two 5 minute 
periods in lml prewarmed basal release media. After the equilibration period, the 
medium was aspirated and replaced with 700111 fresh basal release medium and the 
cells returned to the incubator for 3 hours. The basal release medium was then 
collected as two 350µl aliquots and stored at -20 °C. The basal release medium was 
replaced with 70041 of 56mM potassium -containing medium and the cells returned 
to the incubator for a further 3 hour period. At the end of this time, the medium was 
collected and stored as before and the cells were washed three times with lml of 
prewarmed DMEM. Finally, lml of serum -free culture medium was added to each 
well and the cells returned to the incubator. 
To assess the ability of the cultured neurons to produce AVP throughout the duration 
of the culture period, cultures were subjected to repeated stimulations performed on 
day 7, 10, 13, 16 and 20 of cell culture. 
4.2.8. AVP radioimmunoassay 
Buffer Assay buffer consisted of 0.05M phosphate buffered saline containing 
EDTA (1mmol/1), 0.1 %NaN3 and 0.1% BSA. 
Antibody AVP antiserum (NK -2) was kindly supplied by Dr. N. J. Kasting, 
Department of Medical Physiology, University of British Columbia, Vancouver, 
Canada. NK -2 antibody was raised in a rabbit and shows minimal cross -reactivity 
with oxytocin (<0.2 %, Kasting, Carr, Martin, Blume and Bergland , 1983). NK -2 
antibody was added to the assay at a dilution of 1:100,000. 
Iodination 51.1.g AVP was iodinated by the chloramine -T method and purified by 
passing through a sep -pak column as described in section 3.4.1. 
Standards and Quality Controls lmg AVP peptide (Cambridge Research 
Biochemicals, Northwich, Cheshire) was dissolved in O.1M acetic acid to a 
concentration of 50014/ml. Standards in the range 500pg /ml to 5pg /ml were 
prepared as serial dilutions in assay buffer. Quality controls consisted of three 
different concentrations of AVP in EBSS release medium. 
Separation Bound and free 125I -AVP were separated using magnetic donkey anti - 
rabbit IgG particles as described in section 3.4.3. 
Method l00µ1 of standard, sample or quality control was incubated overnight at 
4 °C with 200µl assay buffer and l00111 NK -2 antiserum. The next day, 10O1=t1 
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radiolabelled AVP (15000cpm /l00111) was added to each tube, the tubes were 
vortexed and incubated overnight at 4 °C. The following day, bound peptide was 
separated by magnetic separation as described previously and the pellet counted for 
60 seconds in a gamma counter. 
Sensitivity The assay had a lower limit of detection of 1.75pg/ml and had intra- 
and inter -assay coefficients of variation of 16% and 21.8% respectively. 
4.2.9. Immunocytochemistry 
A range of AVP antibodies were screened using the avidin- biotin horse radish 
peroxidase (AB -HRP) immunocytochemistry protocol described in section 3.7. 
Cells to be utilised for immunocytochemistry were grown on coverslips as described 
above. The immunocytochemical procedure was carried out in the culture well. The 
coverslip was removed at the end of the staining procedure and mounted onto a glass 
microscope slide for viewing. 
Alkaline phosphatase staining method 
Antibodies raised against the neurophysin molecule were examined utilising an 
alkaline phosphatase detection system which utilises nitro -blue tetrazolium (NBT), 
5- bromo -4- chloro -3- indolyl- phosphate (BCIP) and levamisole as substrates. This 
method follows the same basic protocol as the avidin -biotin HRP method except that 
the avidin -biotin complex is linked to alkaline phosphatase (AB -AP) rather than 
HRP. The method is the same as that described in section 3.7 until the point of 
incubation with the avidin- biotin complex. Following the 30 minute incubation with 
the AB -AP complex, the cells were washed in buffer containing 100mM Tris pH 
9.5, 100mM NaC1 and 50mM MgC12 for 5 minutes. Cells were then incubated in the 
colour development solution containing 0.3mg/ml NBT, 0.175mg /ml BCIP and 
0.24mg /m1 levamisole (all from Sigma). Cells were incubated with the colour 
development solution in a dark humidified chamber at room temperature until 
staining was optimal. 
Antibodies 
Anti -AVP antisera used in this study came from a variety of sources. One antibody 
was obtained commercially (Arg8- AVP: Biogenesis Ltd., Bournemouth, England). 
A range of polyclonal antibodies raised in both rabbit (TG1 and TG2) and sheep 
(S277, S278 and S279) were the gift of Dr. Alberto Smith, Department of Child Life 
and Health, The University of Edinburgh. Two further polyclonal antibodies (4S41 
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and 4S12) raised in sheep were the gift of Dr R.J Bicknell, Institute of Animal 
Physiology and Genetics Research, Babraham, Cambridge. Monoclonal antisera 
raised against the neurophysin carrier molecule (PS41 and PS45), which had 
previously identified AVP -neurophysin containing cells in tissue sections and 
hypothalamic slice culture (Whitnall, Key, Ben -Barak, Ozato and Gainer , 1985, 
Gainer and Wray , 1992), were the kind gift of Dr.S.Wray, National Institute of 
Health, Bethesda, Maryland. Staining for Neuron -specific enolase (NSE: 
Cambridge Research Biochemicals, Northwich, Cheshire) which stains all neurons 
of the central and peripheral nervous system was also performed. 
In order to assess the ability of the antibodies screened in cell culture to perform in 
the immunocytochemical protocol, the antisera were tested on paraffin -wax 
embedded sections of rat hypothalamus prepared as described in section 3.6. 
Specificity of the antisera was assessed by incubation of the antibody with specific 
antigen prior to use in the immunohistochemical procedure. Primary antibody was 
diluted in blocking buffer as described previously to which 51.1M AVP peptide was 
added and the antigen -antibody mixture left to incubate overnight at 4 °C. Following 
preabsorption of the antibody with AVP peptide, the preabsorhed antibody was 
treated as a primary antibody in the protocol. 
4.2.10. Data analysis 
AVP concentration in the culture supernatants was expressed as pg/well. Basal and 
potassium- induced AVP secretion from cells at different days in culture were 
analysed by Analysis of Variance (ANOVA). AVP secretion on different culture 
days from cells plated at different densities or in the presence of varying 
concentrations of IGF was analysed by two -way ANOVA. Where indicated in the 
text, difference between basal and stimulated means were analysed by Students t- 
test. All data are expressed as mean ± standard error of mean (SEM) and values of 
p_< 0.05 were considered to he significant. 
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4.3. Results 
4.3.1. Maintenance of hypothalamic neurons in culture 
Dispersed rat hypothalamic neurons plated at a density of 2.5x105cells/cm2 in 35mm 
cell culture dishes were maintained in culture for 20 days. The dispersion procedure 
yielded a cell suspension with 95.14 ± 0.43% viability and each hypothalami 
contributed on average 1.03x106 cells. 
Figure 4.1 shows the effects of potassium- induced depolarisation of neuronal 
cultures plated at 2.5x105cells /cm2 in a 35mm culture dish on AVP secretion over 
the 20 day culture period. Each value represents the mean of 5 cultures from 
different dispersions and the value for each dispersion is the mean of 3 separate 
culture wells. Throughout the 20 day duration of the culture, the AVP neurons are 
secreting a basal level of AVP into the medium which is not significantly altered 
throughout the duration of the culture period. AVP secretion can be repeatedly 
stimulated by potassium- induced depolarisation throughout the culture period. 
Potassium- induced secretion of AVP is significantly increased (p<0.05) from basal 
levels on days 13, 16 and 20 in vitro. 
The overall aim of the experiment was to identify AVP neurons from an early stage 
in culture and to influence the growth and development of these neurons. Initial 
studies were performed to determine the optimal density for visualisation of neurons 
in culture and to determine a density at which cells could be stained 
immunocytochemically whilst still at a density high enough to respond to potassium 
stimulation. Cells were plated at 2.5x105, 1.5x105 and 0.6x105 cells/cm2 in 22mm 
culture dishes and neuronal outgrowth and response to potassium- induced 
stimulation examined. Cells plated at 2.5x105 cells /cm2 respond to potassium - 
induced stimulation on day 13 and 20 of culture with significantly increased release 
of peptide whilst potassium treatment of cells at the two lower densities did not 
result in significant release of AVP (Figure 4.2). The level of both basal and 
stimulated AVP secretion is lower for the 2.5x105 cells/cm2 than for cells plated at 
the same density in Figure 4.1. The reduced level of secretion is likely to reflect the 
lower overall number of AVP neurons in the smaller dishes. 
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Figure 4.1. AVP secretion in day 17.5 gestation fetal rat hypothalamic cultures 
plated at 2.5x105 cells /cm2 in 35m culture dishes. Basal and potassium- induced 
AVP secretion was measured on day 7, 10, 13, 16 and 20 of culture. Data shown are 
the means of 5 separate dispersions where the value for each dispersion represents 
the mean of 3 culture wells, ± SEM. Significant differences between basal and 
potassium- induced AVP secretion are indicated by asterisks (* p<0.05; t- test). 
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Figure 4.2. Basal and potassium- induced AVP secretion from day 17.5 gestation 
fetal hypothalamic cultures plated at 2.5x105, 1.5x105 and 0.6x105 cells /cm2 in 
22mm culture dishes. Data shown represent the means of 10 or more wells ± SEM. 
Significant differences between basal and potassium- induced AVP secretion are 
indicated by asterisks (* p <0.05; t- test). 
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Visualisation of individual neurons was possible at 2.5x105cells /cm2 by phase - 
contrast microscopy. Cultures of hypothalamic neurons plated at this density on 
poly -l- lysine coated coverslips to be utilised for immunocytochemistry were 
examined frequently during the early stages of the culture period and were 
photographed under phase -contrast to obtain a profile of total neuronal growth of 
hypothalamic neurons in vitro during this period. The profile of neuronal growth of 
cells plated at 2.5x105cells /cm2 obtained over the first 48 hours of cell culture is 
illustrated in Figure 4.3. Development of the neurons from rounded cells following 
the dispersion procedure (Figure 4.3a) to cells of a classical neuronal morphology 
was evident over the first two days of culture. Whilst some neurons developed 
elaborate processes which extended in many directions others were bipolar. By 17 
hours (Figure 4.3b) in culture most cells had extended neural processes. The 
neurons continued to extend neurites and began to form connections with other 
neurons. By the time of the first media change at 24 hours (Figure 4.3c), many 
neurons had attached firmly to the culture dish. Glial cells were also evident in the 
culture as flattened fibroblastic cells. By 48 hours in vitro, the dispersed 
hypothalamic neurons had a morphology typical of neuronal cells and the cells 
formed an extensive network of connections (Figure 4.3d). The cell body of the 
neuron is rich in cytoplasm and could be seen to 'glow' under the phase- contrast 
microscope. More connections between neuronal cells were made with increasing 
duration of the culture (Figure 4.3e ; 30 hours) and by 48 hours in vitro the processes 
between cell bodies had developed to form large cable -like structures. Cells plated 
at the two lower densities followed a similar pattern of development. However, cells 
at the lowest density, 0.6x105 cells /cm2 developed their characteristic neuronal 
morphology at a much slower rate than those at the higher densities (data not 
shown). In view of the data generated by the potassium- induced depolarisation and 
visualisation studies, all subsequent experiments were conducted at a density of 
2.5x105 cells /cm2. 
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Figure 4.3. Phase -contrast microscopy of a representative hypothalamic culture 
illustrating neuronal growth over the first 72 hours of cell culture. Photographs 
represent A. 5 hours, B. 17 hours, C. 22 hours, D. 30 hours, E. 47 hours and F. 72 
hours post -dispersion. All photographs were taken at x20 magnification. 
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4.3.2. Hypothalamic neurons cultured in the presence of IGF -1 
Figure 4.4 shows AVP secretion from neurons cultured in insulin -containing and 
insulin- deficient SFCM. Cells cultured in insulin -containing SFCM secreted more 
AVP under basal conditions and responded significantly better to potassium- induced 
stimulation between days 7 and 13 of culture than cells cultured in the insulin - 
deficient SFCM. Neurons in insulin- deficient medium were able to compensate for 
the lack of insulin over time such that the insulin- deficient and insulin -containing 
cultures had similar responses to potassium- induced stimulation by day 20 of 
culture. Hypothalamic neurons cultured in insulin- containing SFCM containing 
IGF -1 at lOOng/ml, lOng /ml and ing /ml are shown in Figure 4.5. Addition of IGF -1 
does not have an additive effect when added to culture medium which contains 
insulin. Similarly, addition of IGF -1 to insulin- deficient SFCM did not significantly 
influence either basal or potassium- induced AVP secretion from cultured 
hypothalamic neurons when compared to SFCM alone control values (Figure 4.6). 
In both insulin -containing and insulin- deficient groups, basal secretion of AVP was 
not significantly altered over the duration of the culture period. Similarly, basal and 
potassium- stimulated levels of AVP secretion were not significantly different 
between groups at any day in culture. 
4.3.3. Immunocytochemical identification of AVP neurons 
Antibodies to be screened for staining of AVP neurons in vitro were first 
characterised using paraffin- embedded sections of rat hypothalamus. Staining of rat 
hypothalami with anti -NSE antisera resulted in intense staining of the neuronal 
fibres present in the hypothalamus, as shown in figure 4.7a. AVP antibodies 
screened displayed varying degrees of success. Figures 4.7c and 4.7e show 
representative sections of rat hypothalamus which stained successfully for AVP with 
anti -AVP antibodies raised in rabbit. Specificity of NSE and AVP staining in the 
hypothalamus was confirmed by the lack of staining upon omission of the primary 
antibody (Figure 4.7b) or preabsorption of AVP antisera with 511M AVP (Figure 
4.7d and 4.7f). Generally, antibodies raised in rabbit performed better than those 
raised in sheep (Figure 4.7g), which tended to have a higher level of non -specific 
staining as illustrated by the background staining present in the non- immune sheep 
serum negative control of Figure 4.7h. Antibodies which stained specifically for 
AVP in hypothalamic tissue sections were then screened for identification of AVP 
neurons in the culture system. 
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Figure 4.4. Basal and potassium- induced AVP secretion from hypothalamic cultures 
maintained in insulin- containing or insulin -deficient serum -free culture medium. 
Cells maintained in insulin -deficient SFCM tended to secrete less AVP than neurons 
which were maintained in insulin -containing SFCM. By day 16 of culture, there 
was no difference in secreted levels of AVP between the two groups. Data shown 
are the mean values of 4 culture wells ± SEM. Significant differences in basal or 
potAssium- induced AVP secretion from cultures maintained in insulin -containing 
and insulin -deficient SFCM are represented by asterisks (* , * *, * * *, p<0.05, p<0.01 
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Figure 4.5. AVP secretion from hypothalamic neurons maintained in insulin - 
containing serum free culture medium alone or supplemented with IGF -1 at ing/ml, 
lOng /ml or 100ng /ml. There were no significant effects of IGF -1 on basal or 
potassium- induced AVP secretion at any dose tested when compared to SFCM alone 
controls. Two -way ANOVA revealed that basal and potassium- induced secretion of 
AVP did not change significantly over the 20 day duration of the culture period. 
Data shown are the means of 9 culture wells ± SEM. Significant difference between 
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Figure 4.6. AVP secretion from hypothalamic neurons maintained in insulin - 
deficient serum free culture medium alone or supplemented with IGF -1 at ing/ml, 
lOng /ml or 10Ong/ml. Addition of IGF -1 to the SFCM had no significant effect on 
basal or potassium- induced AVP secretion at the doses tested when compared to 
SFCM alone controls. Basal and potassium- induced AVP secretion was not 
significantly altered over the duration of the culture period. Data shown are the 
means of 6 culture wells ± SEM. Significant difference between basal and 




























































































Chapter 4 AVP neurons in hypothalamic cell culture 89 
Figure 4.7. Immunohistochemical staining of rat hypothalamus with antibodies 
raised against NSE (A) and AVP (C, E and G). NSE antiserum resulted in strong 
staining of the neuronal fibres in the hypothalamus. Non -immune rabbit serum was 
used as a negative control for NSE (4.7B). AVP antibodies tested showed varying 
degrees of staining. Rabbit anti -AVP antibodies, TG2 -4 (C) and TG1 -10 (E) 
resulted in strong staining of AVP neuronal fibres. The specificity of staining was 
demonstrated by preabsorption of the antibody with 511M AVP antigen (D, F). Anti - 
AVP antibody, S279 (G) raised in sheep also stained AVP fibres in the 
hypothalamus. Non- immune sheep serum was used as a negative control (H). 
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Hypothalamic cell cultures maintained for 20 days were successfully stained for 
NSE at the end of the culture period (Figure 4.8a). Staining for NSE was therefore 
used to validate many steps of the immunocytochemical protocol such as choice 
fixative and duration of fixation. Since the studies on AVP growth and maturation 
would involve fixation of cultures at many different stages which could then all be 
stained at the one time, cells were cultured to identify the best method of storage of 
the fixed cells awaiting staining. Optimal conditions were those which resulted in 
specific staining for NSE with minimal background staining. The steps involved in 
the optimisation of fixation and storage steps of the protocol are presented in Table 
4.2. 




neutral buffered formalin 
0.2% glutaraldehyde/ 2% 
paraformaldehyde 
all fixatives used for 
10, 30 and 60 
minutes 
all combinations of 
fixatives and fixation times 
stored air -dried or in 70% 
ethanol 
Tablé 4.2. Optimisation of cell fixation and storage for immunocytochemistry 
NSE staining revealed that cells fixed in Bouins fixative for 10 minutes and 
subsequently stored in 70% ethanol gave the best ratio of neuronal to background 
staining of all the protocols tested. Cells processed in this way and stained for NSE 
are shown in figure 4.8a. This fixation time and method of post- fixation storage was 
kept constant throughout the remainder of the study since the neurons were well 
preserved in this protocol and clearly immunocytochemical staining of the neurons 
was possible. Figure 4.8c shows a representative culture stained for AVP with 
rabbit TG2 -4 anti -AVP antibody. The staining pattern generated by the AVP 
antisera was non -specific as all the neurons in the culture were stained and the 
staining pattern was unaltered following preabsorption of the antibody with 5µM 
AVP (Figure 4.8d). The antibodies screened for identification of AVP neurons in 
hypothalamic culture and the immunocytochemical systems utilised are shown in 
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the neurons in the culture, others did not appear to stain any of the cultured cells 
(data not shown). 
Immunocytochemical staining for AVP- associated neurophysin using the alkaline 
phosphatase staining method is illustrated in Figure 4.8e. Omission of primary 
antibody was used as a negative control (4.8f). Staining with the antibody did not 
appear to be specific as all neurons in the culture were immuno -positive. Some 
neuronal cell bodies also appeared to be stained in the non -immune serum control. 
Various methods were employed in an attempt to overcome the lack of success in 
identifying AVP neurons with immunocytochemistry. In order to capture the AVP 
neurons in a highly active state, cells were fixed mid -stimulation in an attempt to 
stimulate maximal amounts of AVP production. However, despite the fact that the 
cells were actively secreting AVP as demonstrated by radioimmunoassay, AVP 
neurons could not be identified immunocytochemically. Similarly, addition of a 
detergent step to the protocol in an attempt to increase the permeability of the 
neurons and therefore increase the access of the antibody to the antigen proved 
unsuccessful. In case the lack of AVP staining was a problem of visualisation, an 
immunofluorescent second antibody, swine anti -rabbit conjugated to fluoroscein 
isothiocyanate was used in the protocol in order to ease the visualisation of stained 
cells over background levels of staining. This too proved unsuccessful (data not 
shown). 
4.4. Discussion 
The objective of this study was to chart the growth and development of AVP 
neurons in cell culture in response to various neurotrophic factors. Functional 
maturation of the neurons was assessed in terms of the secretory response to 
potassium- induced depolarisation whilst development of neuronal morphology was 
to be monitored by immunocytochemistry. AVP secretion was consistently and 
repeatedly stimulated from cultured fetal rat hypothalamic neurons over the 20 day 
culture period. Treatment of the culture with 1, 10 or lOOng /ml IGF -1 in either 
insulin -containing or insulin- deficient medium had no significant effect on either 
basal or potassium- induced secretion of AVP at day 7, 10, 13, 16 or 20 of culture 
when compared to SFCM alone controls. Basal secretion of AVP remained at a 
constant level throughout the duration of the culture period. Despite the success of 
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the AVP antibodies in immunohistochemical identification of AVP in rat 
hypothalamic tissue sections, none of the antibodies screened in this study were able 
to specifically identify AVP neurons within the culture system. 
Previous studies suggest that IGF -1 exerts a neurotrophic influence on hypothalamic 
neurons. Torres -Aleman et al. (1989) describe the growth promoting effects of IGF - 
1 on fetal rat hypothalamic cell lines. The authors described the potent influence of 
IGF -1 on cell growth as measured by cell counts and incorporation of 3H- thymidine. 
Cultures treated with IGF -1 showed a dose -dependant growth response that was 
equal to or greater than that shown in response to insulin. The effect of IGF -1 on the 
cell lines was dependant upon continued presence of IGF -1 and withdrawal from the 
medium produced a decrease in the number of cells compared to continuos IGF -1 
treated controls. Studies on fetal rat hypothalamic primary cultures (Torres -Aleman 
et al., 1990) further substantiate the role of IGF -1 as a neurotrophic factor for 
hypothalamic neurons. IGF -1 was reported to significantly increase the survival of 
hypothalamic neurons and to promote the development of neurite- bearing cells 
within the culture. In addition, the increase in levels of the neuronal differentiation 
marker protein kinase C in IGF -1 treated cultures suggests that IGF -1 may be acting 
to accelerate the rate of neuronal differentiation. The results of the present 
functional study suggest that whilst IGF -1 may act as a neurotrophic factor for 
hypothalamic neurons, AVP neurons do not appear to be the specific target 
population for IGF -1 within the developing fetal hypothalamus. However, the 
inability to stain for AVP neurons within the culture system prevents the 
examination of any possible effects of IGF -1 on the rate of growth or the 
differentiated morphology of the AVP neurons. 
The ability of the AVP antibodies used in the present study to 
immunohistochemically identify AVP neuronal fibres in the rat median eminence 
proves that the antisera were capable of staining for AVP, at least in the intact 
hypothalamus. However, despite extensive screening, none of the antibodies tested 
were able to identify AVP neurons within the culture system. One possibility for the 
lack of success in identifying AVP neurons in culture may be that the AVP neurons 
do not store sufficient amounts of peptide to be stained immunocytochemically. 
Whilst the neurons are actively secreting the peptide and may be stimulated to 
release AVP in response to potassium depolarisation, levels of AVP released into the 
medium are relatively small. Most cultures when maximally stimulated are 
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releasing only about lOpg /well and each well contains a total of 9x105 cells, only a 
proportion of which are AVP neurons. Therefore, AVP neurons, even at times of 
stimulation do not appear to contain large amounts of AVP. Other workers have 
reported difficulties in immunocytochemical staining of AVP neurons in cell culture 
(Denizeau, Dube, Antakly, Lemay, Parent, Pelletier and Labrie, 1981). In 
accordance with the present study, Denizeau et al. (1981) were able to measure AVP 
release into culture medium but were unable to identify AVP neurons in 3 to 7 -day 
old cultures using immunocytochemical techniques. Positive identification of AVP 
neurons in dissociated cell culture has been described (Jirikowski, Reisert and 
Pilgrim, 1981). However, in this study the authors were able to identify AVP 
neurons in only 4 out of 8 cultures examined and then only 1.1% of the 3x106 
hypothalamic cells plated onto each dish were immunopositive. This contrasts 
considerably with the present study in which hypothalamic neurons were non- 
specifically stained. However, it may go some way towards explaining the lack of 
staining in response to some of the antibodies tested. The unsuccessful attempts at 
immunocytochemical detection suggest that the neurons maintained in hypothalamic 
culture do not store significant amounts of AVP and that the amounts which are 
present are below the levels of sensitivity of the immunocytochemical technique. 
AVP peptide is produced in the cell body in association with a specific carrier 
protein, AVP- specific neurophysin. The peptide and neurophysin are encoded on 
the same gene and translated together to form a precursor molecule (Gainer, 
Altstein, Whitnall and Wray, 1988). The prohormone molecule is transported to the 
nerve terminals where endoproteolytic cleavage enzymes act to excise the peptide 
from the precursor. It is possible that the inability to detect AVP within the primary 
culture system reflects the inability of the antibody to access AVP in the AVP - 
neurophysin precursor molecule. The anti -neurophysin antibodies used in this study 
had previously been characterised in tissue sections of fetal rat hypothalami (Ben - 
Barak, Russell, Whitnall, Ozato and Gainer, 1985; Whitnall et al., 1985) and 
recognises both the AVP -NP molecule and the prohormone precursor. 
Immunoreactivity for AVP -NP was first identified at embryonic day 16 and levels 
increased throughout fetal life. The antibody stained neuronal fibres in both the 
internal and external zone of the median eminence illustrating the presence of AVP - 
NP, or the precursor molecule in the neural processes of the hypothalamic cells and 
the ability of the antibody to stain AVP neurons of both magnocellular and 
parvocellular origin. In studies of slice explant culture, Gainer and Wray (1992) 
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reported that only 20% of cultures encompassing the paraventricular nucleus 
contained identifiable AVP neurons and of those that did only 1 -3 cells per culture 
were immunopositive. In the present study, attempts to immunocytochemically 
stain for the AVP -specific neurophysin molecule within the cell cultures proved 
unsuccessful. The reason for the lack of success with the neurophysin antibody is 
unclear. In contrast to the very low levels of positive staining described by Gainer 
and Wray (1992), in the present study all neurons in the culture were 
immunopositive. This perhaps suggests that the integrity of the neuronal cells is 
somehow undermined by the dispersion procedure, resulting in unlimited access of 
the antibodies and non -specific staining. It is of interest that in the stained cultures, 
only the neurons display this high level of non -specific staining with the underlying 
glial cells remaining negative. The identification of underlying cells within the 
culture system as glial cells was determined by immunocytochemical detection of 
the glial specific factor, glial fibrillary acidic protein (GFAP; data not shown). This 
suggests that whatever mechanisms are involved in conferring positive 
immunoreactivity to all the neuronal cells within the dispersed culture system is 
neuron -specific. 
In conclusion, the study presented in this chapter demonstrates that AVP neurons of 
the fetal hypothalamus do not represent a specific target population for IGF -1 in 
terms of functional maturation. However, the inability to identify specific AVP 
containing neurons within the culture system makes it impossible to determine 
whether IGF -1 influences the growth and morphological development of these 
neurons. 
Chapter 5. Ontogeny of POMC gene expression and 
expression of translated products ACTH and 
a -MSH in the ovine fetal pituitary gland. 
5.1. Introduction 
The polypeptide precursor gene proopiomelanocortin (POMC) is expressed in both 
the corticotrophs of the pars distalis and the melanotrophs of the pars intermedia and 
is differentially processed such that ACTH, 13- endorphin and 3- lipotrophin are the 
major POMC- derived products of the anterior pituitary while melanotrophs 
synthesise mainly a -MSH, CLIP and acetylated 13-endorphin. In the ovine fetus, 
POMC mRNA has been detected as early as day 60 gestation by Northern analysis 
(McMillen et al., 1988; Yang et al., 1991). Recently, attempts have been made to 
determine whether or not the late gestation increase in ACTH in fetal circulation in 
accompanied by an increase in pituitary POMC gene expression. However, the 
technique of Northern analysis has produced conflicting data concerning the 
ontogeny of POMC gene expression in the fetal sheep pituitary with some workers 
reporting an increase in POMC expression with advancing gestation (Yang et al., 
1991; Myers et al., 1992) whilst others report a decline in levels as term approaches 
(McMillen et al., 1988; Brooks et al., 1992). The more sensitive technique of in situ 
hybridisation allows a more detailed analysis of the cellular localisation of 
messenger RNA encoding the POMC gene to be studied. Using this technique, 
Myers et al. (1993) reported a significant increase in POMC expression levels in the 
ovine fetus between days 105 -107 and days 138 -140 gestation. During the course of 
this thesis, Matthews et al. (1994) used in situ hybridisation to study the ontogeny 
and distribution of POMC in the ovine fetus and reported, in accordance with studies 
of Northern analysis that POMC mRNA is detectable from day 60 gestation with 
levels increasing to term. These authors also reported a regional distribution of 
POMC mRNA in the anerior lobe of the pituitary gland, with significantly greater 
levels of expression in the region around the base of the gland when compared to the 
region adjacent to the intermediate lobe and described differential expression of 
POMC mRNA in the two regions as gestation proceeds. 
In addition, four POMC -derived peptides, ACTH, (3- endorphin/13- lipotrophin, 
proyMSH and yMSH can been detected in fetal anterior pituitary cells by 
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immunohistochemistry at day 38 gestation (Mulvogue et al., 1986) inferring that the 
POMC gene is actively transcribed and translated very early in gestation. 
In this chapter, the ontogeny of POMC gene expression from a much earlier 
gestational age (day 30) to term was studied by in situ hybridisation. In addition, the 
ontogeny of expression of the POMC- derived peptides a -MSH and ACTH was 
determined by immunohistochemistry. 
5.2. Materials and Methods 
5.2.1. Animals and tissue collection 
29 sheep with known insemination dates were used in this study. At the appropriate 
gestational age, ewes were killed with an overdose of anaesthetic and fetuses 
delivered as described previously (see Chapter 3). Where the ewe was pregnant with 
twins, both fetal pituitaries were collected. Fetal pituitaries were collected at day 30 
(n =6), day 40 (n =6), day 50 (n =3), day 70 (n= 3), day 100 (n =2), day 134 (n =4) and 
day 141 (n =3) gestation. At day 30 gestation the intact fetus was fixed in 4% 
paraformaldehyde. After fixation, the fetus was decapitated and the whole fetal head 
was processed to paraffin wax. At day 40 and day 50 gestation, intact fetuses were 
collected, decapitated and the fetal head was fixed in its entirety. At day 50 
gestation, the top of the skull was removed to expose the fetal brain prior to fixation. 
Day 40 gestation fetal heads were processed to paraffin wax and sectioned intact 
whilst at day 50 gestation pituitaries were isolated under a dissecting microscope 
after fixation and the isolated pituitaries were processed. All isolated pituitaries 
from day 70 gestation to adults were halved in the coronal plane before processing 
to paraffin wax and sectioning as described in section 3.6. In order to allow for 
comparjson between gene expression and localisation of translated POMC -derived 
peptides, consecutive sections were processed for in situ hybridisation and 
immunohistochemistry. 
5.2.2. Northern analysis 
RNA was extracted. from fetal sheep pituitaries at day 70, day 100 and day 130 
gestation, subjected to electrophoresis on 1.5% agarose gel and transferred to nylon 
membrane by capillary blotting as described in section 3.8. The Northern blot was 
then hybridised for 24 hours at 65° with [32P] POMC riboprobe, washed and 
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exposed to X -ray film according to the method described in section 3.11. As an 
internal control for efficiency of RNA transfer, blots were stripped with several 
changes of boiling 0.1 x SSC/ 0.5% SDS for 30 minutes and hybridised with end 
labelled labelled [32P] 18S rRNA oligonucleotide (section 3.10). 
5.2.3. Radioactive in situ hybridisation for POMC 
Radiolabelled [355] POMC riboprobe was prepared as described in section 3.12 and 
radioactive in situ hybridisation for POMC was carried out as described in section 
3.13. For each pituitary in the study 8 tissue sections were mounted as 2 sections 
per slide on 4 separate slides and were treated with antisense riboprobe. 2 slides 
containing 2 tissue sections from each pituitary were treated with sense riboprobe as 
a negative control. Preliminary experiments revealed that POMC expression in pars 
distalis and pars intermedia was optimal at two different exposure times and so half 
of the antisense and sense hybridised slides were developed after 3 days for 
determination of pars intermedia gene expression and the other half developed after 
10 days for determination of pars distalis POMC gene expression. 
5.2.4. Immunohistochemistry 
Immunohistochemical detection of a -MSH and ACTH(18 -39) was performed using 
the avidin- biotin staining procedure described in section 3.7. 
5.2.5. Data analysis 
All tissues in the study were processed together to allow for direct comparison 
between gestaional ages. Each slide in the study contained a tissue section from an 
adult sheep pituitary as a positive control and to ensure standardisation of the 
procedure between slides. Sections were analysed using a computerised image 
analysis program (TCL- image, Multihouse, Amsterdam) for the Macintosh II 
computer which detects the number of autoradiographic silver grains in any given 
area. Data are presented as the number of silver grains per 1001.im2. The position in 
the pituitary at which the analysis was undertaken was consistent throughout. As 
POMC gene expression in the pars distalis is regionally distributed, the area around 
the intermediate lobe and the area at the base of the anterior lobe were analysed 
separately. A minimum of 3 separate tissue sections were analysed from each 
pituitary in the study and 5 fields were counted for each area in the tissue to be 
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analysed. For cell counting of corticotrophs, a minimum of two tissue sections from 
2 -5 different pituitaries from each gestational age were counted. Four fields from 
the corticotroph dense region at the base of the anterior lobe were counted on each 
section. For all photographs; AL, anterior lobe, NL, neural lobe and IL, 
intermediate lobe. 
5.3. Results 
5.3.1. Identification of POMC mRNA by Northern analysis 
Figure 5.1 shows a Northern blot of pituitary RNA extracts hybridised with 
radiolabelled POMC riboprobe. A single RNA transcript was identified at all ages 
examined. Hybridisation with 18S rRNA demonstrates that RNA was evenly loaded 
and efficiently transferred to the Northern blot. 





Figure 5.1. A. Northern blot analysis of total RNA extracts from fetal pituitaries at 
day 70, 100 and 130 gestation hybridised with [32P] POMC riboprobe. 15µg total 
pituitary RNA was loaded onto each lane. A single transcript of approximately 
1.2kb was identified at all three gestational ages. B. The same blot was hybridised 
with 18S rRNA as a control for even lane loading and efficiency of transfer. 
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5.3.2. Cellular localisation of POMC, ACTH and a -MSH 
Figure 5.2 shows a representative section of day 70 fetal pituitary hybridised with a) 
POMC antisense and b) POMC sense riboprobe. Antisense probe showed specific 
hybridisation to the intermediate lobe but not to the neural lobe. There was no 
specific hybridisation to pituitary tissue with the sense riboprobe. 
Day 30 gestation 
At day 30 gestation, POMC mRNA was undetectable by in situ hybridisation in the 
developing pituitary gland (Figure 5.3). Similarly, cx-MSH and ACTH 
immunoreactivity were not detectable at day 30 gestation (Figure 5.4). 
Day 40 gestation 
At day 40 gestation, POMC mRNA was present in both the anterior and 
intermediate lobes of the pituitary (Figure 5.5). In the anterior pituitary, POMC 
expressing cells were arranged in cords whereas those in the intermediate pituitary 
tended to be less uniformly distributed. Both a -MSH and ACTH were detectable by 
immunohistochemistry in the anterior pituitary (Figure 5.6). Immunopositive cells 
were arranged in cords, consistent with the pattern of POMC gene expression. A 
few a -MSH and ACTH immunopositive cells were detected in the intermediate 
pituitary. These cells were always found in the innermost layer of the intermediate 
lobe, that is the layer of cells adjacent to the neural lobe. 
Day 50 gestation 
POMC mRNA was detectable in both the anterior and intermediate lobes of the 
pituitary at day 50 gestation (Figure 5.7). POMC mRNA in the intermediate lobe 
appeared as a narrow hand of expression whilst the pattern of expression in the 
anterior pituitary was more diffuse. ACTH immunopositive cells were detectable in 
both the anterior and intermediate lobes (Figure 5.8). Corticotrophs in the anterior 
pituitary were arranged in cords or palisades and immunopositive cords of cells were 
found throughout the gland separated by areas of vascular mesenchyme. a -MSH 
immunoreactivity was confined to the intermediate lobe in 2 of the day 50 pituitaries 
analysed however, in one pituitary some a -MSH immunopositive cells were 
identified in the anterior lobe (Figure 5.8A, arrows). As at day 40 gestation, 
intermediate lobe cells immunopositive for a -MSH and ACTH tended to border 
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Figure 5.2. Demonstration of probe specificity in consecutive coronal sections of 
intermediate pituitary at day 70 gestation. Tissue sections were hybridised with 35S 
labelled- A) POMC antisene and B) POMC sense riboprobe. Specific hybridisation 
was only found with the antisense riboprobe. A and B x10 magnification. 
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Figure 5.3. In situ hybridisation for POMC mRNA in a representative pituitary at 
day 30 gestation shown in A) darkfield and B) brightfield photomicrographs. No 
specific hybridisation was detected at this gestational age. A and B x10 
magnification. 
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Figure 5.4. Immunohistochemical staining for A) a -MSH and B) ACTH in a 
representative pituitary at day 30 gestation. No immunopositive cells were detected 
at this gestational age. A and B x10 magnification. 
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Figure 5.5. Cellular localisation of POMC mRNA (A and C darkfield; B and D 
brightfield) in 2 separate fields from a representative pituitary at day 40 gestation 
after in situ hybridisation of coronal sections with a 35S- labelled POMC antisense 
riboprobe. POMC gene expression was detected in both the anterior and 
intermediate lobes of the pituitary. Palisades of cells expressing POMC mRNA 
were evident in the anterior pituitary (5.5C). Expression was absent in the region 
immediately adjacent to the intermediate lobe (arrows). All x10 magnification. 
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Figure 5.6. Immunohistochemical detection of a -MSH (A and C) and ACTH (B 
and D) in coronal sections of a representative pituitary at day 40 gestation. a -MSH 
and ACTH were detected in both the anterior and intermediate lobes of the pituitary. 
Immunopositive cells in the intermediate lobe were confined to the layer of cells 
immediately adjacent to the neural lobe. Both a -MSH and ACTH were abundantly 
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Figure 5.7. Localisation of POMC mRNA (A and C darkfield; B and D brightfield) 
in a representative pituitary at day 50 gestation after in situ hybridisation of coronal 
sections with a 35S- labelled POMC antisense riboprobe. POMC gene expression 
was detected as a narrow band of expression in the intermediate lobe of the pituitary. 
Expression in the anterior pituitary was more diffuse. All x10 magnification. 
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Figure 5.8. Immunohistochemical detection of a -MSH (A and C) and ACTH (B 
and D) in coronal pituitary sections at day 50 gestation. a -MSH was largely 
localised to the layer of intermediate lobe cells adjacent to the neural lobe. In the 
pituitary shown, a few faintly stained a -MSH immunopositive cells were found in 
the anterior lobe (5.8A, arrows). ACTH was clearly detectable in both the anterior 
and intermediate lobes of the pituitary. Immunopositive cells in the intermediate 
pituitary are confined to the cell layer adjacent to the neural lobe. A and B x10, C 
and D x 20 magnification. 
HSIN-D 
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with the neural lobe with those cell layers closest to the hypophysial cleft remaining 
unstained. 
Däÿ'70 gestation 
By day 70 gestation, POMC mRNA was abundantly expressed in the intermediate 
lobe of the pituitary (Figure 5.9). In the anterior pituitary, some cord -like expression 
of the gene was evident however, the cord were shorter than at earlier gestational 
ages and gave the appearance of small clusters of expression. Immunohistochemical 
localisation of a -MSH revealed specific staining confined to the intermediate lobe of 
the pituitary (Figure 5.10). Occasional immunostaining for a -MSH evident in the 
anterior lobe was confined to blood vessels. As at earlier gestational ages, the 
immunopositve cells were localised around the neural lobe with those cells closest to 
the anterior lobe of the pituitary remaining unstained. ACTH immunoreactive cells 
were identified in both the intermediate and anterior lobes of the pituitary. In the 
intemediate lobe, ACTH immunoreactive cells were distributed like those 
immunopositive for a -MSH, with those cells closest to the anterior pituitary 
remaining unstained. In the anterior pituitary, ACTH immunopositive cells were 
found in cords or small clusters in keeping with the pattern of POMC gene 
expression, with the region immediately adjacent to the intermediate lobe largely 
devoid of expression. 
Day 100 gestation 
POMC mRNA was abundantly expressed throughout the intermediate pituitary at 
day 100 gestation, and almost all cells within the lobe appeared to express the 
POMC gene (Figure 5.11). In the anterior pituitary, POMC mRNA was localised in 
clusters of varying size which tended to occupy the basal aspect of the gland. 
Immunohistochemical staining for a -MSH and ACTH revealed that staining in the 
intermediate lobe differed significantly at day 100 when compared to day 70 
gestation, with immunopositive cells occupying all of the layers of the intermediate 
lobe, including those layers closest to the anterior pituitary (Figure 5.12). There was 
no detectable a -MSH staining in the anterior lobe. ACTH immunoreactive cells in 
the anterior pituitary were evident as single cells or as weakly stained clusters or 
palisades. 
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Figure 5.9.. Localisation of POMC mRNA (A and C darkfield; B and D brightfield) 
in a representative pituitary at day 70 gestation after in situ hybridisation of coronal 
sections with a 35S- labelled POMC antisense riboprobe. POMC mRNA was 
abundantly expressed in both the anterior and intermediate lobes of the pituitary. 
All x10 magnification. 
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Figure 5.10. Immunohistochemical detection of a -MSH (A and C) and ACTH (B 
and D) in coronal sections of a representative pituitary at day 70 gestation. a -MSH 
immunostaining was confined to the intermediate lobe. The occassional presence of 
a -MSH immunostaining in the anterior lobe was confined to blood vessels. ACTH 
was detected in both the anterior and intermediate lobes of the pituitary. 
Immunostaining in the intermediate lobe was localised to the innermost cell layers, 
with those layers closest to the hypophysial cleft remaining unstained. A and B x4, 
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Figure 5.11. Localisation of POMC mRNA (A and C darkfield; B and D 
brightfield) in a representative pituitary at day 100 gestation after in situ 
hybridisation of coronal sections with a 35S- labelled POMC antisense riboprobe. 
POMC mRNA was widely expressed in the intermediate pituitary. Clusters of 
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Figure 5.12. Immunohistochemical detection of a -MSH (A and C) and ACTH (B 
and D) in coronal sections of a representative pituitary at day 100 gestation. a -MSH 
immunostaining was confined to the intermediate lobe. ACTH was detected in both 
the anterior and intermediate lobes of the pituitary. Immunostaining for a -MSH and 
ACTH was distributed throughout the cell layers of the intermediate lobe. A and B 
x 10, C and D x30 magnification. 
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Day 134 gestation 
The cellular localisation of POMC mRNA at day 134 gestation was not dissimilar to 
day 100 gestation, with the intermediate lobe of the pituitary abundantly expressing 
the POMC gene and many small clusters of expression evident in the anterior 
pituitary (Figure 5.13). a -MSH and ACTH were detected by immunohistochemistry 
throughout the intermediate lobe and ACTH immunopositive cells were present as 
clusters in the anterior pituitary (Figure 5.14). ACTH immunopositive cells in the 
anterior pituitary appeared morphologically different from those seen at earlier 
gestational ages. Individual corticotrophs had a more distinct shape compared to the 
palisade -like appearance of corticotrophs at earlier gestational ages, however, some 
palisades of ACTH immunopositive cells were still evident. 
Day 141 gestation 
POMC mRNA localisation at day 141 gestation reflected the pattern found at day 
134 gestation with abundant expression in the intermediate lobe and clusters of 
expression in the anterior lobe (Figure 5.15). Similarly, the distribution of 
immunoreactive melanotrophs was comparable with that found at day 134 gestation 
(Figure 5.16). ACTH immunopositive cells in the anterior lobe were clearly defined 
as single cells or clusters of cells. Palisades were no longer apparent. 
5.3.2. Analysis of POMC gene expression 
The mean autoradiographic grain count in the anterior and intermediate lobes of the 
pituitary between day 30 and day 141 gestation are shown in Figure 5.17. Due to 
the regional distribution of POMC mRNA in the anterior pituitary, the region around 
the base of the gland and the region around the intermediate lobe were analysed 
separately. The level of POMC mRNA in the intermediate lobe of the pituitary 
gland increased significantly (P <0.05, ANOVA) from day 50 (1.94 ± 0.24 grains/ 
1001=2) to day 70 (4.39 ± 0.28 grains/ 10(4m2) gestation. Levels then remained 
relatively constant to day 141 gestation (Figure 5.17a). In the anterior pituitary, the 
density of silver grains in the basal region of the gland was significntly (p<0.01) 
greater at day 40 gestation than at day 50 (1.32 ±0.21 and 0.59 ± 0.15 grains/ 
1001.tm2 respectively). POMC mRNA levels increased significantly (p <0.05) from 
day 50 to day 134 gestation, and then remained unchanged (Figure 5.17b). The level 
of POMC mRNA in the region of the anterior pituitary adjacent to the intermediate 
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Figure 5.13. Localisation of POMC mRNA (A and C darkfield; B and D 
brightfield) in a representative pituitary at day 134 gestation after in situ 
hybridisation of coronal sections with a 35S- labelled POMC antisense riboprobe. 
POMC mRNA was abundantly expressed in both the anterior and intermediate lobes 
of the pituitary. The level of POMC mRNA expression was variable within the cells 
of the intermediate lobe. In the anterior pituitary, POMC mRNA was localised in 
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Figure 5.14. Immunohistochemical detection of a -MSH (A and C) and ACTH (B 
and D) in coronal sections of a representative pituitary at day 134 gestation. a -MSH 
immunostaining was confined to the intermediate lobe. ACTH was detected in both 
the anterior and intermediate lobes of the pituitary. Some palisades of 
immunopositive corticotrophs were present in the anterior pituitary. More often 
ACTH -immunoreactive cells were evident as individual cells or clusters with a more 
irregular shape. A and B x10, C x20 and D x30 magnification. 
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Figure 5.15. Localisation of POMC mRNA (A and C darkfield; B and D 
brightfield) in a representative pituitary at day 141 gestation after in situ 
hybridisation Of coronal sections with a 35S- labelled POMC antisense riboprobe. 
POMC mRNA was abundantly expressed in both the anterior and intermediate lobes 
of the pituitary. Cellular localisation of POMC mRNA was not disimilar to that 
seen at day 134 gestation. All x10 magnification. 
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Figure 5.16. Immunohistochemical detection of a -MSH (A and C) and ACTH (B 
and D) in coronal sections of a representative pituitary at day 141 gestation. a -MSH 
immunostaining was confined to the intermediate lobe. ACTH was detected in both 
the anterior and intermediate lobes of the pituitary. Immunopositive corticotrophs of 
the anterior pituitary had a distinct irregular shape and were found as individual cells 
or clusters. Palisades of cells were not apparent at this gestational age. A and B 
x2.5, C and D x5 magnification 
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40 50 70 100 134 
Gestational age (days) 
141 
Figure 5.17. Analysis of POMC mRNA expression in the a) intermediate and b) 
anterior lobes of the pituitary at different gestational ages. Data shown represent the 
mean number of silver grains ± SEM /1001=2. Due to regional distribution of 
POMC gene expression in the anterior pituitary the region around the base of the 
gland (black bars) and the region immediatley adjacent to the intermediate lobe 
(grey bars) were analysed separately. a) Values with different superscripts are 
significantly different (a v's b, p<0.05 ANOVA). b) significant differences between 
gestational ages are indicated by asterisks, *p <0.05, * *p <0.01. 
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lobe was consistently lower than that found in the basal aspect of the gland and 
levels were unchanged with advancing gestation. 
5.3.3. Percentage of immunopositive corticotrophs 
Table 5.1. shows the percentage of cells immunopositive for ACTH in the anterior 
pituitary at different gestational ages expressed as a percentage of the total number 
of cells present in the corticotroph dense region of the anterior lobe at each 
gestational age. 
Immunopositive corticotrophs (%) 
30 days 40 days 50 days 70 days 100 days 134 days 141 days 
0 14.0± 1.7 12.4± 1.9 11.4 ±0.7 14.6± 1.1 15.4 ±0.8 15.3 ±0.9 
Table 5.1. Percentages of cells immunopositive for ACTH in the anterior lobe at 
different gestational ages. Data shown are mean ± SEM for all pituitaries at each 
gestational age, where the value for each pituitary represents the mean of 4 fields. 
At day 40 gestation, when ACTH -immunoreactive cells were first identified, 
corticotrophs made up 14% of the cells present in the basal region of the anterior 
pituitary. The percentage of immunopositive corticotrophs fell to 11.4% at day 70 
gestation. The proportion of corticotrophs then recovered to 14.6% by day 100 
gestation and remained relatively constant until day 141 gestation. 
5.4. Discussion 
The study presented in this chapter describes the ontogeny of POMC gene 
expression and that of the translated POMC -derived peptides a -MSH and ACTH in 
the developing ovine fetal pituitary gland. POMC mRNA was first detected by in 
situ hybridisation at day 40 gestation in both the anterior and the intermediate lobe 
of the pituitary gland. The POMC -derived peptides a -MSH and ACTH were also 
detected at this gestational age. At all gestational ages ACTH immunoreactivity was 
found in both the anterior and intermediate lobes of the pituitary. In contrast, a- 
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MSH was confined to the intermediate lobe at most gestational ages examined, 
however, at day 40 and in one case at day 50 gestation, a -MSH immunopositive 
cells were identified in the anterior pituitary also. Ubiquitous expression of a -MSH 
at these early stages of development suggests that the mechanisms required for 
differential post -translational processing of POMC in the anterior and intermediate 
lobes of the pituitary are not yet functional. Post -translational processing of POMC 
is governed by the presence of two prohormone convertase enzymes, prohormone 
convertase 1 (PC1) and prohormone convertase 2 (PC2) which cleave POMC at 
distinct pairs of basic residues. In vitro studies revealed that co- transfection of 
POMC with PC1 yields peptides of the anterior pituitary, notably ACTH whilst 
addition of PC2 resulted in further cleavage of ACTH to produce a -MSH and CLIP 
(Benjannet et al., 1991; Zhou et al., 1993). In the adult rodent pituitary, PC1 mRNA 
is expressed in almost all cells of the anterior pituitary and also in some cells of the 
intermediate lobe (Seidah et al., 1991; Day, Schafer, Watson, Chrètein and Seidah, 
1992). Conversly, PC2 expression was much more abundant in the intermediate 
lobe (Seidah et al., 1991; Day et al., 1992). In contrast to the data available from the 
rodent, expression of PC1 and PC2 in the ovine pituitary has not been studied. The 
results in the present study would suggest that both PC1 and PC2 are active in the 
anterior lobe of the fetal pituitary early in gestation facilitating the production of a- 
MSH from anterior pituitary corticotrophs. This implies that tissue specific 
inhibition of PC2 expression must occur at a later point in development such that 
PC2 is no longer expressed in the anterior pituitary. Localisation of PC1 and PC2 
mRNA in early gestation is needed to clarify this point. From the present study it is 
not possible to ascertain whether the peptides produced in the anterior lobe at day 
40 -50 gestation are bioactive or if they are released into the fetal circulation 
however, it is of interest that the hypothalamo- pituitary portal system is functional at 
this time (Matwijiw et al., 1989; Levidiotis et al., 1989). The physiological 
relevance of abundant anterior pituitary a -MSH expression in early gestation 
remains to be determined however, it is of interest that treatment of intact rat fetuses 
with purified anti -a -MSH inhibits both somatic growth and brain maturation (Swaab 
and Martin, 1981) and a -MSH restores normal fetal growth and placental 
development after removal of the fetal brain (Swaab and Martin, 1981). In addition, 
a -MSH has a more potent stimulatory effect than ACTH on DNA and protein 
synthesis in the fetal adrenal gland of rat, rabbit and guinea -pig in early pregnancy 
(Rudman et al., 1980). Thus, it is interesting to speculate that the fetal anterior lobe 
Chapter 5 Ontogeny of POMC expression 122 
in early gestation acts to produce the a -MSH neeeded at this time for early fetal 
growth and development. 
The present study represents the earliest identification of POMC mRNA in the fetal 
sheep pituitary gland. Previous studies have first identified POMC mRNA, both by 
in situ hybridisation and Northern analysis, from day 60 gestation (Yang et al., 
1991; McMillen et al., 1988; Matthews et al., 1994). However, the identification of 
ACTH immunoreactive cells in the anterior pituitary from as early as day 38 
gestation indirectly implied the activation of the POMC gene at this time. 
Expression of the POMC gene during early fetal life has been demonstrated in other 
species (Lugo, Roberts and Pintar, 1989; Hindelang, Fèlix, Laurent, Klein and 
Stoeckel, 1990; Ma, Milewski, Grossman, Kato and Ellendorf, 1994). In the rat fetal 
pituitary, POMC mRNA is first identified in the anterior lobe followed by 
expression in the intermediate lobe 1 -2 days later (Lugo et al., 1989; Hindelang et 
al., 1990). A similar pattern of expression has been reported in the developing pig 
pituitary, with POMC gene expression first detected in the anterior lobe at day 30 
gestation followed by intermediate lobe expression at day 40 gestation (Ma et al., 
1994). In the present study, POMC mRNA was detectable in both the anterior and 
intermediate lobes of the pituitary at day 40 gestation. However, it is possible that 
the, 10 day gestation period between tissue collections in the present study masks any 
temporal differences in anterior and intermediate pituitary expression of POMC. 
The concomitant appearance of POMC mRNA and immunohistochemical detection 
of a -MSH and ACTH in the present study agrees with data reported from the fetal 
rat (Hindelang et al., 1989) suggesting that there is no delay between the appearance 
of POMC mRNA and that of translated POMC- derived products. However, the 
possibility remains that there is a delay in the appearance of translated POMC 
products in the fetal sheep pituitary following the initiation of gene expression 
between day 30 and day 40 gestation. This appears to be the case in the fetal pig 
(Ma et al., 1994) in which POMC- derived peroducts are first detected 4 -5 days later 
than POMC mRNA, suggesting that maturation of post -trancriptional processing 
mechanisms varies between species. 
POMC mRNA levels in the basal region of the anterior pituitary were significantly 
greater at day 40 gestation when gene expression was first detected, than at 
subsequent gestational ages. The high level of POMC gene expression at day 40 
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gestation may reflect the augmented presence of corticotrophs over other cell types 
in the pituitary in early gestation suggesting that the corticotroph population in the 
anterior pituitary is determined early in gestation. The different cell types of the 
anterior pituitary arise from a common embryonic precursor in a manner which is 
both spatially and temporally regulated. Recently, it has become clear that tissue - 
specific gene expression is controlled by a variety of trans - acting factors. For 
lactotrophs and sommatotrophs, producing prolactin and growth hormone (GH) 
respectively, a single pituitary -specific transcription factor Pit -1 has been identifed 
and shown to activate transcription of the prolactin and growth hormone genes 
(Ingraham, Chan, Mangalam, Elsholtz, Flynn, Lin, Simmons, swnason and 
Rosenfeld,. 1988). Pit -1 is not detected in corticotrophs or melanotrophs of the 
pituitary (Simmons, Voss, Ingraham, Holloway, Broide, Rosenfield and Swanson, 
1990), both of which express the POMC gene suggesting that another factor must be 
responsible for cell -specific expression of POMC. The transcriptional regulation of 
POMC gene expression appears to he more complex than is the case for prolactin 
and GH, involving at least nine regulatory elements all of which act synergistically 
and are equally important for POMC promoter activity (Therrien and Drouin, 1991). 
Thus, determination of corticotrophs as a distinct cell population in the pituitary 
during early development requires the simultaneous action of multiple trans -acting 
factors. 
From day 50 gestation, POMC mRNA levels in the basal region of the anterior 
pituitary increased progressively until day 134 gestation and then remained 
relatively constant. POMC mRNA levels in the region of the anterior pituitary 
adjacent to the intermediate lobe were consistently lower than in the rest of the 
anterior pituitary and levels were unchanged with advancing gestation. In the 
intermediate lobe, POMC mRNA levels increased significantly from day 50 to day 
70 gestation. Levels continued to increase until day 134 gestation and were 
relatively unchanged at day 141. This data is in broad agreement with that of 
Matthews et al. (1994) who describe a similar increase in POMC mRNA levels in 
the intermediate lobe and basal region of the anterior lobe of the fetal sheep pituitary 
between day 60 and day 100 gestation. Matthews et al. (1994) also describe a rapid 
increase in POMC gene expression in the fetal anterior lobe in the days immediately 
preceeding parturition (day 145 -147) gestation. However, this time period was not 
examined in the present study. 
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The gradual increase in POMC mRNA in the anterior pituitary described in the 
present study is concordant with reports of increased CRH mRNA in the 
paraventricular nucleus of the hypothalamus between day 100 and day 130 gestation 
(Myers et al., 1993) and an increase in CRH secretory capacity of the fetal 
hypothalamus (Brooks et al., 1989). These events correspond with increased 
concentrations of ACTH in the fetal plasma at this time (Challis and Brooks, 1989). 
In agreement with the present study, Matthews et al. (1994) reported an increase in 
the proportion of ACTH -immunopositive cells in the anterior pituitary between day 
60 and day 100 gestation. The present study extends this finding and suggests that 
earlier in gestation (day 40), corticotrophs make up a larger percentage of the total 
cell population present in the anterior pituitary. The fall in the proportion of 
corticotrophs from day 40 to day 70 gestation is likely to reflect an increase in the 
total number of cells present in the anterior pituitary at this time due to cell 
proliferation and is accompanied by a concomitant fall in the density of silver grains 
indicative of gene expression. Due to the marked regional distribution of 
corticotrophs in the anterior pituitary it was decided that determination of 
corticotroph number would he analysed in the corticotroph dense region at the base 
of the anterior pituitary. Thus, in the present study, the percentage of 
immunopositive corticotrophs was consistently greater than that reported by 
Matthews et al. (1994) as these workers expressed the number of corticotrophs 
relative to the total cell population in the entire anterior lobe. 
In conclusion, the POMC gene is abundantly expressed and translated in both the 
intermediate and anterior lobes of the pituitary during fetal life. Levels of POMC 
mRNA in the anterior and intermediate lobes increase with advancing gestation and 
reach a constant level in late gestation. In addition, initial expression of the POMC 
gene in the anterior pituitary is highly abundant and is not subject to the post - 
translational modifications seen at later stages of development. Clearly, further 
studies are warranted to examine the regulation of POMC expression in early 
gestation. 
Chapter 6. Dopaminergic regulation of pituitary POMC 
peptide and adrenal cortisol secretion in the 
ovine fetus 
6.1. Introduction 
Although ACTH is believed to be the main regulating hormone for the fetal adrenal 
cortex during the last third of gestation, discordance in the pulse characteristics of 
the two hormones (Apostolakis et al., 1992; Brooks and Challis, 1991) and adrenal 
activation in the absence of increased plasma ACTH concentrations (Jacobs et al., 
1994) has led some to suggest that ACTH may not be solely responsible for driving 
cortisol secretion from the fetal adrenal in late gestation. In this respect, a -MSH, a 
POMC- derived peptide secreted from the intermediate lobe of the pituitary has been 
implicated as a trophic factor for the fetal adrenal gland and could be involved in the 
drive to the adrenal necessary for the prepartum cortisol surge. For instance, a- 
MSH has been shown to stimulate cortisol secretion both in vivo from fetal sheep, 
newborn lambs (Llanos et al., 1979; Glickman et al., 1979) and rabbits (Challis and 
Torosis, 1977) and from fetal sheep and human adrenal cells in culture (Glickman et 
al., 1979). Furthermore, the stimulatory effect of a -MSH on fetal sheep adrenal 
cells could not be reproduced using adult cells suggesting a fetal specific role for 
this peptide (Glickman et al., 1979). The intermediate lobe of the pituitary gland of 
many species is well developed during fetal life and in man diminishes progressively 
after birth (Visser and Swaab, 1979). POMC mRNA is abundantly expressed in the 
intermediate lobe of the ovine fetal pituitary (Matthews et. al., 1994; chapter 5) and 
intense immunocytochemical staining for ACTH and other POMC- derived peptides 
within the fetal intermediate lobe has been demonstrated (Matthews et al., 1994; 
Mulvogue et al., 1986; chapter 5). Furthermore, the lack of immunostaining for 
ACTH in the adult intermediate lobe suggests ontogenic differences in the 
processing of the POMC precursor molecule (Mulvogue et al., 1986). 
Evidence that the fetal intermediate lobe is under tonic dopaminergic inhibitory 
control comes from experiments in fetal sheep which demonstrate marked 
hypertrophy of the intermediate lobe after hypothalamo- pituitary disconnection 
(Antolovich et al., 1991). During adult life, tuberohypophysial dopaminergic 
neurons innervate the intermediate lobe of the pituitary and inhibit intermediate lobe 
function via activation of dopamine D2 receptors (Björkland, Moore, Nobin and 
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Stevani, 1973; Munemura et al., 1980a; Goudreau et al., 1992; 1995; Beaulieu et al., 
1984; Engler, Pham, Fullerton, Clarke and Funder, 1989). However, the role of 
dopamine in the regulation of intermediate lobe function during fetal development is 
unknown. 
The present study was designed to test the hypothesis that secretion of POMC- 
derived peptides from the ovine fetal pituitary is subject to tonic inhibitory 
dopaminergic regulation. Removal of this tone may release adrenal active peptides 
which in turn will elicit cortisol secretion from the fetal adrenal gland. Specifically, 
a -MSH, ACTH and cortisol responses to a 72 hour administration of either the 
dopamine agonist bromocriptine, the dopamine antagonist sulpiride or vehicle 
control in fetal sheep at day 131 gestation have been measured and effects on plasma 
concentrations and pulsatile characteristics of these hormones has been examined . 
6.2. Materials and methods 
6.2.1. Animals and surgery 
27 sheep of mixed breed with known insemination dates were used in this study. 
Fetal catheterisation was carried out at day 125 - 126 gestation (term =145 days) as 
described previously in Chapter 3. After overnight recovery the ewes were moved 
to metabolism crates and at least 5 days were allowed before experiments began. 
6.2.2. Experimental Protocol 
Beginning on day 131 gestation, fetuses received an intravenous infusion of either 
the dopamine antagonist sulpiride (0.3mg /0.5m1/hr ; n =12,), the dopamine agonist 
bromocriptine (0.03mg/0.5m1/hr ; n =7) or vehicle (0.1M tartaric acid in saline ; n =8) 
alone. Bromocriptine, sulpiride and tartaric acid were obtained from Sigma. Blood 
samples (1m1) were withdrawn at 10 minute intervals for a period of four hours 
beginning two hours before the start of the infusion. Infusions commenced between 
1100 and 1300 hours and continued for 72 hours with a second period of intensive 
sampling (10 minute intervals) carried out during the final 4 hours. The samples 
were collected in chilled heparinised tubes and centrifuged within 30 minutes in a 
refrigerated centrifuge at 3000ipm for 15 minutes. Plasma was stored at -20 °C until 
assayed. Fetal and maternal blood samples were also collected twice daily (0900 
and 2100hr) throughout the experimental period beginning the day before the start of 
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the infusion. At various times during the intensive sampling and at the time of the 
twice daily sampling an additional 0.2ml blood sample was withdrawn for 
measurement of pH, p02 and pCO2 as described in Chapter 3. All fetuses included 
in the analysis were within the normal range; pH 7.352 ± 0.01, p02 20.28 ± 0.49, 
pCO2 49.39 ± 0.59. 
6.2.3. Measurement of plasma hormone concentrations 
a -MSH and cortisol concentrations in fetal plasma were determined by 
radioimmunoassay and ACTH concentrations by immunoradiometric assay as 
described in section 3.4 and 3.5. All plasma samples were assayed in duplicate. 
6.2.4. Statistical Analysis 
Daily hormone concentrations were compared by Analysis of Variance (ANOVA) 
with repeated measures using the Abacus Concepts, Statview® package for the 
Apple Macintosh (Abacus Concepts, Inc., Berkeley, Ca, , 1992). 
Pulse analysis was performed using the MUNRO algorithm as previously described 
(Martin, Taylor and McNeilly , 1987, Brooks and Challis , 1991), which detects 
significant excursions from a baseline followed by post -hoc t -test. A moving 
average of 100 minutes was used to determine the baseline value and data which 
increased by 2 standard deviations or more from the previous nadir were considered 
to be significant pulses. Data from the MUNRO pulse analysis was then subjected 
to two -way ANOVA on the Statview® package. All data are expressed as mean ± 
standard error of the mean (SEM) and values of p.0.05 were considered to be 
significant. 
6.3. Results 
6.3.1. Changes in basal a -MSH, ACTH and cortisol concentrations over the 
experimental period 
The concentration of a -MSH, ACTH and cortisol in fetal plasma samples collected 
at 12 hour intervals, beginning 24 hours prior to the start of the infusions is shown in 
Figure 6.1. Values shown are grouped data, such that each data point represents the 
mean value of all fetuses within the treatment group. There were no significant 
differences in the basal concentration of a -MSH, ACTH or cortisol between groups 
in the period before the infusions began. Infusion of the dopamine antagonist 
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sulpiride caused a significant (p <0.01) increase in plasma a -MSH concentrations 12 
hours after the start of the infusion, and concentrations remained significantly 
elevated for the remainder of the treatment period. Plasma ACTH concentrations 
were also significantly (p <0.05) stimulated by infusion of sulpiride. The response to 
sulpiride was less rapid for ACTH than for a -MSH, with ACTH concentrations 
reaching significance 24 hours after the start of the infusion. Elevated ACTH 
concentrations were maintained throughout the treatment period. Treatment with the 
dopamine agonist bromocriptine caused a significant (p <0.05) and sustained 
decrease in concentrations of a -MSH beginning 12 hours after the start of the 
infusion. Bromocriptine had no effect on plasma ACTH concentrations. Cortisol 
concentrations were unaffected by either treatment. Additional analysis confirmed 
that cortisol concentrations following 72 hour infusion of bromocriptine or sulpiride 
were not significantly different from vehicle treated controls (Mann -Whitney U test; 
p= 0.99 and p= 0.44 respectively). 
6.3.2. Acute hormone responses to treatment with bromocriptine or sulpiride 
Figure 6.2 shows plasma a -MSH concentrations in a representative fetus from each 
treatment group during the course of the first 4 hour period of intensive blood 
sampling. There was a rapid increase in a -MSH secretion to the fetal plasma with 
significantly increased levels of a -MSH apparent in the fetal circulation within 10 
minutes of the start of the sulpiride infusion. The response to bromocriptine is less 
rapid with plasma a -MSH concentrations steadily declining throughout the duration 
of the sampling period. In contrast to the changes in circulating a -MSH 
concentration, plasma concentrations of ACTH (Figure 6.3) and cortisol (Figure 6.4) 
were not acutely influenced by treatment with either bromocriptine or sulpiride. 
The profiles of a -MSH, ACTH and cortisol secretion obtained during the period of 
intensive sampling, of which figures 6.2 to 6.4 are representative, were further 
analysed in terms of pulsatile characteristics. Data shown in figures 6.5 to 6.7 are 
grouped values representing the mean value for all fetuses within each treatment 
group. 
The Munro pulse analysis program successfully detected pulses of a -MSH, ACTH 
and cortisol in all fetuses examined. There were no changes in either the frequency, 
amplitude or mean hormone concentrations of any of the hormones measured in 
response to vehicle alone. Mean plasma a -MSH concentration, pulse amplitude and 
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Figure 6.1. a -MSH, ACTH and cortisol concentrations in fetal plasma samples 
collected at 12 hour intervals over a four day period from day 130 to day 134 
gestation. Intravenous infusion of vehicle (n =8), bromocriptine (n =7) or sulpiride 
(n =12) began after 24 hours and continued for 72 hours. Data shown are the mean 
values ± SEM for all fetuses within each treatment group . Significant differences 
are represented by a) p<0.05 and h) p <0.01 from vehicle control. 
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Figure 6.2. Plasma a -MSH concentrations in 3 representative fetuses, one from 
each treatment group. Plasma samples were collected at 10 minute intervals over a 
four hour period. Intravenous infusion of vehicle, bromocriptine or sulpiride 
commenced after the first 2 hours of sampling. Significant pulses identified by the 
MUNRO pulse analysis program are represented by an arrowhead. 
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Figure 6.3. Plasma ACTH concentrations in 3 representative fetuses, one from each 
treatment group. Plasma samples were collected at 10 minute intervals over a four 
hour period. Intravenous infusion of vehicle, bromocriptine or sulpiride commenced 
after the first 2 hours of sampling. Significant pulses identified by the MUNRO 
pulse analysis program are represented by an arrowhead. 
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Figure 6.4. Plasma cortisol concentrations in 3 representative fetuses, one from each 
treatment group. Plasma samples were collected at 10 minute intervals over a four 
hour period. Intravenous infusion of vehicle, bromocriptine or sulpiride commenced 
after the first 2 hours of sampling. Significant pulses identified by the MUNRO 
pulse analysis program are represented by an arrowhead. 
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Figure 6.5. Analysis of pulse characteristics of a -MSH secretion comparing the 2 
hour basal period with the first 2 hours of vehicle (n =8), bromocriptine (n =7) or 
sulpiride (n =12) infusion. Data shown are means ± SEM of all fetuses in each 
treatment group. Significant differences compared with corresponding controls are 
indicated by asterisks, * p<0.05, * ** p <0.001. 
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Figure 6.6. Analysis of pulse characteristics of ACTH secretion comparing the 2 
hour basal period with the first 2 hours of vehicle (n =8), bromocriptine (n =7) or 
sulpiride (n =12) infusion. Data shown are means ± SEM of all fetuses in each 
treatment group. There were no significant differences between treated and control 
groups for any of the measured characteristics. 
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Figure 6.7. Analysis of pulse characteristics of cortisol secretion comparing the 2 
hour basal period with 2 hours of vehicle (n =8), bromocriptine (n =7) or sulpiride 
(n =12) infusion. Data shown are means of all fetuses in each treatment group ± 
SEM. There was no significant effect of any treatment on mean measured plasma 
ACTH concentration, ACTH pulse amplitude or pulse frequency. 
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pulse frequency in the two hour period before the infusion and the two hour period 
following the start of the infusion are shown in Figure 6.5. The mean plasma 
concentration of a -MSH increased significantly (P <0.001) in the 2 hour post - 
infusion period in sulpiride- treated fetuses when compared to the 2 hour period prior 
to the start of the infusion. This increase in mean plasma a -MSH concentration was 
accompanied by a significant (P <0.05) increase in a -MSH pulse amplitude during 
this period. a -MSH pulse frequency was unaffected by sulpiride treatment. The 
steady decline in a -MSH levels during the course of the bromocriptine infusion was 
not sufficient to produce a significant decrease in mean plasma a -MSH 
concentration in the two hour infusion period when compared to the pre- infusion 
period. Similarly, bromocriptine treatment had no significant effect on either a- 
MSH pulse frequency or pulse amplitude. 
Examination of the pulsatile characteristics of ACTH (Figure 6.6) and cortisol 
(Figure 6.7) secretion in response to the two hour infusion of either bromocriptine or 
sulpiride revealed that neither treatment had any significant effect on the mean 
plasma concentration, pulse amplitude or pulse frequency of these hormones. 
6.3.3. Hormone responses after 72 hours of treatment with bromocriptine or 
sulpiride 
The profile of a -MSH, ACTH and cortisol secretion in a representative fetus from 
each of the three treatment groups following a continuous 72 hour infusion, of either 
vehicle, bromocriptine or sulpiride are shown in Figures 6.8, 6.9 and 6.10 
respectively. 'After 72 hour treatment with bromocriptine, a -MSH was suppressed 
to concentrations that were at or below the level of sensitivity of the assay. 
There were no changes in plasma ACTH or cortisol concentrations following 
bromocriptine infusion. In contrast, sulpiride treatment significantly increased the 
plasma concentration of both a -MSH and ACTH when compared to vehicle treated 
controls. 
The pulse profiles of individual fetuses obtained during the second intensive 
sampling period were analysed using the MUNRO pulse analysis program. Grouped 
data for mean plasma a -MSH concentration, pulse amplitude and pulse frequency 
for all fetuses in each treatment group following the 72 hour infusion period are 
shown in Figure 6.11. 72 hour infusion of sulpiride resulted in an increase in basal 
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secretion of a -MSH, such that the mean concentration of a -MSH was significantly 
(P<0.01) greater in sulpiride- treated fetuses compared to vehicle - treated control 
fetuses over the four hour period. Sulpiride- treated fetuses also displayed a 
significant (P<0.001) increase in the amplitude of a -MSH pulses, together with a 
significant (p<0.01) decrease in pulse frequency. Following bromocriptine infusion 
there was a significant (p <0.001) decrease in mean plasma a -MSH concentration 
and pulse frequency when compared to vehicle -treated controls. The decrease in 
pulse frequency was such that only 1 pulse was detected in each of two fetuses (i.e. a 
total of 2 pulses) and so it was not possible to compare the amplitude of these pulses 
statistically. The mean amplitude for these two pulses is shown in Figure 6.11. 
ACTH pulse characteristics are shown in Figure 6.12. The mean ACTH 
concentrations in sulpiride -treated fetuses were significantly (p <0.001) higher than 
in control fetuses. ACTH pulse amplitude and pulse frequency were unaffected by 
infusion of either bromocriptine or sulpiride. 
72 hour infusion of bromocriptine or sulpiride did not significantly alter the mean 
plasma cortisol concentration, cortisol pulse amplitude or pulse frequency (Figure 
6.13) when compared to vehicle -treated controls. 
6.4. Discussion 
The results presented in this chapter demonstrate that secretion of a -MSH and 
ACTH from the fetal pituitary gland is regulated by dopamine. The secretion of a- 
MSH from the fetal pituitary gland is significantly increased by intravenous infusion 
of the dopamine antagonist sulpiride and decreased by infusion of the dopamine 
agonist bromocriptine, whilst, the secretion of ACTH is increased by sulpiride but 
unaffected by bromocriptine. Despite these changes in a -MSH and ACTH there 
were no significant changes in fetal plasma cortisol concentrations. 
The results presented in this chapter represent the first identification of pulsatile 
secretion of a -MSH from the fetal pituitary gland. Secretion of ACTH and a -MSH 
into the circulation of adult sheep has been investigated using a rapid blood 
sampling procedure (Engler et al., 1989). In this study, blood samples were 
collected from conscious adult sheep at 10 minute intervals for 4 hours and in 
another group at 2 minute intervals for 1 hour. The authors demonstrated the 
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Figure 6.8. Plasma a -MSH concentrations in 3 representative fetuses, one from 
each treatment group. Blood samples were collected at 10 minute intervals over a 4 
hour period at the end of a 72 hour infusion vehicle, bromocriptine or sulpiride. 
Significant pulses identified by the MUNRO pulse analysis program are represented 
by an arrowhead. 
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Figure 6.9. Plasma ACTH concentrations in 3 representative fetuses, one from each 
treatment group. Blood samples were collected at 10 minute intervals over a 4 hour 
period at the end of a 72 hour infusion vehicle, bromocriptine or sulpiride. 
Significant pulses identified by the MUNRO pulse analysis program are represented 
by an arrowhead. 
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Figure 6.10. Plasma cortisol concentrations in 3 representative fetuses, one from 
each treatment group. Blood samples were collected at 10 minute intervals over a 4 
hour period at the end of a 72 hour infusion vehicle, bromocriptine or sulpiride. 
Significant pulses identified by the MUNRO pulse analysis program are represented 
by an arrowhead. 
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Figure 6.11. Analysis of a -MSH pulse characteristics following 72 hour infusion of 
vehicle (n =8), bromocriptine (n =7) or sulpiride (n =12). Data shown are means ± 
SEM of all fetuses in each treatment group. Significant differences compared with 
corresponding controls are indicated by asterisks, ** p<0.01, * ** p<0.001. 
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Figure 6.12. Analysis of ACTH pulse characteristics following 72 hour infusion of 
vehicle (n =8), bromocriptine (n =7) or sulpiride (n =12). Data shown are means ± 
SEM of all fetuses in each treatment group. Significant differences compared with 
corresponding controls are indicated by asterisks, * ** p <0.001. 
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Figure 6.13. Analysis of cortisol pulse characteristics following 72 hour infusion of 
vehicle (n =8), bromocriptine (n =7) or sulpiride (n =12). There was no significant 
effect of any treatment of mean measured plasma cortisol concentration, pulse 
amplitude or pulse frequency. 
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pulsatile secretion of ACTH, a -MSH and [3-endorphin into the adult circulation and 
presented a variety of profiles in which these hormones are secreted both in 
synchrony and asynchrony with each other. One such profile was the concomitant 
secretion of ACTH and a -MSH leading the authors to suggest that this represents 
secretion of both hormones from the anterior pituitary. The contribution of the 
anterior pituitary was assessed by chronically treating animals with dexamethasone. 
Together with decreasing plasma ACTH concentrations, dexamethasone 
significantly reduced the mean plasma levels of a -MSH and decreased a -MSH 
pulse amplitude whilst a -MSH interpulse interval increased. The authors suggested 
that a -MSH of anterior pituitary origin released in concert with ACTH contributes 
to the circulating plasma concentrations of a -MSH. However, the effects of 
dexamethasone in the study of Engler et al. (1989) could be accounted for by the 
recent identification of functional glucocorticoid receptors in the fetal intermediate 
lobe (Bertini, Westphal, deKloet and Kiss, 1989; Sheppard, Autelitano, Roberts and 
Blum, 1993). Engler et al. report that the decrease in plasma a -MSH concentrations 
following bromocriptine infusion is accompanied by a decrease in pulse frequency 
with no change in interpulse interval. This is at odds with the data presented in this 
chapter as we found that the bromocriptine- induced decrease in plasma a -MSH 
concentration reflects a significant decrease in pulse frequency such that pulsatile 
secretion is almost abolished. Indeed, in the present study a -MSH pulses were 
detected in only two of the 7 bromocriptine treated fetuses. 
Treatment of fetuses with sulpiride induced an immediate massive release of a -MSH 
into the fetal circulation accompanied by an increase in pulse amplitude. These data 
demonstrate that a -MSH secretion is subject to tonic dopaminergic inhibition and 
suggests that a -MSH is stored in the fetal pituitary gland as a readily releasable 
pool. However, the fact that bromocriptine is capable of further inhibiting a -MSH 
concentrations suggests that a -MSH is not completely suppressed by these tonic 
inhibitory mechanisms. The more rapid response to the antagonist sulpiride when 
compared to the agonist bromocriptine is supportive of the concept of a releasable 
pool as infusion of the antagonist will act to release the pituitary gland from the 
inhibitory tone and allow rapid release of available a -MSH stores. 
The results presented in this chapter are in accordance with those of Newman et al. 
(1987) who demonstrated stimulated plasma a -MSH secretion following a bolus 
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injection of the dopamine receptor antagonist metoclopramide to fetuses at day 116- 
138 gestation. The response to a bolus injection of metoclopramide is comparable to 
the response seen to sulpiride infusion in that there is a rapid increase in a -MSH 
secretion maximal 15 minutes after injection. The study of Newman et al. did not 
include any period of intensive sampling and therefore there is no indication of 
pulsatile secretion of a -MSH. 
Following 72 hours of treatment, bromocriptine and sulpiride both significantly 
reduced a -MSH pulse frequency. One possible explanation for this apparent 
paradox may be that dopamine acts to regulate the level of basal secretion of a -MSH 
rather than influencing the generation of pulses. If this were the case, significantly 
elevated basal concentrations of a -MSH in response to sulpiride would act to mask 
pulses of smaller amplitude and so pulse frequency decreases. Similarly, 
bromocriptine treatment suppresses basal a -MSH concentrations to the extent that 
pulses are no longer evident, perhaps reflecting a decrease in pituitary a -MSH 
content. This suggests that something other than dopamine is acting to regulate the 
generation of a -MSH pulses. In this respect, CRH has been shown to stimulate the 
secretion of a -MSH from rat intermediate lobe cultures (Meunier, Lefevre, Dumont 
and Labrie, 1982), raising the possibility that CRH acts to regulate pulsatile 
secretion from the intermediate lobe, as it does in the anterior lobe of the pituitary 
gland. 
The secretion of ACTH from the pituitary gland is unaffected by infusion of 
bromocriptine whilst 72 hour infusion of sulpiride significantly increases the plasma 
concentration of ACTH. Analysis of the pattern of ACTH secretion following the 
72 hour infusion reveals that the increase in plasma ACTH concentration is 
independent of any effects on pulse amplitude or pulse frequency. Thus, 
dopaminergic regulation of ACTH secretion from the fetal pituitary gland reflects 
regulation of the basal secretion of ACTH. Bromocriptine treatment did not further 
suppress the level of ACTH in fetal plasma and suggests that the system is optimally 
suppressed, that the secretion of ACTH is largely outwith the inhibitory control of 
dopamine or that the dose of bromocriptine used was insufficient. Whilst the dose 
of bromocriptine was sufficient to induce a marked decrease in circulating a -MSH 
concentrations, it remains possible that the secretion of a -MSH is more responsive 
to bromocriptine than that of ACTH. The increased ACTH concentrations in 
response to sulpiride treatment may reflect an indirect action of dopamine on 
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anterior pituitary ACTH secretion via an action on hypothalamic CRH and/or AVP 
neurons. In this respect, dopaminergic innervation of the paraventricular nucleus 
has been demonstrated however, there is little data examining the effects of 
dopamine on CRH and/or AVP secretion. An alternative mechanism by which 
dopamine could influence ACTH secretion could be by direct action on the 
intermediate lobe. Dopaminergic regulation of the intermediate lobe is well 
established and it is interesting to speculate that the ACTH released in response to 
sulpiride- infusion is of intermediate lobe origin (see chapter 7). Indeed, this could 
account for the lack of effect on ACTH pulse characteristics following sulpiride 
infusion is the removal of dopaminergic inhibition may facilitate the release of a 
basal level of ACTH from the intermediate lobe whilst the normal pulsatile secretion 
of ACTH from the anterior pituitary remains unaffected. 
Despite the increased plasma concentrations of ACTH and a -MSH following 
intravenous infusion of sulpiride, the concentration of cortisol in fetal plasma was 
unaffected. This was a surprising (and disappointing) result. It is possible that the 
fetal adrenal gland is unable to respond to increased ACTH in the fetal circulation at 
this stage of gestation. For this reason, the inclusion of an adrenal response 
challenge test at the end of the infusion period may have been helpful. However, in 
the absence of such a test, it remains unlikely that the adrenal gland was simply 
unresponsive during this stage of gestation as previous studies have demonstrated 
the presence of the cytochrome P450 steroid hydroxylase enzymes (Tangalatis et al., 
1990) necessary for cortisol biosynthesis at this stage of gestation. Moreover, these 
enzymes are 'ACTH -inducible and activate increased steroidogenesis in response to 
exogenous ACTH, further supporting the proposal that the ACTH released in 
response to sulpiride infusion is not acting at the fetal adrenal gland. The inability to 
stimmùlate the secretion of cortisol from the adrenal gland suggests that the ACTH 
released in response to sulpiride infusion is not bioactive. The IRMA system used in 
these studies is unable to distinguish between bioactive ACTH(I -39) and 
immunoreactive high molecular weight precursors. Therefore, manipulation of the 
dopamine system could influence the post -translational processing of POMC to 
favour production of immunoreactive fragment which are not involved in adrenal 
steroidogenesis. Alterations in the post -translational processing of intermediate lobe 
[3- endorphin by dopamine has previously been demonstrated in the rat (Millington, 
O'Donohue and Mueller, 1987). Thus, it is possible that altered post -translational 
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processing of the POMC molecule in the intermediate lobe of the pituitary could 
result in the release of biologically inactive ACTH of intermediate -lobe origin. 
In support of this hypothesis, surgical disconnection of the hypothalamus from the 
pituitary in the fetal sheep results in hypertrophy of the intermediate lobe and 
increased basal levels of ACTH (Antolovich et al., 1991). However, in agreement 
with the data presented in this chapter, the increase in ACTH in response to HPD is 
not associated with an increase cortisol secretion, suggestive of the release of 
biologically inactive ACTH, which may originate in the intermediate lobe. The 
pulsatile secretion of other POMC -derived peptides has not been studied in the HPD 
fetal sheep. However, in the adult sheep this procedure is accompanied by the 
hypersecretion of ACTH, 13- endorphin and a -MSH (Clarke, Clements, Cummins, 
Dench, Smith, Robinson and Funder, 1986). 
The lack of an effect of elevated a -MSH on concentrations of cortisol in the fetal 
plasma contrasts considerably with the study of Llanos et al. (1979) who 
demonstrated that exogenous administration of a -MSH to fetal sheep between day 
121 -130 gestation stimulates cortisol concentrations. However, in this study a dose 
of 7514 a -MSH was administered which would be expected to elevate plasma a- 
MSH to concentrations of around 200ng/ml. This is far in excess of both the normal 
and sulpiride- induced concentrations found in the present study and suggests that 
their results are not physiologically relevant. 
In conclusion, this study demonstrates the inherent ability of the fetal pituitary to 
secrete POMC -peptides in a pulsatile manner and illustrates the presence of a tonic 
dopaminergic inhibitory system regulating the release of ACTH and a -MSH from 
the pituitary gland during fetal life. 
Chapter 7. Dopaminergic regulation of peptide content 
in the ovine fetal pituitary gland 
7.1. Introduction 
The studies presented in Chapter 6 illustrates the presence of a tonic dopaminergic 
inhibitory mechanism regulating the secretion of a -MSH and ACTH into the fetal 
circulation. As it is not always possible or practical to gain repeated access to the 
fetal circulation, previous studies have utilised determination of pituitary peptide 
content in an attempt to gain insight to the peptide stores present in the fetal 
pituitary. These studies are largely concerned with the ontogeny of ACTH - 
immunoreactive species in the pituitary during fetal life. Silman et al. (1979) used a 
variety of radioimmunoassays to characterise ACTH related peptides in fractions of 
fetal and adult pituitaries which had been extracted and subjected to Sephadex 
column chromatography. The authors identified a number of ACTH -related species 
of varying molecular weight. In addition to the presence of ß -MSH, 3- lipotrophin 
(3 -LPH), y-LPH, f3-endorphin and ACTH, they reported the presence of three peaks 
of high -molecular weight which are believed to be precursors of ACTH. These high 
molecular weight immunoreactive species were predominant in the fetal pituitary 
whilst ACTH was the dominant peptide in the adult pituitary, suggesting differential 
processing of the POMC precursor molecule in the fetal and adult pituitary gland. 
These workers also reported that there was little or no evidence for the presence of 
a -MSH or CLIP in the pituitary gland of either fetal or adult sheep. A further study 
using isolated anterior and intermediate lobes of the pituitary revealed that the high 
molecular weight species were present only in the anterior lobe (Silman, Street, 
Holland, Chard, Falconer and Robinson, 1981). 
More recently, and contrary to the suggestions of Silman et. al. (1979; 1981), 
immunohistochemical identification of it -ACTH has been demonstrated in the 
intermediate lobe of the fetal sheep pituitary gland (Mulvogue et al., 1986; 
Matthews et al., 1995; Chapter 5). In addition, intense immunostaining for a -MSH 
in the fetal intermediate lobe has been identified during the present series of 
experiments (Chapter 5). However, whilst immunohistochemical detection of 
peptides gives valuable information concerning the presence and cellular localisation 
of immunoreactive species it does not provide any information regarding the 
molecular nature of the peptides that are present. This is particularly important in 
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this instance as the peptides are derived from differential processing of the same 
precursor molecule. 
The present study was designed to allow direct determination of pituitary ACTH and 
a -MSH content, and to examine what influence the dopaminergic regulation of 
POMC- derived peptide secretion described in Chapter 6 has on the pituitary content 
of these peptides. Specifically, fetal pituitaries removed following a 72 hour 
administration of either the dopamine agonist bromocriptine, the dopamine 
antagonist sulpiride or vehicle control to fetal sheep at day 131 gestation were 
dissected into anterior and intermediate lobes, subjected to peptide extraction and 
measurement of ACTH and a -MSH content by radioimmunoassay. In order to 
further characterise the nature of the immunoreactive forms of a -MSH and ACTH in 
the pituitary, extracts were separated on the basis of molecular weight using 
Sephadex chromatography prior to radioimmunoassay. 
7.2. Materials and methods 
7.2.1. Animals and surgery 
11 sheep of mixed breed with known insemination dates were used in this study. 
Fetal catheterisation was carried out at day 125 - 126 gestation (term =145 days) as 
described previously in Chapter 3. 
7.2.2. Experimental protocol 
Beginning day 131 gestation, fetuses received an intravenous infusion of either the 
dopamine antagonist sulpiride (0.3mg /0.5m1 /hr; n =4), the dopamine agonist 
bromocriptine (0.03mg/0.5m1 /hr; n =4) or vehicle (0.1M tartaric acid in saline ; n =3) 
alone. Infusion continued for 72 hours. At various times during the 72 hour 
infusion period, a 0.2ml fetal blood sample was withdrawn for measurement of p02, 
pCO2 and pH as described previously. 
7.2.3. Tissue collection 
At the end of the 72 hour infusion period, ewes were killed, fetuses removed and 
intact fetal pituitaries were collected immediately. The intermediate lobe of the 
pituitary gland was dissected free of the anterior lobe, weighed and snap frozen in 
liquid nitrogen. A small coronal slice, 2 -3mm thick was removed from the middle 
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of the anterior lobe and placed in 4% paraformaldehyde, processed to paraffin wax 
and immunohistochemically stained for a -MSH as described in section 3.6. The 
remaining two pieces of anterior lobe were cut in the sagittal plane and opposing 
quarters were weighed and snap frozen together in liquid nitrogen. All frozen tissue 
samples were stored in liquid nitrogen prior to extraction. 
7.2.4. Peptide extraction 
Weighed tissue was added to lml of boiling O.1M HC1/1M acetic acid (1:1 v /v) 
containing 250KIU /ml aprotinin and boiled for 5 minutes. The mixture was then 
cooled on ice and homogenised in a glass homogeniser (Uniform homogeniser; 
Jencons Scientific, Bedfordshire). The homogenate was removed to a fresh tube and 
the homogeniser rinsed with 500µ1 of the acid solution, which was added to the 
homogenate and 5011.1 was removed for determination of protein content. The 
homogenate was vortexed briefly and then the extracts were centrifuged at 10,000g 
(Beckman J2 -21 Centrifuge; Beckman Instrument Inc., California). The supernatant 
was divided into aliquots which were freeze -dried and stored at -20 °C. 
7.2.5. Protein content 
Protein concentrations in the tissue homogenates were determined using a 
commercially available assay kit (Biorad Protein Assay Dye, Biorad, California, 
USA). Tissue proteins were dissolved by boiling 50111 tissue homogenate in 950111 
0.1M NaOH for 30 mins. A protein standard curve was prepared by double 
diluting BSA (Sigma) in 0.1M NaOH in the range 25 -1.56 µg/ml. 200111 of 
chromagen was added to 800µ1 of the sample or standard, the tubes were vortexed 
and incubated at room temperature for 30 minutes and the absorbance of the 
samples at 595nm (Uvikon 880 Spectrophotometer, Zurich, Switzerland) was 
measured. All samples and standards were assayed in triplicate. Samples were 
assayed at a range of dilutions to ensure they read on the standard scale. The 
protein concentrations in the samples were calculated relative to the readings for 
the standard curve. 
7.2.6. Peptide content 
Lyophilised tissue extracts were reconstituted in the appropriate assay buffer and 
assayed for aMSH and ACTH content by radioimmunoassay (section 3.4) and also 
for ACTH using the IRMA method (section 3.5). In order to ensure that peptide 
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concentrations were assayed on the most sensitive part of the standard curve, a range 
of dilutions were assayed for each sample. The content of hormone in the tissues 
was then expressed relative to wet weight of the tissue. 
7.2.7. Column chromatography 
Sephadex G50 superfine (Sigma) was swollen for 2 hours at room temperature in 
O.1M HC1. The slurry was then packed into a 50cm xlcm glass column (Amicon 
Ltd.) under gravity. The column was then transferred to a cold room (4 °C) and 
perfused overnight with O.1M HC1 at a rate of 4m1/hour (Watson Marlowe Pump, 
Type 202U; Falmouth, Cornwall). The column was primed with 5m1 10% BSA in 
water to prevent binding to non -specific sites in the gel matrix. The column was 
calibrated by addition of a 'cocktail' containing a -MSH and ACTH or CLIP in lml 
HC1 which was eluted at a flow rate of 4ml/hour. 800µl fractions were collected by 
an electronic fraction collector (Gilson Model 203). Fractions were divided into two 
aliquots, frozen, lyophilised and stored at -20 °C. Blue dextran (2mg/ml, Pharmacia) 
exclusion was used to determine the void volume of the column. Selected pituitary 
extracts (two extracts from each treatment group) were diluted in 0.1M HCL and 
applied to the column and fractions collected, frozen and lyophilised as described 
above. Column fractions were assayed for a -MSH and ACTH by 
radioimmunoassay as described in section 3.4. 
7.2.8. Data analysis 
Intermediate lobe weights, protein content and a -MSH and ACTH levels in 
intermediate and anterior lobes of the pituitary from the three treatment groups were 
compared by ANOVA followed by post -hoc t- test. All data are expressed as mean 
± standard error of mean (SEM) and p <0.05 was considered to be significant. 
7.3. Results 
7.3.1. Efficacy of dissection 
Tissue slices removed from the anterior pituitary were sectioned and stained 
immunohistochemically for a -MSH, as a marker of intermediate lobe melanocyte 
presence to determine the efficiency of separation of the intermediate lobe from the 
anterior lobe of the pituitary. Figure 7.1. shows representative sections of anterior 
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pituitary stained for a -MSH following intermediate lobe dissection. The lack of 
immunostaining for a -MSH suggests that the intermediate lobe was removed in its 
entirety at the time of dissection and that anterior pituitary tissues collected are not 
contaminated by the presence of intermediate lobe tissue. A section of fetal pituitary 
with an intact intermediate lobe was included as a positive control. 
7.3.2. Fetal pituitary content of ACTH and a -MSH 
The average wet weight of the intermediate lobe from vehicle -treated control fetuses 
was 17.13 ± 0.5 1mg. The mean intermediate lobe weight from pituitaries in each 
treatment group are shown in Table 7.1. The average intermediate lobe weight was 
unaffected by treatment with either bromocriptine or sulpiride when compared to 
vehicle treated controls (Table 7.1). 
Treatment Mean intermediate lobe weight 
(mg ± SEM) 
vehicle 17.13 ± 0.51 (n =3) 
bromocriptine 14.22 ± 1.45 (n=4) 
sulpiride 18.85 ± 2.53 (n =4) 
Table 7.1. Intermediate lobe weight for all three treatment groups. Data expressed 
represent the mean values for all tissues collected in each treatment group ± SEM. 
Pituitary a -MSH content expressed relative to wet tissue weight is shown in Figure 
7.2. a -MSH was present in both the intermediate and anterior lobes of the pituitary. 
The intermediate lobe of the pituitary contained large amounts of a -MSH and the 
content was unaffected by treatment with either bromocriptine or sulpiride. 
Significantly less a -MSH was identified in the anterior pituitary and this too was not 
significantly altered by infusion of either bromocriptine or sulpiride. Pituitary 
ACTH content was measured by both radioimmunoassay, which identifies many 
ACTH -like peptides (ACTH(1 -39), ACTH(1 -10), ACTH(1_24) and a -MSH all show 
significant cross -reactivity) and the more specific two -site immunoradiometric assay 
which recognises specifically the ACTH(1 -39) molecule. The ACTH RIA 
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Figure 7.1. Immunohistochemical staining for a -MSH in anterior pituitary sections 
following intermediate lobe dissection. 7.1(a) illustrates positive immunostaining 
for a -MSH in a section of intact fetal pituitary. Representative pituitary sections 
following intermediate lobe dissection are shown in Figure 7.1(b and c). 
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Figure 7.2. Content of a -MSH in the anterior (open bars) and intermediate (closed 
bars) lobes of the pituitary. Peptide contents were expressed as ng/mg tissue. Data 
shown are the mean ± SEM of all tissues from each treatment group. 
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consistently measured more ACTH -immunoreactive species than ACTH IRMA 
(Figure 7.3). In both systems, ACTH was most abundant in the anterior pituitary 
and the content was unaffected by treatment with either bromocriptine or sulpiride. 
ACTH was also measured in the intermediate lobe both by RIA and IRMA. Whilst 
ACTH content in treated groups did not differ significantly from vehicle -treated 
controls, the intermediate lobe ACTH content, as measured both by RIA and IRMA 
was significantly greater (p<0.05) in bromocriptine- treated fetuses when compared 
to sulpiride- treated fetuses (Figure 7.3b). Thus, bromocriptine treatment tended to 
increase and sulpiride treatment tended to decrease the intermediate pituitary content 
of ACTH. The total protein content of the anterior and intermediate lobes of the 
pituitary was unaffected by infusion with either bromocriptine or sulpiride when 
compared to vehicle- treated controls (Figure 7.4). 
3.3. Column chromatography 
Following column calibration, pituitary extracts from vehicle, bromocriptine and 
sulpiride infused fetuses were subjected to column chromatography. Figure 7.5 
shows immunoreactive a -MSH and ACTH in fractions obtained from a 
representative anterior pituitary extract from each treatment group following 
Sephadex chromatography. Chromatography was performed on two pituitaries from 
each treatment group and both gave similar results. Two immunoreactive peaks 
were detected in anterior pituitary extracts from all three treatment groups. One 
peak eluted in fractions 26 -31 and co- eluted with synthetic a -MSH. The second 
immunoreactive peak cross- reacted in the ACTH RIA and eluted in fractions 20 -25, 
corresponding to elution of synthetic ACTH(1_39). An additional peak of 
immunoreactivity which cross -reacted in the ACTH RIA was identified in fractions 
10 -15 of vehicle and bromocriptine treated anterior pituitary extracts and in fractions 
14 -18 of anterior pituitary extracts from sulpiride- treated fetuses. The intermediate 
pituitary also contained a large peak of immunoreactive a -MSH which eluted in the 
same position as synthetic a -MSH and two peaks which contained ir- ACTH (Figure 
7.6). As with the anterior pituitary extracts, ir-ACTH was identified in a peak that 
corresponded with the elution of synthetic ACTH(1_39) (fractions 20 -25) and also a 
peak of higher molecular weight. Immunoreactive ACTH was also identified in 
fractions corresponding to the elution of synthetic ACTH(18 -39) (CLIP). The profile 
of a -MSH and ACTH immunoreactive species resulting from intermediate pituitary 
extracts was unaffected by treatment with bromocriptine or sulpiride. 
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Figure 7.3. Content of ACTH in the (a) anterior and (b) intermediate lobes of the 
pituitary, measured by RIA (open bars) and IRMA (closed bars). Peptide contents 
were expressed as ng/mg tissue. Data shown are the means ± SEM of all tissues 
from each treatment group. 
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Figure 7.4. Total protein content in extracts from a) anterior lobe and b) 
intermediate lobes of vehicle, bromocriptine and sulpiride treated pituitaries. 
Protein contents are expressed as tg protein/mg tissue. Data shown are the mean ± 
SEM of all tissues from each treatment group. 
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Figure 7.5. ACTH and a -MSH immunoreactivity determined after chromatography 
of anterior pituitary extracts prepared from a) vehicle treated, b) bromocriptine 
treated and c) sulpiride treated fetuses. The elution positions of standard ACTH, a- 
MSH and CLIP are shown by the filled bars. Blue dextran (M.Wt 2 X 106) eluted at 
Vo. 
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Figure 7.6. ACTH and a -MSH immunoreactivity determined after chromatography 
of intermediate lobe extracts prepared from a) vehicle treated, b) bromocriptine 
treated and c) sulpiride treated fetuses. The elution positions of standard ACTH, a- 
MSH and CLIP are shown by the filled bars. Blue dextran (M.Wt 2 X 106) eluted at 
Vo. 
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7.4. Discussion 
The aim of this study was to investigate the effects of intrafetal infusion of 
bromocriptine and sulpiride on the pituitary content of ACTH and a -MSH. ACTH 
and a -MSH were identified in both the anterior and intermediate lobes of the 
pituitary. The content of a -MSH and ACTH in the anterior and intermediate lobes 
of the pituitary was not significantly altered by treatment with either bromocriptine 
or sulpiride when compared to vehicle - treated controls. However, the intermediate 
lobe content of ACTH tended to increase following bromocriptine treatment and 
decrease in response to sulpiride treatment. 
This is the first demonstration of the presence of ACTH(1_39) in the intermediate 
lobe of the fetal pituitary measured using a specific two -site immunoradiometric 
assay. The IRMA system used in this study recognises the ACTH(1_39) molecule but 
does not recognise either a -MSH or CLIP which are characteristically produced in 
the intermediate lobe by processing of ACTH. However, from the present study it is 
not possible to ascertain whether this ACTH is bioactive as well as immunoreactive. 
Further studies investigating the effects of pituitary extracts on cortisol secretion 
would be needed to clarify this matter. 
When investigating peptide content it is important to remember the dynamic nature 
of the pituitary gland. Thus, the amount of peptide present in the pituitary gland at 
any one time represents a balance between the rate of peptide synthesis and 
processing and that of peptide secretion. From investigation of peptide content 
alone it is not possible to determine whether any change in content represents an 
altered rate of peptide synthesis or an altered rate of peptide secretion. In addition, 
as determination of peptide content represents a static measurement it may not be 
fully representative of the functional response of the pituitary unless it is examined 
in concert with measures of peptide secretion and synthesis. For this reason, the 
lack of effect of bromocriptine and sulpiride on pituitary a -MSH and ACTH content 
in the present study does not necessarily imply a lack of response on the part of the 
pituitary gland. 
Hypothalamo- pituitary disconnection in the adult sheep results in a two -fold 
increase in intermediate pituitary a- N- acetylated endorphin (NacEP) and a -MSH 
content (Smith, Wallace, Clarke and Funder, 1989). In order to determine whether 
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this response reflected the loss of dopaminergic input to the intermediate lobe, adult 
sheep were treated with either bromocriptine or haloperidol for 10 days. In 
consonance with the results of the present study, the intermediate lobe a -MSH 
content was increased by haloperidol and decreased by bromocriptine although these 
effects failed to reach significance (Smith et al., 1989). By contrast, the 
intermediate lobe content of ir-NacEP was significantly altered by treatment with 
both bromocriptine and haloperidol. 
The influence of hypothalamic dopaminergic input on pituitary a -MSH content has 
previously been studied in adult rats bearing electrothermic lesions of the 
mediobasal hypothalamus (Tilders and Smelik, 1978). Eight hours after lesioning 
pituitary a -MSH content was decreased by 75% when compared to non -lesioned 
controls, and this fall could he prevented by bromocriptine treatment. In agreement 
with the data presented in this chapter, the authors reported no effect of 
bromocriptine on pituitary a -MSH content of intact control rats. A single injection 
of the dopamine antagonist haloperidol induced a significant reduction in pituitary 
a -MSH content which was maximal at 4 -5 hours post -injection. However, despite 
continued elevation of plasma a -MSH concentrations in response to sulpiride 
infusion (Chapter 6) there was no significant change in pituitary a -MSH content in 
the present study. One possible explanation for the lack of effect in the present work 
is the reduced daily dose of antagonist administered to the fetuses. In the present 
study fetuses received a total of 21.6 mg sulpiride over the 72 hour period. The 
average fetal weight at post -mortem was 4.2kg equating to a dose of around 5mg/kg 
over the 72 hour period. This is comparable with the range of doses used by Tilders 
and Smelik (1978) who administered a variety of doses and found significant effects 
at 2.5 and 5.0 mg/kg. However, the 5.0mg/kg dose used by Tilders and Smelik was 
administered as a single injection whereas in the present study the continuous mode 
of administration resulted in fetuses receiving only 1.7mg/kg/day. It is possible that 
the continuous infusion used in the present study was insufficient to induce lasting 
changes at the level of pituitary content. Indeed, Tilders and Smelik were unable to 
influence pituitary a -MSH content at doses of 1.0 and 0.6 mg/kg. In addition, the 
present study and that of Tilders and Smelik (, 1978) utilised different antagonists 
and as haloperidol is a more potent antagonist than sulpiride, displaying greater 
affinity for anterior pituitary dopamine binding sites (Enjalbert and Bockaert, 1982), 
direct comparison between doses may not be appropriate. 
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Conversely, it may be that the dose of sulpiride administered during the present 
study was sufficient to influence pituitary content but that the chronic nature of the 
infusion allows the pituitary to compensate and adjust peptide contents accordingly. 
Thus, the rapid increase in circulating a -MSH concentrations in response to 
sulpiride shown in Chapter 6 may indeed result in a transient decrease in pituitary 
content but, by the end of the 72 hour infusion period the a -MSH content is restored 
to control levels. One possible mechanism by which the pituitary can readjust the 
intermediate lobe a -MSH content in the face of continuous hypersecretion is by 
alteration of the rate of a -MSH biosynthesis. This hypothesis is supported by the 
demonstration that reduced a -MSH content in response to haloperidol is 
accompanied by an increased capacity of intermediate lobe cells to synthesis a -MSH 
(Beaulieu et al.., 1984) and also an increased level of POMC mRNA. As mentioned 
previously, the maintenance of intermediate lobe content in the present study may 
also be reflected in the level of POMC gene expression and this possibility is 
investigated further in Chapter 8. 
In contrast to the study of Tilders and Smelik (1978) and in support of the 
hypothesis of altered biosynthesis, a biphasic response of pituitary a -MSH content 
following bromocriptine treatment has been reported (Beaulieu et al., 1984). Adult 
rats treated with bromocriptine for 2 days displayed a significant increase in 
intermediate lobe content of a -MSH. This increase in a -MSH content was coupled 
with a decrease in the synthesis of a -MSH like peptides. However, after 5 days of 
treatment with bromocriptine there was a marked reduction in intermediate lobe a- 
MSH content and following long term administration for up to 21 days the a -MSH 
content of the intermediate lobe was decreased by 70% when compared to controls. 
This is at odds with the present study in which 3 day infusion of bromocriptine did 
not significantly alter the pituitary content of a -MSH. However, it is possible that 
the 3 day period in the present study represents the transition period in the biphasic 
response to bromocriptine reported by Beaulieu and co- workers. In the study of 
Beaulieu et al., rats were treated with bromocriptine administered as a daily injection 
at a dose of 10mg/kg /day which is significantly greater than the doses used both in 
the present study and in that of Tilders and Smelik (1978). In addition, the 
minimum dose of 0.3mg/kg /day for 4 days tested by Beaulieu et al.,which resulted 
in reduced levels of POMC synthesis, was almost 2 times greater than the dose used 
in the present study and suggests that the dose and mode of administration, together 
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with the time -frame of the response may be critically important in studies such as 
this. 
Beaulieu et al. (1984) also reported a 39% decrease in total protein content in the 
intermediate lobes of bromocriptine treated rats when compared to vehicle -treated 
controls. No such change was identified in the present study. However, this is 
perhaps not surprising as there was no corresponding decrease in intermediate lobe 
content of peptide in response to bromocriptine. 
In the present study, there was no significant effect of sulpiride on intermediate lobe 
ACTH content when compared to vehicle -treated controls. However, ACTH content 
of the intermediate lobe tended to decrease in response to sulpiride infusion and 
increase following bromocriptine infusion. It is conceivable that, given increased 
group sizes or perhaps a longer infusion period, intermediate lobe ACTH content 
may be significantly altered. Reduced intermediate lobe ACTH content in response 
to sulpiride infusion would be consistent with the hypothesis that sulpiride acts to 
increase the rate of secretion of ACTH from the intermediate lobe (see Chapter 6 
discussion). However, if this was the case it is difficult to explain the lack of effect 
on a -MSH content when circulating levels of a -MSH are also significantly elevated 
by sulpiride infusion. Indeed, if the hypothesis of altered biosynthesis to 
compliment an altered rate of secretion was correct then it is not unreasonable to 
expect that pituitary ACTH and a -MSH content be regulated in the same manner. 
However, it is possible that the reduced content of ACTH in the intermediate lobe 
reflects an increased rate of processing of ACTH to produce a -MSH. Thus, ACTH 
is more rapidly processed to a -MSH resulting in maintained pituitary content of a- 
MSH coupled with a decreased pituitary content of ACTH. Support for this 
hypothesis comes from the finding that expression of the prohormone convertase 
enzymes PC1 and PC2 is regulated by dopamine (Day et al., 1992). Levels of PC1 
and PC2 mRNA in the intermediate lobe of adult rats significantly increased 
following haloperidol treatment and decreased following treatment with 
bromocriptine (Day et al., 1992). Corresponding changes in POMC mRNA levels 
have also been reported (Day et. al., 1992). Interestingly, intermediate lobe PC2 
mRNA levels were increased to a greater extent than PC1 and POMC mRNA levels 
for an identical dose of haloperidol (4 -6 fold compared with 2 -3 fold respectively). 
This differential regulation of PC1 and PC2 gene expression provides a mechanism 
for increased post -translational processing of the POMC precursor whereby ACTH 
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produced in the intermediate lobe following enzymatic cleavage of the precursor 
molecule by PC1 would be rapidly processed to a -MSH by the action of PC2. 
- The further possibility exists that regulation of peptide content in the fetal pituitary 
in response to altered rates of secretion occurs by mechanisms which are distinct 
from those utilised in the adult. However, the very similar results of Smith et al. 
(1989) suggest that this is not the case. In addition, all the evidence collated so far 
suggests that dopaminergic regulation of the fetal pituitary utilises many of the same 
mechanisms in the fetus as in the adult with respect to peptide secretion and gene 
regulatiön and therefore it seems at least possible that similar regulation of peptide 
content - will occur. It remains possible, however, that regulation of pituitary 
function in-the sheep is distinct from that in the rat. If this were the case then 
extrapolation from the studies of adult rats may be misleading. 
In agreement with the results presented in this chapter, Smith et al. (1989) reported 
that the elution profiles of a -MSH immunoreactivity from bromocriptine and 
haloperidol treated sheep intermediate lobe extracts, subjected to HPLC analysis did 
not differ from that of vehicle- treated controls. In contrast, the pattern of NacEP 
processing observed in the inermediate lobe extracts of haloperidol treated sheep 
was similar to that obtained from HPD sheep, suggestive of dopaminergic regulation 
f post -translational processing in the intermediate lobe of the adult sheep. 
Using Sephadex G100 chromatography, Silman et al.. (1979) identified three peaks 
of high molecular weight which were distinct from ß -MSH, ß -LPH, y --LPH, [3- 
endorphin and ACTH. The 3 high molecular weight species were present in 
relatively greater proportions in the fetus than in the adult sheep pituitary 
de nonstrating the existence of differential processing for the POMC molecule in the 
fetal pituitary compared to the adult pituitary gland. Dissection of the fetal pituitary 
and investigation of the anterior and intermediate lobes of the pituitary separately 
revealed that 2 of the high molecular weight peaks were present in the intermediate 
pituitary in significantly reduced quantities (Silman et. al., 1981). This concurs with 
the result of the present study in which a high molecular weight peak of ACTH - 
immunoreactivity was evident in the anterior lobe and, in reduced amounts, in the 
intermediate lobe of the pituitary suggestive of similar processing mechanisms in the 
anterior and intermediate lobes of the pituitary. However, Silman and co- workers 
failed to detect a peak corresponding to ACTH(1_39) in intermediate lobe extracts. 
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This differs significantly from the findings in the present study as intermediate lobe 
extracts contained significant amounts of ACTH(1 -39) immunoreactivity as detected 
both by IRMA and by RIA following Sephadex chromatography. The marked 
difference in these results is difficult to explain. The possibility of anterior pituitary 
contamination of intermediate lobe extracts in the present study cannot be ruled out. 
However, this seems unlikely as great care was taken during the dissection 
procedure and subsequent histological examination of the coronal pituitary slice 
confirmed that the intermediate lobe had been cleanly removed. It is also feasible 
that the ACTH(1 -39) detected in the present study arises from degradation of ACTH 
precursors during the extraction process and a protease inhibitor was included in the 
extraction procedure to reduce this possibility. Furthermore, the presence of 
substantial immunoreactivity for ACTH in the fetal intermediate lobe at this stage 
(see Chapters 5 and 8) suggests that the intermediate lobe does contain significant 
amounts of ACTH at this time in development. In addition, Silman et al. (1981) 
reported that the there was little evidence for the existence of a -MSH or CLIP in the 
pituitary gland of the fetus. In the present study however, a -MSH was evident in the 
intermediate and anterior lobes of the pituitary as detected both by direct 
radioimmunoassay of pituitary extracts and following Sephadex chromatography. 
This too conforms with the presence of abundant a -MSH immunostaining in the 
intermediate lobe (Chapters 5 and 8). In agreement with the present study, Smith 
and Funder (1988) reported that the anterior and intermediate lobes of the sheep 
pituitary contained significant a -MSH immunoreactivity characterised by HPLC 
analysis. 
The presence of high molecular weight species of ACTH in the fetal pituitary gland 
has been demonstrated by others (Brieu and Durand, 1989a) and these molecules 
have been shown to antagonise ACTH -induced cortisol secretion from adrenal cells 
in vitro (Jones and Roebuck, 1980). As the relative proportion of high molecular 
weight forms of ACTH to ACTH(1_39) falls with advancing gestation (Roebuck et 
al., 1980) it is possible that the changing ratio of high molecular weight ACTH to 
ACTH(1 -39) plays a role in the late gestation cortisol surge from the fetal adrenal 
gland. The results of the present study would suggest that the intermediate lobe may 
contribute to the pool of high molecular weight ACTH precursors and could be an 
important source of ACTH(1_39) during fetal life. There was no evidence in the 
present study for dopaminergic modulation of POMC processing in the fetal 
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intermediate lobe as the profiles of immunoreactive ACTH and a -MSH species were 
unaltered by treatment with bromocriptine or sulpiride. However, in anterior 
pituitary extracts from sulpiride treated fetuses there was a tendency for the high 
molecular weight ACTH -immunoreactive peak to shift to the right, indicative of a 
lower molecular weight. It is possible that this peak represents the 'intermediate' 
ACTH described by Brieu and Durand (1989a) which eluted between the void 
volume of the column and standard ACTH(1 -39) In that study, large amounts of 
'big' ACTH (eluting in the void volume) and 'intermediate' ACTH were identified in 
extracts of cultured fetal pituitary cells and in total pituitary extracts, whereas the 
predominant form of ACTH immunoreactivity released into the incubation medium 
was ACTH(1 -39) However, some 'intermediate' ACTH was released into the 
incubation media and this was found to be highly steroidogenic. By comparison, 
'big' ACTH had only very weak steroidogenic activity. Thus, it is possible that the 
smaller molecular weight ACTH -immunoreactive molecule induced by sulpiride 
treatment in the present study represents a change in processing of the POMC 
molecule in the anterior pituitary to favour the production of a bioactive ACTH 
molecule. An in vitro bioassay of column fractions is needed to further elucidate the 
nature of the ACTH -immunoreactive peaks in the present study. 
In conclusion, the present study demonstrates the presence of ACTH in both the 
anterior and intermediate lobes of the fetal pituitary. Immunoreactive ACTH was 
evident in both lobes as ACTH(1 -39) and as a higher molecular weight species. The 
intermediate pituitary ACTH content was regulated by sulpiride and bromocriptine 
treatment. In addition, a -MSH was evident in both the anterior and intermediate 
lobes and pituitary content was unaltered by treatment with bromocriptine or 
sulpiride. These data suggest that the POMC precursor molecule undergoes similar 
processing in both lobes of the fetal pituitary, albeit to a different extent in each lobe 
and suggests that the intermediate lobe is a rich source of both ACTH and a -MSH 
during fetal life. The role of intermediate lobe ACTH in fetal life remains to be 
determined. 
Chapter 8. Dopaminergic regulation of POMC gene 
expression in the ovine fetal pituitary gland 
8.1. Introduction 
The results presented in Chapter 6 clearly demonstrate the presence of a tonic 
dopaminergic inhibitory mechanism regulating the secretion of a -MSH and ACTH 
into the fetal circulation. However, analysis of pituitary peptide content (Chapter 7) 
suggests that the modified rate of peptide secretion in response to dopamine agonist 
or antagonist treatment does not influence the stored pituitary content of these 
peptides. Maintenance of pituitary peptide content occurring concomitantly with an 
altered rate of secretion may reflect regulation at the level of POMC gene 
expression. 
The inhibitory influence of dopamine on POMC expression in the pituitary of adult 
rats has been extensively demonstrated. The capacity of the rat intermediate lobe to 
synthesise POMC, as measured by incorporation of [3H] tyrosine was decreased by 
the dopamine agonist bromocriptine and increased by administration of the 
dopamine antagonist spiperidol (Beaulieu et al., 1984). It has since been 
demonstrated that the altered level of POMC synthesis was reflected in parallel 
changes in the level of POMC mRNA in the intermediate lobe, with mRNA levels 
reduced by bromocriptine and increased by haloperidol (Chen et al., 1983; Beaulieu 
et al., 1984; Autelitano et al., 1987; Chronwall et al., 1987; Levy and Lightman, 
1988). In all reports, the level of POMC gene expression in the anterior lobe was 
unaltered. Similar effects of bromocriptine and haloperidol have been demonstrated 
in primary cultures of isolated anterior and intermediate lobes of rat pituitary 
(Loeffler, Demeneix, Kley and Höllt, 1988). However, whilst the role of dopamine 
in the modulation of POMC gene expression in the rat pituitary has been studied by 
many workers, there is little information concerning dopaminergic regulation of 
POMC gene expression in sheep. 
Thus, it was hypothesised that dopamine regulates POMC gene expression in the 
ovine fetal pituitary gland such that pituitary stores of POMC- derived peptides can 
be maintained during periods of enhanced or suppressed peptide secretion. To test 
this hypothesis, expression of POMC mRNA in the fetal pituitary in response to 
treatment with either the dopamine agonist bromocriptine or the dopamine 
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antagonist sulpiride was determined by in situ hybridisation. In addition, pituitary 
expression of the translated POMC products ACTH and a -MSH was determined by 
immunohistochemistry. 
8.2. Materials and Methods 
8.2.1. Animals and tissue collection 
27 sheep of mixed breed with known insemination dates were used in this study. 
Fetal catheterisation was carried out at day 125 - 126 gestation (term =145 days) as 
described previously in Chapter 3. After overnight recovery the ewes were moved 
to metabolism crates and at least 5 days were allowed before experiments began. 
8.2.2. Experimental Protocol 
Beginning on day 131 gestation, fetuses received an intravenous infusion of either 
the dopamine antagonist sulpiride (0.3mg/0.5m1/hr ; n =8,), the dopamine agonist 
bromocriptine (0.03mg/0.5m1/hr ; n =3) or vehicle (0.1M tartaric acid in saline ; n =4) 
alone. Infusions commenced between 1100 and 1300 hours and continued for 72 
hours. At the end of the infusion period, ewes were killed with an overdose of 
,anaesthetic, fetuses delivered and fetal pituitaries collected as described previously 
(see Chapter 3). All isolated pituitaries were halved in a coronal plane before 
processing to paraffin wax and sectioning as described in section 3.6. In order to 
allow for comparison between gene expression and localisation of translated POMC- 
derived peptides consecutive sections were processed for in situ hybridisation and 
immunohistochemistry. 
8.2.3. Radioactive in situ hybridisation for POMC 
Radiolabelled riboprobe was prepared as described in section 3.11 and radioactive in 
situ hybridisation for POMC was carried out as described in section 3.12. For each 
pituitary in the study 8 tissue sections were mounted as 2 sections per slide on 4 
separate slides and were treated with antisense riboprobe. 2 slides containing 2 
tissue sections from each pituitary were treated with sense riboprobe as a negative 
control. Preliminary experiments revealed that POMC expression in pars distalis 
and pars intermedia was optimal at two different exposure times and so half of the 
antisense and sense hybridised slides were developed after 3 days for determination 
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of pars intermedia gene expression and the other half developed after 10 days for 
determination of pars distalis POMC gene expression. 
8.2.4. Immunohistochemistry 
Immunohistochemical detection of a -MSH and ACTH(18 -39) was performed using 
the avidin- biotin staining procedure described in section 3.7. 
8.2.5. Data analysis 
All tissues in the study were processed together to allow for direct comparison 
between gestational ages. Each slide in the study contained a tissue section from an 
adult sheep pituitary as a positive control and to ensure standardisation of the 
procedure between slides. Sections were analysed using a computerised image 
analysis program (TCL- image, Multihouse, Amsterdam) for the Macintosh II 
computer. The position in the pituitary at which the analysis was undertaken was 
consistent throughout. As POMC gene expression in the pars distalis is regionally 
distributed, the area around the intermediate lobe of the pituitary and the area at the 
base of the anterior lobe were analysed separately. A minimum of 3 separate tissue 
sections were analysed from each pituitary in the study and 5 fields were counted for 
each area in the tissue to be analysed. 
8.3. Results 
Localisation of POMC mRNA in a representative pituitary section from each 
treatment group is shown in Figure 8.1. POMC mRNA was abundantly expressed in 
the intermediate and anterior lobes of the pituitary in all three groups. The regional 
distribution of POMC mRNA was unaffected by either bromocriptine or sulpiride 
treatment when compared to vehicle -treated controls. 
Computerised image analysis of silver grains revealed that the POMC mRNA in the 
intermediate lobe of the pituitary was significantly (p<0.05) decreased following 
bromocriptine treatment (Figure 8.2a). There was no significant effect of sulpiride 
on POMC mRNA expression in the intermediate lobe. POMC expression in both 
the basal region of the anterior pituitary and the region surrounding the intermediate 
lobe was not significantly altered by treatment with either bromocriptine or sulpiride 
(Figure 8.2b). 
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Figure 8.1. Localisation of POMC mRNA in a representative pituitary at day 134 
gestation by radioactive in situ hybridisation following 72 hour infusion of A and B) 
vehicle, C and D) bromocriptine or E and F) sulpiride. POMC mRNA was detected 
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Figure 8.2. Histogram showing the number of silver grains per 100 square microns 
of tissue in a) the intermediate lobe and b) the anterior lobe of the pituitary. In the 
anterior lobe, the region at the base of the gland (black bars) and the region 
immediately adjacent to the intermediate lobe (grey bars) were analysed separately. 
Significant difference from corresponding vehicle control is indicated by an asterisk, 
* P <0.05. 
sulpiride 
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However, the levels of POMC mRNA in the basal region of the anterior pituitary 
tended to decrease in response to bromocriptine when compared to vehicle treated 
controls (Figure 8.2b; p =0.09) 
Immunohistochemical detection of a -MSH and ACTH in a representative pituitary 
section from each treatment group are shown in Figures 8.3 and 8.4 respectively. a- 
MSH immunoreactivity was confined to the intermediate lobe and almost all cells of 
the lobe were immunopositive (Figure 8.3). For this reason it was not possible to 
count the number of a -MSH immunopositive cells. The intensity of staining was 
not altered by either bromocriptine or sulpiride treatment. ACTH immunopositive 
cells were identified in both the anterior and intermediate lobe of the pituitary gland. 
In keeping, with the pattern of POMC gene expression, ACTH -ir cells were 
regionally distributed with the region of the anterior lobe closest to the intermediate 
lobe largely devoid of corticotrophs (Figure 8.4). The number of immunopositive 
corticotrophs in the corticotroph dense region around the base of the gland was 
unaltered by treatment with bromocriptine or sulpiride (Figure 8.5). 
8.4. Discussion 
The aim of this study was to determine the effect of a 72 hour intrafetal infusion of 
the dopamine agonist bromocriptine or the dopamine antagonist sulpiride on 
pituitary POMC gene expression. POMC mRNA expression in the intermediate 
lobe of the pituitary was significantly reduced following bromocriptine treatment 
and was unaffected by treatment with sulpiride. There was no significant effect of 
either treatment on POMC mRNA in the anterior lobe of the pituitary. In addition, 
the number of immunopositive corticotrophs in the anterior pituitary was unaltered 
by either bromocriptine or sulpiride treatment when compared to vehicle controls. 
The decreased POMC mRNA levels in the intermediate lobe following 
bromocriptine treatment reported in the present study are consistent with previous 
reports in the adult rat (Chen et al., 1983; Beaulieu et al., 1984; Autelitano et al., 
1987; Chronwall et al., 1987; Levy and Lightman, 1988). In all of the studies in 
rats, the fall in POMC mRNA in the intermediate lobe was greater than that 
described here (50 -80 %). However, the dose of bromocriptine used was typically 5- 
10 fold greater than that used in the present study. This suggests that the 
suppression of POMC mRNA levels induced by bromocriptine treatment in 
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Figure 8.3. Immunohistochemical detection of a -MSH in a representative pituitary 
section following 72 hour treatment with (A, B) vehicle, (C, D) bromocriptine or (E, 
F) sulpiride. a -MSH immunostaining was confined to the intermediate lobe. The 
distribution and intensity of staining was affected by treatment of bromocriptine or 
sulpiride when compared to vehicle treated controls. A, C and E xl magnification, 
B, D and F x20 magnification. 
Figure 8.4. Immunohistochemical detection of ACTH(18 -39) in a representative 
pituitary section following 72 hour treatment with (A, B) vehicle, (C, D) 
bromocriptine or (E, F) sulpiride. ACTH immunoreactive cells were identified in 
both the anterior and intermediate lobes of the pituitary. Anterior pituitary 
corticotrophs tended to be regionally distributed with the majority of 
immunopositive cells occupying the basal aspect of the gland. A, C and E xl 
magnification, B, D and F x20 magnification. 




Figure 8.5. The percentage of immunopositive corticotrophs in the basal aspect of 
the anterior pituitary in fetuses treated for 72 hours with vehicle, bromocriptine or 
sulpiride expressed as a percentage of the total number of cells present. The 
percentage of immunopositive corticotrophs was unaffected by infusion of 
bromocriptine or sulpiride when compared to vehicle treated controls. Data shown 
represent the mean ± SEM for all fetuses in each treatment group. 
Chapter 8 Dopaminergic regulation of POMO gene expression 191 
the present study is perhaps not maximal and could be enhanced by increased doses 
of bromocriptine. Dose -response studies would be needed to clarify this point. 
Chronwall et al. (1987) reported that autoradiographic grains over intermediate lobe 
melanotrophs were heterogeneously distributed, indicating that different cells 
maintained different levels of POMC gene expression. The decrease in POMC 
mRNA levels following acute bromocriptine treatment occurred concomitantly with 
a diminished heterogeneity of grain distribution, suggestive of differing responses of 
individual cells. Following chronic administration of bromocriptine, the rate of cell 
proliferation was altered, as determined both by incorporation of [3H]thymidine and 
measurements of mitotic index. This data suggests that the decrease in POMC 
mRNA levels in response to bromocriptine results from a change in both the level of 
gene expression and in the number of melanotrophs present in the intermediate lobe. 
A decreased level of POMC mRNA in the fetal intermediate lobe following 
bromocriptine may represent either a decrease in synthesis and processing of the 
POMC mRNA precursor molecule or increased translation of the mature mRNA. In 
the present study it is likely that the decrease in POMC mRNA levels represents a 
decreased rate of POMC mRNA synthesis as there was no concomitant increase in 
pituitary content of POMC -derived peptides (Chapter 7). In addition, an increased 
rate of translation with no increase in cell content would imply an increased level of 
peptide secretion. However, the secretion of a -MSH from the intermediate lobe to 
the fetal circulation is reduced following bromocriptine treatment (Chapter 6). 
In the present study there was no effect of sulpiride on intermediate lobe POMC 
mRNA expression. This contrasts considerably with data generated in adult rats in 
which the dopamine antagonist haloperidol has been demonstrated to significantly 
increase the level of POMC mRNA in the intermediate lobe of the pituitary (Chen et 
al., 1983; Autelitano et al., 1987; Chronwall et al., 1987). The lack of effect of 
sulpiride on POMC mRNA levels in the present study may simply be due to the fact 
that the mechanisms controlling POMC expression are fundamentally different in 
the rat and sheep or that the mechanisms are sufficiently different in the adult 
compared to the fetus. It is not possible to rule out these potential factors 
completely. However, an alternative explanation lies in the already very high level 
of expression of POMC mRNA in the fetal intermediate lobe. Levels of POMC 
mRNA are consistently high in the intermediate lobe, indeed they are significantly 
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greater than those in the anterior lobe at any point in late gestation (Matthews et al., 
1994; Chapter 5). Consequently it is possible that the gene is maximally expressed 
during late gestation and as such can not be further stimulated by dopamine 
blockade. If this is the case, factors other than increased gene expression must be 
acting to account for the increased levels of POMC- derived peptides present in the 
fetal circulation and the maintenance of intra- pituitary peptide content following 
sulpiride treatment. One likely mechanism by which this could occur is by 
regulation of the post -translational processing of the POMC protein precursor 
molecule. Support for this hypothesis comes from the demonstration that the post - 
translational processing of [3- endorphin in the rat intermediate pituitary is modified 
by dopamine (Millington et al., 1987). Long -term treatment of rats with either 
dopamine agonists or antagonists selectively altered the molecular forms of 13- 
endorphin contained in and released from the intermediate lobe (Millington et al., 
1987). Thus, it is possible that sulpiride influences the post -translational processing 
of existing stores of POMC in the intermediate lobe to maintain the increased 
demand for secreted peptide. As discussed in Chapter 7, increased POMC mRNA 
expression following dopamine antagonist treatment in adult rats is accompanied by 
increased levels of PC1 and PC2 mRNA, with PC2 mRNA levels showing the 
greatest increase (Day et al., 1992). It would be very interesting to investigate the 
levels of PC1 and PC2 expression in the present system as altered post -translational 
processing of the POMC molecule to favour production of a -MSH from the 
intermediate lobe would facilitate increased a -MSH production from a steady state 
level of POMC gene expression. Thus, POMC mRNA levels in the intermediate 
lobe of the pituitary need not necessarily increase to fulfil the demands of 
augmented peptide secretion. 
The lack of effect of bromocriptine and sulpiride on anterior pituitary POMC mRNA 
expression is consistent with studies in the adult rat (Chen et al., 1983; Levy and 
Lightman, 1988). However, there was a tendency towards a decrease in POMC 
mRNA levels in the basal aspect of the anterior pituitary, although this decline did 
not reach significance. The lack of a significant effect on anterior pituitary POMC 
gene expression is less surprising since there is little evidence to suggest that 
anterior pituitary corticotrophs are regulated by dopamine. In contrast to the well 
documented regulation of the intermediate lobe of the pituitary by dopamine, the 
anterior pituitary is primarily under the influence of the hypothalamic neuropeptides 
CRH and AVP (Challis and Brooks, 1989). In the late gestation fetal sheep there is 
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a concomitant rise in the levels of POMC mRNA in the anterior pituitary and that of 
CRH mRNA levels in the paraventricular nucleus of the hypothalamus (Myers et al., 
1993). As bromocriptine is administered intravenously it is likely that it has several 
sites of action. Thus, it is possible that bromocriptine treatment acts indirectly on 
the hypothalamus to reduce levels of CRH mRNA which in turn may precipitate a 
decline in POMC mRNA in the anterior pituitary. To this end, levels of POMC 
mRNA in the anterior pituitary of adult rats have been shown to increase 
significantly in response to 15 day administration of CRH (Bruhn et al., 1984). It 
remains possible that, following a longer treatment period with bromocriptine, 
expression of POMC mRNA in anterior pituitary corticotrophs of the ovine fetus 
may be significantly reduced. As the number of anterior pituitary corticotrophs was 
unaltered by infusion of either bromocriptine or sulpiride it seems likely that any 
influence of bromocriptine on POMC mRNA in the anterior pituitary, occurring 
either directly or indirectly, reflects a down -regulation in the expression levels of 
individual cells rather than an effect on the number of cells actively expressing the 
POMC gene within the corticotroph population. 
In conclusion, this study demonstrated that dopaminergic modulation of the fetal 
intermediate lobe can occur at the level of gene expression. Moreover, it suggests 
that mechanisms other than modification in the rate of gene expression, such as post - 
translational processing are important in the pituitary response to dopaminergic 
blockade by sulpiride. 
Chapter 9. Dopaminergic regulation of fetal prolactin 
secretion 
9.1. Introduction 
Previous studies in the ovine fetus have demonstrated that plasma prolactin 
concentrations are modulated by dopamine. Administration of the dopamine 
agonists bromocriptine or apomorphine by intravenous infusion or bolus injection 
can suppress circulating plasma prolactin concentrations in fetal sheep (Gluckman et 
al., 1979; Lowe, Beck, McNaughton, Gluckman, Kaplan, Grumbach and 
Nathanielsz, 1979) and in neonatal lambs (Gluckman et al., 1979). Conversely, 
administration of the dopamine antagonist haloperidol acts to stimulate the release of 
prolactin into the fetal circulation in fetuses from day 106 gestation, demonstrating 
the presence of a tonic inhibitory dopaminergic mechanism regulating the secretion 
of prolactin in the developing fetal sheep (Gluckman et al., 1979). 
Prolactin concentrations in adult sheep are influenced by season such that circulating 
concentrations are high during the long days of the summer months and low during 
the short days of the winter months (Curlewis, 1992). A daily rhythm in prolactin 
concentrations has also been demonstrated, with a peak of plasma prolactin 
concentrations associated with the onset of darkness (Brinklow and Forbes, 1984; 
Walton, Evins, Fitzgerald and Cunningham, 1989). Recently it has become clear 
that fetal plasma prolactin concentrations are also influenced by the duration of the 
external photoperiod (Basset, Bomford and Mott, 1988). Fetal plasma displays a 
diurnal rhythm of both prolactin (McMillan, Thorburn and Walker, 1987) and 
melatonin (Zembegs, McMillen, Walker, Thorburn and Nowak, 1988) which reflects 
that found in the maternal circulation. Experimental manipulation of the 
photoperiod experienced by the ewe confirmed that photoperiodic information 
transmitted from the ewe to the fetus influences fetal plasma prolactin 
concentrations (Bassett, Curtis, Hanson and Weeding, 1989). Fetal plasma prolactin 
concentrations can be suppressed under long days by maternal infusion of melatonin 
(Bassett et al., 1989), demonstrating that the nocturnal increase in plasma melatonin 
in the ewe is instrumental in the release of fetal prolactin. Moreover, pinealectomy 
of the ewe abolishes the diurnal rhythm of melatonin in both the ewe and the fetus 
(Yellon and Longo, 1989; McMillen and Nowak, 1989). 
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It has been suggested that the response of the ovine fetal pituitary to the prolactin 
releasing factor thyrotropin -releasing factor (TRF) increases with advancing 
gestational age (Thomsett, Marti -Henneberg, Gluckman, Kaplan, Rudolph and 
Grumbach, 1980). Similarly, Gluckman et al. (1983) report an increase in response 
of the fetal pituitary to a bolus injection of the dopamine antagonist haloperidol with 
advancing gestation. More recently, Bassett et al. (1989) report that fetal response 
to TRH and the dopamine antagonist metoclopramide are primarily determined by 
photoperiod rather than ontogenic development. 
The aim of this study was to determine the extent to which season influences the 
dopaminergic regulation of prolactin secretion in the late gestation ovine fetus. 
Specifically, fetuses at day 131 gestation were treated with 72 hour intravenous 
infusion of either bromocriptine or sulpiride between January and March or between 
May and July, and the response in terms of fetal plasma prolactin concentrations was 
determined. 
9.2. Materials and Methods 
9.2.1. Experimental protocol 
Fetuses were prepared with indwelling femoral catheters at day 125 -126 gestation as 
described in section 3.2. The experiment consisted of two groups of animals. One 
experiment was performed between January and March (n =12; hereafter called the 
winter group) and the other was performed between May and July (n =11; hereafter 
called the summer group). Beginning on day 131 gestation, fetuses received a 3 day 
intravenous infusion of either bromocriptine (0.03mg/0.5m1/hr) or sulpiride 
(0.3mg/0.5ml/hr) as described previously (section 6.2.2). Fetal blood samples (1m1) 
were collected at 12 hour intervals (0900 and 2100 hours) beginning 24 hours before 
the start of the infusion for the determination of plasma prolactin concentrations by 
radioimmunoassay (section 3.4.2). At the end of the infusion period, ewes were 
killed and fetal pituitaries were collected into 4% paraformaldehyde for prolactin 
immunohistochemistry (section 3.6). Pituitaries collected during the summer 
months were collected and fixed intact whilst those collected during the winter 
months were dissected to remove the intermediate lobe for the study of peptide 
content described in Chapter 7. In these fetuses, a 2 -3mm thick coronal slice of 
anterior pituitary was removed from the middle of the pituitary gland following 
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dissection of the intermediate lobe, fixed in 4% paraformaldehyde and utilised for 
prolactin immunohistochemistry. 
The percentage of lactotrophs in the pituitary was determined by counting the 
number of cells immunopositive for prolactin relative to the total number of cells 
present in the anterior lobe of the pituitary. Lactotrophs tended to be regionally 
distributed with less cells present in the central region of the anterior lobe. Four 
fields were counted in the lactotroph dense region of the anterior lobe in each tissue 
section and at least two tissue sections were counted for each pituitary in the study. 
9.2.2. Data analysis 
The effects of bromocriptine and sulpiride infusion on plasma prolactin 
concentrations over the 72 hour period was analysed by Analysis of Variance 
(ANOVA) with repeated measures using the Statview package (Abacus Concepts, 
Inc., Berkeley, Ca , 1992) for the Apple Macintosh. Comparison of means was 
analysed using Students t -test where indicated. All data shown are mean ± SEM and 
in all analysis, p<0.05 was considered to be significant. 
9.3. Results 
9.3.1. Plasma concentrations 
Basal prolactin concentrations in fetuses during winter and summer months are 
shown in Figure 9.1. Data shown represent the mean plasma prolactin concentration 
in the three daily blood samples withdrawn from all fetuses treated in winter (n =12) 
and summer (n -11) prior to the start of the experimental infusion. Mean measured 
plasma prolactin concentrations were significantly (p<0.001; Students t -test) higher 
in summer fetuses (127.61 ng /ml ± 8.26, mean ± SEM) when compared to winter 
fetuses (6.28 ± 0.49). 
The plasma prolactin concentrations in representative fetuses infused with vehicle, 
bromocriptine or sulpiride are shown in Figure 9.2 a, b and c respectively. Profiles 
in the upper panel were generated during the summer months whilst those in the 
lower panel represent fetuses treated during the winter. In both seasons, plasma 
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winter summer 
Figure 9.1. Mean plasma prolactin concentration in fetuses sampled prior to the start 
of the infusion, between January and March (winter ; n =12) and May and July 
(summer ; n =11). There was a highly significant ( * * *, p<0.001) difference between 
winter and summer basal prolactin concentrations 
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Figure 9.2. Plasma prolactin concentrations in blood samples collected every 12 
hours in representative fetuses infused with a) vehicle, b) bromocriptine and c) 
sulpiride. Profiles in the upper panel are from fetuses infused during the summer 
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prolactin concentrations were unaffected by infusion of vehicle. Infusion of 
bromocriptine (9.2b) precipitated a steady decline in prolactin concentrations in both 
summer and winter fetuses. Conversely, sulpiride infusion (9.2c) induced a rapid 
increase in circulating prolactin concentrations irrespective of season. 
The mean fetal plasma prolactin response of all fetuses in each treatment group to a 
72 hour infusion of vehicle control, bromocriptine or sulpiride in both the summer 
and winter months is shown in Figure 9.3. In both summer (9.3a) and winter (9.3b) 
fetuses, plasma prolactin concentrations were significantly (p< 0.001) increased 
above basal values following sulpiride infusion and levels were significantly 
(p<0.001 and p <0.01; summer and winter respectively) reduced following 
bromocriptine treatment. Infusion of sulpiride resulted in a rapid increase in 
circulating prolactin concentrations in both winter and summer fetuses which was 
maximal at least 12 hours after the start of the infusion. By contrast, the response to 
bromocriptine at both times of year was more gradual, with plasma concentrations 
steadily declining over a 24 -36 hour period and then remaining consistently low for 
the remainder of the infusion period. The response of winter fetuses to 
bromocriptine infusion is not easily discernible on the scale of Figure 9.3a due to the 
large increase in concentrations following sulpiride infusion. However, the fall in 
prolactin levels in response to bromocriptine is clearly shown in Figure 9.2b (lower 
panel). 
The change in plasma prolactin concentration from basal pre- infusion values over 
the 72 hour infusion period is shown in Figure 9.4. The basal pre- infusion value was 
calculated by averaging the three daily blood samples withdrawn prior to the start of 
the experimental infusion and the mean prolactin concentration in samples collected 
during the 72 hour infusion period were expressed as a change from the pre- infusion 
value. Whilst treatment of fetuses with sulpiride during the summer months resulted 
in the greatest absolute plasma prolactin concentrations (Figure 9.3), the change 
from baseline concentrations was similar for both summer and winter fetuses. 
Winter fetuses displayed a 2.7 fold increase in prolactin concentrations compared to 
the 2.2 fold increase over basal prolactin concentrations in summer fetuses. 
Chapter 9 Doparninergic regulation of prolactin 201 






30 - b) winter 
20 - 
10- 
0 i l l 
-24 -12 0 
infusion 
a 
-0- vehicle -- bromocriptine 
A sulpiride 
12 24 36 48 60 72 
Time (hours) 
Figure 9.3. Change in fetal plasma prolactin concentrations in a) summer and b) 
winter fetuses infused with vehicle, bromocriptine or sulpiride. Data shown 
represent the mean concentrations at 12 hour intervals from all fetuses in each 
treatment group. Significant differences from corresponding controls are indicated 
by a, p< 0.001;b, p <_ 0.01. Note the different scale on the y -axis for summer and 
winter periods. 
















Figure 9.4. Change in prolactin concentrations from basal values in a) summer and 
b) winter fetuses averaged over the entire 72 hour infusion period. Significant 
differences from corresponding vehicle treated controls are indicated by asterisks 
( ** p <0.01; * ** p< 0.001). 
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Although sulpiride treatment significantly increased plasma prolactin concentrations 
in winter fetuses, the maximum prolactin concentration remained considerably lower 
than basal levels of vehicle -treated control fetuses in the summer period (Table 9.1). 
Mean plasma prolactin concentrations during the 72 hour bromocriptine infusion in 
summer treated fetuses did not reach the low basal levels of winter control fetuses. 
However, the fall in prolactin concentration from the high summer values occurs 
gradually over the first 24 hour of the infusion period. Determination of the mean 
plasma prolactin concentration in the final 48 hours of the infusion, after the 24 hour 
period of declining values, reveals that prolactin concentrations in summer fetuses 
are reduced to a lower final concentration than winter fetuses (Table 9.1). The 
multiplicative response to bromocriptine treatment was significantly greater in 
fetuses treated during the summer months (18 fold reduction) compared to winter 
months (2 fold reduction). 
Mean plasma prolactin concentration (ng/ml) 
Treatment 
complete 72 hour infusion 
summer winter 
last 48 hours of infusion 
summer winter 
vehicle 119.63 ± 6.64 4.12 ± 0.26 124.08 ± 5.73 4.22 ± 0.37 
bromocriptine 6.56 ± 2.51 2.86 ± 0.91 0.96 ± 0.07 2.85 ± 0.28 
sulpiride 264.86 ±12.75 20.77 ± 5.44 266.53 ±13.24 21.62 ± 5.43 
Table 9.1. Effects of infusion of vehicle, bromocriptine or sulpiride on mean 
measured fetal plasma prolactin concentration. 
9.3.2. Prolactin immunostaining 
Immunohistochemical identification of lactotrophs in the pars distalis revealed that 
lactotrophs tended to occupy the lateral wings of the anterior pituitary. Figure 9.5 
shows representative anterior pituitary sections from summer (9.5a) and winter 
(9.5b) fetuses which were immunostained for prolactin. Cell counts of prolactin 
immunopositive cells in the lactotroph dense regions revealed that there was a 
significantly (p< 0.001) smaller percentage of immunopositive lactotrophs during 
the winter months (15.01 ± 0.7 %) when compared to the summer months (21.52 ± 
0.5 %, Figure 9.6a). The percentage of immunopositive lactotrophs was unaffected 
by infusion of bromocriptine or sulpiride in either the summer or winter season 
(Figure 9.6b). 
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Figure 9.5. Immunohistochemical localisation of prolactin in representative 
pituitary sections collected from a summer (a) and a winter (b) fetus. Lactotrophs 
were regionally distributed with less immunostaining present in the central region of 
the pars distalis. 












Figure 9.6. a) The percentage of prolactin immunopositive cells in the lateral 
region of the pars distalis of vehicle -infused fetuses treated in summer (n =4) and 
winter (n =3). There was a significant ( * ** p<0.001) difference in the number of 
lactotrophs between summer and winter. b) The percentage of immunopositive 
lactotrophs was unaffected by infusion of bromocriptine or sulpiride in summer or 
winter. 
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9.4. Discussion 
Previous studies have reported that prolactin secretion in the ovine fetus is 
modulated both by dopamine and by external photoperiod. The present study 
investigated the prolactin response to dopaminergic modulation in different seasons. 
Fetuses received an intravenous infusion of bromocriptine or sulpiride during the 
winter (January - March), when basal prolactin concentrations are low or during the 
summer (May - July), when basal prolactin concentrations are high. Plasma 
prolactin concentrations were significantly elevated in response to infusion of 
sulpiride in both seasons, demonstrating that the tonic dopaminergic inhibition of 
prolactin secretion is present during both the winter and the summer months. 
The mean concentration of prolactin in the fetal plasma was significantly greater in 
the summer than in the winter. This is in accordance with the previously reported 
influence of external photoperiod on fetal plasma prolactin levels (Bassett et al., 
1988). Bassett and co- workers measured prolactin concentrations in late gestation 
fetal and adult sheep during hormonally- extended breeding seasons from October to 
June and demonstrated that the level of prolactin in fetal plasma was closely 
correlated with the variation in ambient photoperiod, with levels increasing as 
daylength increased. The present study suggests that the decreased levels of 
prolactin in the fetal circulation during the winter months can be accounted for, at 
least in part, by the reduced number of immunopositive lactotrophs in the pars 
distalis of the pituitary in the winter as opposed to the summer. This suggests that 
there are fewer functional lactotrophs actively contributing to the basal release of 
prolactin during the winter. 
In the present study, the highest concentrations of prolactin were achieved after 
sulpiride treatment of fetuses during the summer. Whilst dopamine receptor 
blockade during the winter months resulted in a rapid increase in circulating 
prolactin concentrations, plasma prolactin levels remained considerably lower than 
basal levels of vehicle -treated control fetuses in the summer period. This finding is 
at odds with the proposal that low plasma prolactin concentrations during short day 
photoperiods are a result of increased dopaminergic inhibition (Curlewis, 1992). 
Whilst it is clear that dopamine acts to suppress the level of prolactin in winter 
fetuses it is clearly not solely responsible since levels remain low following 
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dopamine receptor blockade. The results reported in this chapter are consistent with 
the findings of Bassett et al. (1989) who reported that neither TRH nor the dopamine 
antagonist metoclopramide was able to increase plasma prolactin concentrations of 
winter lambs to levels experienced by summer lambs. 
The inability of the winter pituitary to secrete prolactin in response to sulpiride at 
concentrations that are comparable with basal levels from summer fetuses could be a 
consequence of the reduced number of lactotrophs in the winter. As well as limiting 
the amount of prolactin available for basal secretion, the reduced number of 
lactotrophs in the winter pituitary are likely to limit the extent to which the pituitary 
can respond to dopamine receptor blockade. Despite the great difference in 
maximum measured concentration of prolactin in response to sulpiride infusion in 
winter and summer fetuses, the scale of the increase was in fact comparable in both 
seasons, with sulpiride inducing a 2.2 fold increase in secretion during the summer 
and a 2.7 fold increase during the winter. This suggests that individual lactotrophs 
have much the same capacity to respond to dopamine receptor blockade in the 
summer and winter periods i.e. individual cells can double their prolactin output 
upon removal of tonic dopaminergic inhibition. It is possible that the slightly 
greater increase following sulpiride treatment of winter fetuses reflects the lower 
basal secretion of prolactin from the active lactotrophs during the winter thereby 
allowing a greater store for release following removal of the inhibitory influence of 
dopamine. 
The significantly reduced number of functional lactotrophs in the winter pituitary 
and the finding that prolactin concentrations in winter fetuses are lower than in 
summer fetuses, even after the removal of the inhibitory dopaminergic tone may 
reflect the suppressive influence of melatonin. Maternal pinealectomy abolishes the 
diurnal rhythm of melatonin in both the ewe and fetus (Yellon and Longo, 1988; 
McMillen and Nowak, 1989) whilst infusion of melatonin to pregnant ewes during 
long days, to mimic the short day duration of the melatonin signal, results in 
decreased prolactin concentrations in both the maternal and fetal plasma (Bassett et 
al., 1989). Therefore, the duration of the nocturnal melatonin release in the pregnant 
ewe and thus, in the fetus is increased during the winter and this in turn decreases 
plasma prolactin concentrations in both the ewe and the fetus. The mechanisms by 
which melatonin acts to regulate the secretion of pituitary prolactin are not fully 
understood. It seems likely that melatonin exerts its influence directly at the level of 
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the pituitary since disconnection of the pituitary from the hypothalamus does not 
disrupt the photoperiodic regulation of prolactin secretion (Lincoln and Clarke, 
1994). More recently, hypothalamic -pituitary disconnection of the fetus has 
confirmed that the fetus also maintains the prolactin response to external 
photoperiod in the absence of a functional link between the hypothalamus and the 
pituitary gland (Houghton, Young and McMillen, 1995). The persistence of a 
prolactin response to external photoperiod in HPD adults and fetuses suggests that 
melatonin has an extrahypothalamic mode of action, that is, melatonin acts directly 
at the level of the pituitary gland. 
In the present study, the approximately two -fold increase in plasma prolactin 
concentrations in both photoperiods following sulpiride infusion suggests that the 
level of tonic dopaminergic inhibition on pituitary lactotrophs is similar in summer 
and winter fetuses. The twofold increase in prolactin concentrations in both 
photoperiods is in accordance with the data presented by Houghton et al. (1995). In 
their study of HPD fetuses maintained under short and long days, Houghton et al. 
administered a bolus of the dopamine antagonist chlorpromazine intravenously at 
day 141 -142 gestation. They reported that the increase in plasma prolactin in intact 
fetuses in response to chlorpromazine was the same in both photoperiods when 
expressed as a percentage increase from baseline values. HPD fetuses did not 
respond to chlorpromazine in either photoperiod indicating that the effects of 
external photoperiod on fetal prolactin secretion are not mediated entirely by the 
inhibitory influence of hypothalamic dopamine on pituitary function. 
In this respect, Lincoln and Tortonese (1995) investigated the extent to which 
dopaminergic pathways are involved in the prolactin response to chronic 
administration of melatonin in the adult sheep. Sheep were treated with micro - 
implants of bromocriptine or sulpiride given alone or in combination with 
melatonin. Bromocriptine given in combination with melatonin produced the same 
effect as melatonin give alone; a significant decrease in plasma prolactin 
concentrations. Sulpiride given in combination with melatonin also produced the 
same effects as melatonin alone. The authors concluded that it is unlikely that the 
short day melatonin signal acts through a hypothalamic dopaminergic system to 
inhibit the secretion of prolactin since administration of bromocriptine in 
combination with melatonin did not further suppress prolactin concentrations when 
compared to the effects of melatonin alone and sulpiride given in combination with 
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melatonin was unable to negate the effects of melatonin. The hypothesis that 
melatonin acts to suppress plasma prolactin concentrations independently of 
dopamine is supported by the finding that sulpiride treatment of HPD rams under 
short days or after melatonin treatment failed to elicit the release of prolactin 
(Lincoln and Clarke, 1995). 
In the present study, since it was not possible to construct dose -response 
relationships, it is not possible to determine the extent to which the level of 
dopamine receptor expression in winter and summer pituitaries is involved in 
mediating the response to bromocriptine and sulpiride. However, it is interesting to 
speculate that the attenuated response to bromocriptine in summer fetuses reflects a 
change in the level or specificity of dopamine receptor expression. It is possible that 
the overriding inhibitory presence of dopamine during the winter months acts to 
desensitise the receptors whereas the reduced dopamine influence in the summer has 
the opposite effect. This would mean the effect of a given dose of dopamine agonist 
would be more effective in the summer when the receptors are more sensitive. 
Alternatively, the increased response to bromocriptine in the summer could simply 
reflect the increased number of lactotrophs present and therefore, presumably, an 
increased level of dopamine receptor expression. However, these explanations 
appear to be at odds with the similar response of both summer and winter pituitaries 
to dopamine receptor blockade, which suggests that the number of receptors and 
their level of sensitivity is comparable in both photoperiods. Studies investigating 
the dose -response to bromocriptine and sulpiride in both seasons are needed to 
clarify this point. 
In conclusion, the study presented in this chapter demonstrates that the secretion of 
prolactin into the fetal circulation is subject to tonic dopaminergic inhibition in both 
the summer and winter months and that dopaminergic inhibition is not solely 
responsible for low plasma prolactin levels during the winter months . 
Chapter 10. General Discussion 
The sequential maturation of the fetal hypothalamo- pituitary- adrenal axis is essential 
for the co- ordinated development of many organ systems and in species such as the 
sheep is pivotal in the initiation of parturition. The studies described in this thesis 
aimed to investigate the neuroendocrine regulation of hypothalamo- pituitary 
function during fetal life. 
The timely maturation of the hypothalamic neuropeptides CRH and AVP is essential 
for the subsequent induction of ACTH release from the fetal pituitary gland. 
However, little is known about the factors controlling the development of these 
important hypothalamic neuronal populations. The first objective of the studies 
presented in this thesis was to chart the development of hypothalamic AVP neurons 
in cell culture in an attempt to investigate the role of putative neurotrophic factors on 
the growth and functional maturation of this neuronal population. The study 
presented in chapter 4 described the maintenance of fetal rat hypothalamic neurons 
in cell culture for periods of up to 20 days. The functional maturation of AVP 
neurons in vitro was not significantly altered by treatment with IGF -1 however, due 
to the inability to specifically identify AVP neurons within the culture system it was 
not possible to elucidate any possible effects of IGF -1 on the rate of neurite 
outgrowth of the AVP neurons. Whilst cell culture is an invaluable tool in the 
analysis of complex systems such as the hypothalamo- pituitary axis, the study 
presented in Chapter 4 illustrated limitations of such a technique. Thus it was not 
possible to determine whether the inability to identify AVP neurons in cell culture 
reflects the insensitivity of the immunocytochemistry procedure or a fundamental 
difference between AVP neurons in vivo and in vitro. At present, the identity of 
factors regulating the growth and development of AVP neurons in the fetal 
hypothalamus remains undetermined. This is a most interesting area and one which 
clearly warrants further study. However, it seems that an alternative approach is 
necessary before specific effects of putative growth factors, such as those on neurite 
extension and differentiated morphology can be investigated. One such approach 
might be the use of expiant cultures. One can envisage extension of neuntes from 
fetal hypothalamic expiants towards the source of a putative growth factor. Fixation 
and processing of the entire expiant may overcome some of the problems of cell 
culture experienced in the study of Chapter 4. 
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The remainder of the studies presented in this thesis dealt with the ontogeny and 
dopaminergic regulation of the fetal pituitary gland. Chapters 6 -8 revealed that 
secretion of the POMC- derived peptides a -MSH and ACTH was subject to tonic 
dopaminergic inhibition. Thus, bromocriptine treatment significantly reduced and 
sulpiride treatment significantly increased the concentrations of a -MSH in the fetal 
circulation. In addition, circulating ACTH concentrations were significantly 
increased following sulpiride treatment. There was no influence of either treatment 
on pituitary a -MSH or ACTH content and, whilst bromocriptine treatment resulted 
in a significant reduction in the level of POMC mRNA present in the intermediate 
lobe there was no effect of sulpiride. These results suggest that the dopaminergic 
regulation of POMC- derived peptide secretion from the fetal sheep intermediate 
pituitary is complex (see Figure 10.1). 
In the adult rat, long -term administration of dopamine agonists induces a decrease in 
the content and secretion of POMC- derived peptides and reduce the rate of POMC 
biosynthesis by decreasing POMC mRNA levels in the intermediate lobe (Beaulieu 
et al., 1984; Chen et al., 1983; Millington et al., 1986). Conversly, dopamine 
antagonists produce a sustained increase in the content and secretion of POMC- 
derived peptides and accelerate the rate of POMC biosynthesis by elevating 
intermediate lobe POMC mRNA expression (Chronwall et al., 1987; Hollt et al., 
1982, Millington et al., 1986). However, the results presented in this thesis suggest 
that this is not the case in the fetal sheep. Whilst the decrease in circulating a -MSH 
concentrations in response to bromocriptine can be directly attributed to a decline in 
POMC mRNA levels, the situation in response to dopamine receptor blockade by 
sulpiride is more complex. Plasma a -MSH concentrations are rapidly increased 
following sulpiride treatment. As discussed in Chapter 6, this response is indicative 
of a readily releasable pool of a -MSH from the fetal intermediate lobe. However, 
plasma a -MSH concentrations remain high for the duration of the 72 hour treatment 
period without depletion of intra- pituitary a -MSH content (Chapter 7) or any 
alteration in the level of POMC mRNA expression (Chapter 8). Therefore, 
hypersecretion of a -MSH induced by removal of inhibitory dopaminergic tone must 
reflect altered processing of the POMC molecule post -transcriptionally. Post - 
transcriptional regulation of POMC mRNA may occur by attenuation of the rate of 
translation to produce the POMC protein precursor, an increased rate of post - 
translational processing of the precursor molecule or a combination of both events. 
These events, either alone or in combination would account for the pattern of gene 
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expression, peptide secretion and pituitary content described in this thesis in 
response to sulpiride. Thus, the fetal pituitary is capable of inducing a complex 
array of regulatory mechanisms in order to supply the increased demand for peptide. 
Dopamine could regulate these events at any number of sites in the POMC pathway. 
Potential sites for dopaminergic modulation are illustrated in figure 10.1. The 
results presented in this thesis suggest that post -transcriptional events are involved in 
the acute regulation of POMC -peptide expression by dopamine however, it is likely 
that long -term regulation (ie. longer than 72 hours) involves modulation of the rate 
of gene transcription. The mechanisms whereby dopamine modulates these post - 
transcriptional events remains to be elucidated. Other potential sites of actions of 
dopamine may include action on CRH nerve terminals in the median eminence and 
possible interaction between dopamine released at the intermediate lobe with the 
anterior lobe of the pituitary gland (shown as question marks in Figure 10.1). 
The studies presented in this thesis represent investigation of only one possible 
regulatory mechanism influencing intermediate lobe function during fetal life. It is 
likely that other neural factors are involved in control of intermediate lobe function 
during development. Evidence for this comes from the finding that treatment with 
bromocriptine alone fails to fully restore pituitary function after hypothalamo- 
pituitary disconnection. In addition, whilst haloperidol tended to increase 
intermediate lobe a -MSH and a- N- acetylated endorphin content (Smith et al., 1989; 
as discussed in Chapter 7), the increase was substantially less than that induced by 
HPD. Another neural factor likely to be involved in regulation of intermediate lobe 
function is y -amino butyric acid (GABA). GABA -ergic projections to the 
intermediate lobe have been identified in the adult rat (Vincent, Hokfelt and Wu, 
1982) and GABA- mediated inhibition of a -MSH release has been demonstrated 
(Tomiko, Taraskevich and Douglas, 1983). Therefore, it is important to appreciate 
that no one system is likely to govern the regulation of the many -POMC- derived 
peptides from the fetal pituitary gland but rather many systems act in concert to 
maintain a balance of peptide production and secretion. 
One important finding of this thesis is that, in direct contrast to previous reports 
(Llanos et al., 1979; Glickman et al., 1979; Baird et al., 1983) a -MSH does not 
appear to have any steroidogenic effects on the fetal adrenal gland in late gestation. 
This raises the original question as to the role of the intermediate lobe and a -MSH 
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Figure 10.1. Schematic diagram illustrating potential sites of dopaminergic 
regulation of the POMC pathway in the fetal sheep pituitary gland. Results 
presented in this thesis suggest that post -transcriptional events are important in the 
initial response to dopamine blockade. Long -term regulation of POMC- derived 
peptide expression is likely to involve regulation at the level of gene transcription 
(solid arrows). Additional dopaminergic influence on POMC products may occur in 
the anterior lobe of the pituitary via inhibitory effects on hypothalamic CRH nerve 
terminals in the median eminence or interaction between dopamine released at the 
intermediate lobe with the anterior lobe of the pituitary gland (dashed arrows). 
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during fetal life. It is clear from the ontogeny study presented in Chapter 5 that the 
fetal pituitary abundantly expresses a -MSH at a very early stage during fetal 
development. Investigation into the nature of this peptide in the early stages of 
development is necessary to determine whether it is actively secreted into the fetal 
circulation and if so is it active at the fetal adrenal gland during the early stages of 
development. As it stands, very little is known about the role of a -MSH in the fetus. 
Whilst it is recognised that levels of a -MSH are higher in the late gestation fetus 
than in the adult there is no information regarding the relative concentrations of a- 
MSH throughout the course of gestation. A possible hypothesis is that a -MSH is the 
peptide of choice released from the fetal intermediate lobe during early gestation and 
that it is preferentially replaced later in gestation by ACTH. This would be 
inkeeping with the reported influence of a -MSH on growth and maturation of the 
fetal brain and placental development (Swaab and Martin, 1981). Regulation of this 
nature could occur by temporal changes in the expression of prohormone convertase 
enzymes. Thus, it is possible that processing of the POMC precursor molecule early 
in development favours the production of a -MSH and that the rate of both 
processing and secretion of a -MSH is reduced following the onset of dopaminergic 
innervation. This would be consistent with the observed negative influence of 
dopamine on PC2 expression, the prohormone convertase enzyme that facilitates the 
cleavage of ACTH to a -MSH and CLIP in the intermediate lobe of the pituitary 
gland (Day et al., 1992). To date, little is known about the development and 
regulation of the dopaminergic system in the fetal sheep and this too is an area 
worthy of further study. Indeed, the possibilities for further study in this system are 
manifold with so many important questions remaining unanswered. 
In conclusion, the results presented in this thesis suggest that a -MSH and ACTH 
from the fetal intermediate lobe are not fundamentally important for the late 
gestation drive in adrenal stimulation necessary for the initiation of parturition in the 
sheep. The extent to which POMC- derived peptides other than ACTH are involved 
in this process remains to be determined. However, the result presented in this 
thesis do not preclude a role for a -MSH in the development and maturation of the 
fetal adrenal gland nor do they rule out a potential role for other POMC- derived 
peptides of the intermediate lobe, notably the N- terminal fragments in the late 
gestation increase in adrenal function. 
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